

Dear Congress Participants, Readers and Colleagues

This issue of Biomedical Papers (Vol. 146, No 1) contains abstracts of the scientific papers to be presented at the 1<sup>st</sup> Central European Congress on Intensive Care Medicine.<sup>1</sup> The abstracts appear in order of presentation from Thursday 13 through Saturday 15 June 2002. This abstract book would have been impossible to produce without the help of several people from organizing and scientific committee, special thanks must be given to the Editorial Board of Biomed. Papers, which provided immense help toward successful completion of accepted papers. Our thanks also must go to people from Publishing Centre of Palacky University.

On behalf of Organizing and Scientific Committee of 1<sup>st</sup> Central European Congress on Intensive Care Medicine we wish you a pleasant stay at Olomouc.

Vladimír Černý, MD, PhD, FCCM  
Chairman of the Scientific Committee

Oldřich Marek, MD  
Chairman of the Organising Committee

---

<sup>1</sup> Each lectures agreed to provide a written version or synopsis of the lecture for this abstract book. Despite request, we regret that the speaker did not provide a written text of the lecture. Editors

**June 13, Thursday**

15.00–17.00

Room **B**

**Section: Ethics**

Chair: Drábková, Sprung, Ruokonen, Nalos

**Invited speakers: (30 + 10 min)**

1. **Sprung C.** (Israel)  
End of life decisions
2. **Drábková J.** (Czech Republic)  
Is there a difference in ethical access to critical patients without severe premorbidity and with chronic disabling comorbidity?
3. **Nalos D., Pařízková R., Novák I., Černý V.** (Czech Republic)  
End of life decisions in critically ill – current status in Czech republic
4. **Ruokonen E.** (Finland)  
How quality is monitored in Finnish ICU's – benchmarking and quality control

Discussion

**Workshop**

1. Transfusion-Alternative strategies

Break

**Oral presentation (10 + 5 min)**

1. **Pařízková R., Černý V., Dostál P.** (Czech Republic)  
Limitating of life support in critically ill patients: a retrospective analysis of frequency and practice
2. **Wiedermann J., Smolka V., Reitingger J., Klásková E.** (Czech Republic)  
Current state of intensive care in pediatrics and some ethic aspects
3. **Škulec R., Linhart A., Hnátek T., Špundová H., Mrázek V., Holm F., Aschermann M.** (Czech Republic)  
Effect of statin therapy on long-term health-related quality of life in patients after acute myocardial infarction treated by PTCA
4. **Forró M., Mándli T., Gondos T.**  
Experience in selection of liver transplantation recipients in anaesthetic aspect based on the first 100 cases

Discussion

**Panel discussion**

(Drábková, Sprung, Ruokonen, Nalos)

**June 14, Friday**  
**8.30–12.30**  
**Room A**  
**Section: Infection**

Chair: Romand, Zandstra, Eggiman, Ševčík

**Invited speakers: (30 + 10 min)**

1. **Romand J. A.** (Switzerland)  
Infection versus colonization and implications for antibiotic therapy
2. **Zandstra D. F.** (The Netherlands)  
Future perspectives of the selective decontaminations of the digestive tract with emphasis on the control of the emergence of resistance in the critically ill
3. **Eggiman P.** (Switzerland)  
Catheter-related infections in the ICU, with special emphasizes on prevention
4. **Ševčík P.** (Czech Republic)  
Ventilator-associated pneumonia: never ending story

Discussion

**Workshop**

1. **Maurer E.** (Germany)  
Value of clinical examination EEG and evoked potential monitoring in ICU
2. **Adamus M., Adamus P.** (Czech Republic)  
Automatic control of neuromuscular blocker delivery during general anaesthesia Datex-Ohmeda Workshop

Break

**Oral presentation (10 + 5 min)**

1. **Kolář M., Látal T., Berta E., Marek O., Čermák P., Blahut L. and Working Group** (Czech Republic)  
Frequency of gramnegative bacterial pathogens in bloodstream infections in the Czech Republic
2. **Sobanska D., Stryjski A., Mazurek J., Stryjska M.** (Poland)  
Bacterial and mycotic infections after oesophagus carcinoma operations
3. **Balík M., Kolář M., Šedivý J., Hendl A.** (Czech Republic)  
Can bioimpedance measurement of extracellular water help to estimate the distribution volume of antibiotics in severe capillary leak syndrome?
4. **Kapš R., Starič S., Furlan P., Avšič-Županc T.** (Slovenia)  
Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia a 10-year survey
5. **Zvoníček V., Ondrovčík P., Sas I., Novák I., Šrámek V.** (Czech Republic)  
Cryptococcus neoformans on ICU – case reports

Discussion

**Panel discussion**

(Romand, Zandstra, Eggiman, Ševčík)

**June 14, Friday**  
**8.30–12.30**  
**Room B**  
**Section: Metabolism**

Chair: Leverve, Gašparović, Phelan, Novák

**Invited speakers: (30 + 10 min)**

1. **Leverve X.** (France)  
Energy metabolism in critically ill patients: lactate is a major substrate
2. **Novák I., Rokyta R. jr., Matějovič M., Kroužecký A.** (Czech Republic)  
Early enteral nutrition in critically ill patients: where is a benefit?
3. **Gašparović V.** (Croatia)  
Continuous hemofiltration as a tool for control of homeostasis: renal support or renal replacement?
4. **Phelan D.** (Ireland)  
Catheter related sepsis and metabolic complications in TPN patients

Discussion

**Workshop**

1. **Černý V.** (Czech Republic)  
Activated protein C – a Novel agent for severe sepsis

Break

**Oral presentation (10 + 5 min)**

1. **Rokyta R. jr., Matějovič M., Kroužecký A., Novák I.** (Czech Republic)  
Effects of early postpyloric enteral nutrition on hepatosplanchnic hemodynamics and metabolism in severe sepsis
2. **Balík M., Jabor A., Kolář M., Hendel A.** (Czech Republic)  
Monitoring of the residual renal functions during continuous renal replacement therapy – the application of the analysis of cystatin C and natriuretic peptides
3. **Král J., Šetina M., Králová I., Tesařík R.** (Czech Republic)  
Acute renal failure requiring renal replacement therapy after cardiac surgery
4. **Suk J., Hruša J., Zvoníček V., Šrámek V.** (Czech Republic)  
Low urine output in acute renal dysfunction diagnosis in long term ICU patients
5. **Studená A., Bračková I., Firment J.** (Slovakia)  
Hemorrhagic hypovolemia and some of its markers in experimental and clinical medicine

Discussion

**Panel discussion**

(Leverve, Gašparović, Phelan, Novák)

**Poster session:**

1. **Adorján K., Donáth K.** (Hungaria)  
Fluid and electrolyte disturbance resulting in tonic-clonic seizures, respiratory and renal failure (a case report)
2. **Balík M., Plašil P., Stehlíková M.** (Czech Republic)  
The diagnosis and therapy of heparin induced thrombocytopenia syndrome in a Czech general ICU

**June 14, Friday**

14.00–17.00

Room A

## **Section: Cardiovascular dynamics**

Chair: Hasibeder, Černý, Voga

### **Invited speakers: (30 + 10 min)**

1. **Hasibeder V., Dünser M., Mayr A., Friesenecker B.** (Austria)  
Arginine vasopressin in vasodilatory shock
2. **Černý V.** (Czech Republic)  
Hemodynamic goals in septic shock
3. **Voga G.** (Croatia)  
Myocardial dysfunction in sepsis and MOF
4. **Briegel J.** (Germany)  
Steroids in septic shock

Discussion

Break

### **Oral presentations (10 + 5 min)**

1. **Illias W.** (Austria)  
Non-invasive haemodynamic monitoring in intensive care and anesthesia
2. **Balík M., Pachi J., Hendl J.** (Czech Republic)  
Influence of the degree of tricuspid regurgitation on cardiac output measurements by thermodilution
3. **Bělohávek J., Škulec R., Pšenička M., Linhart A., Aschermann M.** (Czech Republic)  
Papillary muscle rupture with severe acute mitral regurgitation – rare complication of acute myocardial infarction.  
Our experience with three consecutive patients.
4. **Fazakas J., Gondos T., Horovitz P.** (Hungaria)  
Relationships between conventional hemodynamic and blood volume monitoring during and after orthotopic liver transplantation
5. **Mándli T., Forró M.** (Hungaria)  
Application of continuous autotransfusion system during liver transplantation

Discussion

### **Panel discussion**

(Černý, Hasibeder, Voga, Briegel)

My “first line” approach to treat unstable patients with septic shock?

### **Poster session:**

1. **Krivec B., Voga G., Skale R., Parežnik R., Podbregar M., Gabršček L.** (Slovenia)  
Diagnosis of shock due to massive pulmonary embolism

**June 14, Friday**

14.00–17.00

Room B

## **Section: Systemic inflammation and sepsis**

Chair: Radermacher, Träger, Trenkler, Matějovič

### **Invited speakers: (30 + 10 min)**

1. **Radermacher P.** (Germany)  
Goal-directed therapy in the treatment of severe sepsis and septic shock: does it exist?
2. **Matějovič M., Rokyta R. jr., Kroužecký A., Novák I.** (Czech Republic)  
Sepsis, septic shock and multiple organ dysfunction: new thinking about their pathophysiology
3. **Träger K., Radermacher P.** (Germany)  
Gastrointestinal tract resuscitation in critically ill patients
4. **Trenkler Š.** (Slovakia)  
Genetics behind sepsis

Discussion

Break

### **Oral presentation (10 + 5 min)**

1. **Gabršček L., Voga G., Krivec R., Skale R., Parežnik R., Podbregar M.** (Slovenia)  
Differentiation between local and systemic bacterial infection: the value of procalcitonin
2. **Fazakas J., Gondos T., Sárvári E., Varga M., Horovitz P.** (Hungary)  
The systemic and regional procalcitonin serum level changes during and after liver transplantation
3. **Borkowski J., Jedynak S., Wolczynski S., Siemiatkowski S., Czaban S. L.** (Poland)  
Luteinizing hormone, prolactin and testosterone plasma levels in patients with septic shock
4. **Kroužecký A., Matějovič M., Rokyta R. jr., Bílek M., Novák I.** (Czech Republic)  
Hypermyoglobinemia in critically ill patients: what does it mean?
5. **Dziurdzik P., Krawczyk L., Jalowiecki P., Dudek-Dyczkowska D., Kondera-Anasz Z.** (Poland)  
Serum interleukin-10 in patients with isolated acute intracranial lesions
6. **Hruda J., Šrámek V.** (Czech Republic)  
The impact of oversedation on septic shock severity

Discussion

### **Panel discussion**

(Radermacher, Träger, Trenkler, Matějovič)

**June 15, Saturday**

8.30–12.30

Room A

**Section: Acute respiratory failure**

Chair: Mutz, Putensen, Šrámek, Pavlík, Nalos jr.

**Invited speakers: (30 + 10 min)**

1. **Putensen C.** (Germany)  
Patophysiology of ALI and ARDS
2. **Nalos M., Růžička J., Šrámek V., Novák I.** (Czech Republic)  
Respiratory mechanics at the bedside
3. **Pavlík M.** (Czech Republic)  
Open lung maneuvers – how to perform, how to monitor, possible side effects
4. **Šrámek V.** (Czech Republic)  
Non-invasive ventilation in acute respiratory failure
5. **Mutz N.** (Austria)  
Muscle fatigue and respiratory failure

Discussion

Break

**Oral presentation (10 + 5 min)**

1. **Matuška P., Pilařová O., Merta Z., Skříčková J., Dušek L.** (Czech Republic)  
The influence of co-morbidity on the outcome of non-invasive ventilatory support in patients with acute respiratory failure in chronic obstructive pulmonary disease
2. **Rindoš R., Hamžík J., Piovarčí D., Havelka V.** (Slovakia)  
Postintubation tracheal lesions with acute respiratory failure – Serious problem of the intensive care today
3. **Kolek V., Marek O.** (Czech Republic)  
Stent insertion in benign stenoses of central airways
4. **Pachl J., Zábrodský V., Roubík K., Waldauf P., Krejzl J.** (Czech Republic)  
Criteria for prediction of HFOV treatment efficiency in adult patients with ARDS

Discussion

**Panel discussion**

(Mutz, Putensen, Šrámek, Pavlík, Nalos jr.)

**Poster session:**

1. **Pavlík M., Štětka P., Šrámek V.** (Czech Republic)  
ARDS due to fat embolism – a case with a prolonged course
2. **Škulec R., Bělohlávek J., Pšenička M., Holm F., Aschermann M.** (Czech Republic)  
Diffuse alveolar hemorrhage – unusual complication of combined antiaggregation therapy for acute myocardial infarction
3. **Řehořková D., Bosáková H., Horký P., Hude P., Wendsche P.** (Czech Republic)  
The prone position as a part of the respiratory management in tetraplegic patients
4. **Bosáková H., Řehořková D., Horký P., Hude P., Wendsche P.** (Czech Republic)  
Respiratory management of patients with spinal cord injuries (SCI)

## SECTION: ETHICS

01

### END OF LIFE DECISIONS

Sprung C.

*General Intensive Care Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel, sprung@cchuj.ac.il*

No abstract available.

02

### IS THERE A DIFFERENCE IN ETHICAL ACCESS TO CRITICAL PATIENTS WITHOUT SEVERE PREMORBIDITY AND WITH CHRONIC DISABLING COMORBIDITY?

Drábková J.

*University Hospital Motol, Dept. of Chronic Intensive Care, Prague, Czech Republic, jarmila.drabkova@fnmotol.cz*

Modern intensive care has an enormous technical and medical potential. The demand for intensive care has increased especially in patients at advanced disease stages with a steeply increasing proportion of elderly patients. The sequelae are rising costs, prolonged length of stay and increasing numbers of specialized staff and personnel. All these factors are confronted with limited economic resources and not always with positive clinical outcome.

Ethical principles in evidence based intensive medicine have to withstand economic pressures, to assist in formulations of up-to-date definitions and in benchmarking of indicated versus abundant therapy; to support the ideas of appropriate aftercare; to describe the borderline between shared decision making and benevolent paternalism etc.

#### Ethical aspects, principles and expectations

Common medical and ethical expectations of conscious adult critical patients:

- state-of-the-art activities of the attending physicians and all health care providers,
- preservation of dignity,
- absence of pain and suffering,
- holistic medical care with optimal prognostic outcome.

The patients don't feel responsibility for the economic burden. Their main focus is concentrated on successful outcome, future quality of life, even on favourable quality adjusted life years. Protracted and complicated life crisis in the ICU increases abolition of circadian rhythmicity, emotional stress, depression, dysexecutive syndrome or posttraumatic stress syndrome. In very rare cases patients insist on being told mere and pure truth on hopeless prognosis with a rapid shortage of life expectancy or with severe disability. The emotional stability of these informed patients can nevertheless change abruptly afterwards in an unexpected way. Light sedation without amnesic effect is the best choice.

The physician's view is rather different. He is out of his patient's life crisis but he is engaged in the doctor-patient relationship. His view is a combination of several factors:

- his own ethical principles and compassion capacity,
- professional ethics with rules of beneficence, non-maleficence, respect for patient's autonomy and medical justice, cited by Beauchamp and Childress (1989, 1994),
- medical evaluation of his patient's physiologic reserve, his response to therapy, genetic and gender predisposition, diagnosis, complications, family background, age and personality.

Ethics and bioethics are not isolated theoretical sciences. Their performance is visible in all activities of intensive care personnel, in behaviour of all patients without brain traumatic or non-traumatic injuries. Actual ethical principles and individual behaviour and inter-relations influence the entire team in the ICUs or step-down units.

#### Specific features in the ICUs

- 50 % of survivors do not remember their stay and time in the intensive care due to primary unconsciousness or heavy sedation. This gap can afterwards stimulate the posttraumatic stress syndrome.
- 30 % do feel the ICU environment as a distressing factor; approximately 50 % of them estimate this could be improved if the carers had more ethical compassion and empathy.
- Previously healthy subjects, mainly from the group of younger males, feel shocked, embarrassed, deeply surprised, depressive or agitated. They are overwhelmed with fear of death, loss of autonomy and integrity. They suddenly have communication difficulties. The feeling of life insecurity can lead to loss of trust in the attending staff. Lack of uninterrupted sleep or long-term sedation provoke loss of orientation in time and space. All these negative impressions disturb the ethical stereotypes and barriers. In elderly patients they can completely desintegrate the previous personality.

#### Ethics and psychologic changes

Bioethics and psychology are tightly bound to each other especially in chronically limited, ill and disabled patients. This is more manifest in young patients, in males, in dominant personalities. Without scrutiny they can demand "best available care", "rooming-in of their beloved ones", iterative consultations and discussions considering their health status and future life style, compensatory equipment, participation of invited healers etc. On the other side elderly patients with chronic diseases feel depressed, taken aback with no perspective to be dismissed and return home as non-dependent on assistance of others as they were used to. Nevertheless they don't express their more hidden feelings with such vivid vitality as the former group. Extreme reaction is mental apathy and nearly passive suicide rejecting medications, mobilization, weaning-off the ventilator.

Physicians and nurses have to handle both types of patients with identical ethical access. The longer the stay of these patients in the ICU or HDU the more relevant is the ethical background of the triangle patient-relatives-attending carers. Iterative complications, chronic ventilator therapy, immobilization, lack of good prognosis and new interests, loss of voice with tracheostomy can lead to disruption of ethical barriers and depress the social threshold of the patient and his relatives; their adverse reactions induce escalation of the burn-out syndrome in health care providers. Impatience and hostile feelings of carers are directed not only to the actual patient, they generate mental discomfort in the



ICU. Prophylactic measures have to be taken in time including the participation of clinical psychologist dealing with patients, relatives and personnel.

### **Ethics and decision-making process**

Ethics is connected not only to psychology, deontology and human relations in units with acute or long-term critical patients. It is implemented in the decision-making process of physicians considering evaluation of anamnestic data, clinical history of the present injury or decompensation of a progressive chronic disease, comorbidity, age, presumed quality adjusted life years, amount of economic/financial resources, event. legal prospective wishes and directives in different countries. Professional ethics is not different in its basic principles but the actual role in different situations in emergency medicine, in intensive medicine and palliative care has distinct individual features.

### **CPR and ethics**

CPR in the field is a typical example of a postponed definite decision. The overall survival rate of patients dismissed from the hospital is 3–5 % in the USA. If we judge the patient's perception of the benefit of outcome as the most important element, we have to admit a rather ambivalent reality, that 35 % survivors of myocardial infarction are living in constant fear of another coming attack, reducing their daily activities and 42 % of them complaining of stressful social isolation. After CPR in the field results and outcome in adults are still worse; 54 % of resuscitated patients do not survive already at the scene, 25 % die during the transport and 4 % are dismissed neurologically disabled. Especially poor outcome we see in trauma patients. Nevertheless even these statistical data (Kettler) don't justify general omission of CPR. In countries with high and lawful respect to patients' autonomy and capacity to determine own destiny 41 % elderly and limited patients opt for CPR if they lead an active life. This percentage is dropping to 11 % if they are chronically ill and the progress of their dominant disease offers the life expectancy less than 1 year. Severe comorbidity in elderly patients with discomfort decreases the option for CPR to 5 %.

Respect for autonomy in CPR and other rescue manoeuvres is not the only principle and should not be overvalued if it conflicts with other aspects. Autonomy cannot replace beneficence. Justice in the field is considered as CPR, helicopter transport in polytrauma emergencies and severe burns etc. to appropriate intensive care establishment. The exact evaluation of prognosis and the final decision is postponed to the hospital and to the moment of sufficient information.

### **Intensive care and ethics**

In the intensive care ethical principles are based on positive motivation of patients towards favourable prognosis. Ideally, patients with no chance of recovery should be identified prior to their admission to intensive care (Booth 2002) and care decisions should be made on data, proven by means of evidence based medicine, using dynamic prognostic scoring systems merely as basic support for individually tailored decisions. Otherwise public will fear premature computer rationing and withholding or withdrawing of futile therapy only as a tool due to economic restriction.

In the acute period the patient is incompetent for serious discussions concerning his real prognosis and for expression of directives, informal consent or disagreement. In our country best interest of the patient concerning the decision making process and treatment is directed

to his attending physician. Guidance on healthcare ethical issues is the role of ethics committees, exceptionally of a state attorney. Legislation changes are expected with our membership in the European Union. Topics with ethical background include numerous issues – some of them general and some with different medico-legal validity in different countries:

- extent of therapy, life prolonging treatments and treatments to alleviate suffering, withholding and withdrawing therapy and its selected elements,
- issues of palliative care and basic life support,
- assistance of prognostic criteria as a result of dynamic scoring systems,
- criteria of brain death and donor programme,
- dimension of withholding/withdrawing crucial therapy incl. mechanical ventilation in respiratory insufficiency during end-stage chronic untreatable illness,
- definition of futile therapy,
- omission or refusing indicated therapy,
- rescue therapy and manoeuvres,
- off label medications and alternative care,
- moral difficulties in giving information to the patient, his relatives, insurance companies, police; scientific evaluation in congresses and periodicals etc.
- clinical trials of new drugs and methods in the non-autonomous patient,
- the role of relatives, the patient's proxy and surrogate,
- patient's prospective directives concerning CPR, emergency and intensive care,
- iterative informed consent and signature of directive of a mentally competent patient demanding euthanasia.

### **Conclusion**

There is a difference between patients formerly healthy and patients with severe diseases after a recent primary hit. Basic ethical issues are common, no civilian triage is used, rationing is supported with state-of-the-art criteria. More sophisticated ethical image and reactions of patients, their relatives and carers differ including validation of specific features: stage of severe chronic and ultimately untreatable disease, decreased reserve of elderly people etc. Patient-carer relationship and behavior is judged ethically from both sides. Ethics has many topics in emergency and intensive medicine. Only few of them are covered and can be covered by legislation. Professional ethics is rather independent, its basic human principles are valid and economic restriction cannot beat them. Evidence based medicine offers new views to implement more exact arguments and definitions to individual topics; we don't expect radical change of ethical principles in peaceful and developed countries for next future.

In Czech Republic topics of specific professional bioethics, ethical behavior of staff and personnel, moral difficulties, economic aspects, redefinition of legislation in emergency and intensive care form a burning challenge just now and for coming days.

### **References**

- Booth M: Ethics issues in critical care outcome. Chapt 11 in: Ridley S: Outcomes in Critical Care. Oxford, Butterworth Heinemann, 2002, pg. 223–248.
- Kettler D, Mohr M: Ethical aspects of resuscitation. Resuscitation 15, 1998; 6: 721–724.
- Randall F, Downie RS: Palliative Care Ethics. 2<sup>nd</sup> edn. New York, Oxford University Press 1999.

03

## END OF LIFE DECISIONS IN CRITICALLY ILL – CURRENT STATUS IN CZECH REPUBLIC

Nalos D., Pařížková R., Novák I., Černý V.

*Anaesthesiology Department and ICU, Masaryk Hospital, Ústí nad Labem, Czech Republic, daniel.nalos@mnul.cz*

End of life decision (EOLD), is a constant component of decision making in ICUs. The role of EOLD has been increasing in USA, Europe in last decade. The Czech Association of Intensivist is beginning to discuss this issue. The main reasons for the controversy are: dignity of dying process and economic arguments.

The society relation to death and dying process is multifactorial. We assume that national and local traditions, intensity and differences of religions, living standards and accessibility of literary sources, play a major role.

Only after many years rapid economic and political changes reflect in lifestyle and ethics standards. The non-medical society is not yet prepared to adapt EOLD principals.

Some rules of socialist relationship between patients and medical staff are continuing nowadays. The former assumption that "Health is a matter of the whole society", is the main cause of strong medical paternalism as well as very low autonomy feeling of the patient.

Medical students have learned at medical faculty a lot about saving the lives, but constantly only few about dignity of dying. Medical staff has not accepted the basic concept and principles of EOLD yet.

Technical and pharmacological standards of ICUs reached European level in the last decade. The number of patients who has met the criteria of futile treatment is rising currently. The amount of EOLD is increasing nowadays. Although I have only fragmentally data I will try to define the current situation in EOLD in the Czech republic in comparison to published data.

Article from American ICUs (Prendegast and Luce) reported an increase in withdrawal of life support from 51 % to 90 % in the period between 1988 and 1993. In a French study Ferrand et al have reported that 53 % of the ICU deaths were preceded by a decision to withhold or withdraw life –support therapies. Last year Esteban et al. published the following data: 34.3 % of patients in Spanish ICUs died following withholding or withdrawing order. We assumed that consideration of dying process is extremely various in ICUs in Czech republic.

We present data from three different Czech ICUs using withholding and withdrawing order.

In ICU No. 1 The incidence of withholding and withdrawing order were 23 % of all admitted patients in the two years period between 2000 and 2001.

In ICU No. 2 In 2001 foregoing live-sustaining treatment occurs in 11 % of patients admitted in ICU and in 43 % of dying patients.

In ICU No3 the withholding and withdrawing was performed in 61 % patients before death.

ICU No 1 and 2 were participated on Ethicus study. ICU No 3 not gained ethics committee agreement for Ethicus study nevertheless they had all data for Ethicus study available.

Participation on European studies can fundamentally contribute to better provision of dying process and help us in making difficult ethical decisions for critically ill.

04

## HOW QUALITY IS MONITORED IN FINNISH ICU's – BENCHMARKING AND QUALITY CONTROL

Ruokonen E.

*Department of Anesthesiology and Intensive Care Medicine, Kuopio University Hospital, Kuopio, Finland, esko.ruokonen@kuh.fi*

No abstract available.

05

## LIMITATING OF LIFE SUPORT IN CRITICALLY ILL PATIENTS: A RETROSPECTIVE ANALYSIS OF FREQUENCY AND PRACTICE

Pařížková R., Černý V., Dostál P.

*Charles University, Faculty of Medicine, Department of Anaesthesiology and Intensive Care, 500 05 Hradec Kralove, Czech Republic*

### Introduction

An increasing number of deaths in the intensive care setting involve withholding or withdrawing multiple life-sustaining therapies. Terminal care decisions are increasingly common, however the practice of limiting life support therapy in dying critically ill patients varies between countries. The aim of the study was to examine the frequency and practice of limiting therapy at tertiary care hospital ICU in Czech Republic.

### Methods

A retrospective, descriptive study of all patients who died or in whom life support was withdrawn or withheld in period 1998–2001 was conducted. Number of admissions, number of patients with limiting therapy, Apache II score, SOFA score, length of ICU stay in days (LOS), type of admission (primary, secondary within 24 h, secondary after 24 h), diagnostic category, reason for limiting therapy, way of limiting therapy (withdrawing or withholding), time from admission to decision, time from decision to death and adequacy of documentation were evaluated. Statistical analysis was performed using SigmaStat Statistical Software.

### Results

Only selected results are presented. There were 130 deaths out of 681 patients admitted in 1998–2001. Except for four, all patients were admitted at the time of admission for unrestricted and full therapy. There were 60 patients with severe brain damage and 70 patients without severe brain damage. Decision to limit life support therapy before death was made in 80 patients (61.5 %). Withholding therapy was performed in 17 patients, withdrawing therapy in 63. Terminal weaning as a part of withdrawing therapy was employed in 46 patients (73 % of all withdrawal therapy).

## Conclusion

End-of-life care is an important part of high-quality intensive care unit. The rate of withdrawing or withholding therapy decisions in dying patients occurred more frequently comparing to some studies<sup>1,2</sup>. Increasing proportion of employment of ventilatory support withdrawal has been found in years 2000 and 2001.

## References

1. Smedira NG, Evans BH, Grais LS et al: Withholding and withdrawal of life support from the critically ill. NEJM, 1990, 322, 309–315.
2. Zimmermann JE, Knaus WA, Sharpe SM et al: The use and implications of do not resuscitate orders in intensive care units. JAMA, 1986, 255, 351–356.

## 06

### CURRENT STATE OF INTENSIVE CARE IN PEDIATRICS AND SOME ETHIC ASPECTS

Wiedermann J., Smolka V., Reitinger J., Klásková E.

*Department of Pediatrics, University Hospital, Olomouc, Czech Republic*

Intensive care in the present-day paediatrics is featured by rigid organisation structure while it is given a minimum personal and technical background.

Primary concerns of the intensive and resuscitating care (IRC) continue to be focused on solution of urgent states but for the last decade there has been increasing number of patients suffering from irreversible organ alterations and chronic diseases that require chronic IRC to be applied. Such care is performed in IRC regional centres.

Patients mentioned above include in particular: a) those affected by CNS hypoxia b) those suffering from sequelae resulting from urgent care complications c) those suffering from progression of a basic disease of degenerative type that cannot be influenced d) those suffering from progression of a basic disease of chronic type that cannot be influenced.

Present-day IRC in paediatrics is furthermore distinguished by: 1) increasing proportion of relapsing chronic diseases 2) enhanced intensity of pre-hospital treatment of urgent states 3) changing spectrum of urgent states in favour of doubtful complex multi-factorial emergent states (proportion of typical respiratory and gastro-intestinal diseases decreases) 4) growing influence of effects of perinatal pathology on the development of urgent states in later age.

Trends in the present-day IRC in paediatrics are:

- Strict INDICATION OF INVASIVE TREATMENT TO BE APPLIED
- PREVENTION FROM COMPLICATIONS – technical, infective, toxic
- Emphasis given to performance of all interventions in ANALGOSEDATION
- Application of SCORING SYSTEMS
- Introduction of STANDARD PROCEDURES IN TREATMENT AND DIAGNOSTICS
- Growing role of CHRONIC INTENSIVE AND RESUSCITATING CARE

Ethic problems in IRC are related chiefly to states of irreversible failure of organ functions, which in particular require patient's involvement and patient prevention from any "harm" to be taken into consideration. In the light of the current theoretical knowledge the extent of the offered care is limited by economic conditions. There is some endeavour to solve this antagonism (of "what we wish to and what we actually

can") by categorising the patients according to the care to be offered: 1) standard – maximum therapy 2) nonexpanding therapy – "withholding" 3) limiting therapy – "withdrawing". In Scandinavia, in particular, the protocols of limited care are developed for states with unfavourable prognosis based on the scoring. In our opinion maximum therapy should be offered initially (72 to 96 h). This view is supported by the difference between real (0.009) and predicted (0.039) mortality in the IRC patient file at the Clinic of Paediatrics of FNO we have traced during evaluation of PRISM in 2001.

Increasing parental involvement in childcare is in accordance with the Charter of Hospitalised Children's Rights. Contacts between parents and patients are constantly improving and the room for parental attendance even in IRC is increasing. But close contacts between parents and child-patient may cause pressure and subsequent conflicts with IRC ward staff.

Conflicts are: a) positive – stimulating b) negative – demotivating.

## 07

### EFFECT OF STATIN THERAPY ON LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION TREATED BY PTCA

Škulec R., Linhart A., Hnátek T., Špundová H., Mrázek V., Holm F., Aschermann M.

*2<sup>nd</sup> Department of Internal Medicine, 1<sup>st</sup> School of Medicine, Charles University, Prague, Czech Republic*

#### Purpose of study

Beneficial effect of statine treatment in patients with acute coronary syndrome has been studied. However, a little is known about its effect on long term health-related quality of life (HRQOL). Thus, we decided to analyze impact of statine therapy on HRQOL in patients who underwent direct or rescue percutaneous transluminal coronary angioplasty (PTCA) because of acute myocardial infarction (AMI).

#### Methods

We performed a retrospective single-center study in 127 patients who underwent direct or rescue PTCA because of AMI in 2<sup>nd</sup> Dep. of Internal Medicine, 1<sup>st</sup> School of Medicine, Charles University, Prague in the year 2000. 11 (SD ± 3.2) months after the procedure the patients were sent by the 36-Item Short-Form Health Survey (SF-36) and the questionnaire about actual symptomatology of coronary artery disease and concomitant medication. SF-36 quantifies HRQOL in eight parameters: physical functioning (PF), role limitations as a result of physical health problems (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations caused by emotional health problems (RE), and general mental health (MH). All parameters were scored from 0 (worst score) to 100 (best score).

#### Results

Response-rate was 52 %, 95.5 % of responses were evaluable. 22.7 % of responders were women. Average age was 62.8 years (SD ± 10.8). Responders (47.6 %) were treated by statines in the time of completing the questionnaire, 52.3 % were not. We found out a significantly

better score in the statine treated group then in the group without statine treatment in PF (77.9 vs 64.8), RP (64.1 vs 36.5), BP (83.1 vs 68.8) ( $p < 0.05$ ) and borderline score in SF (84.2 vs 73.0) ( $p < 0.05$ ).

### Conclusions

Statine treatment in patients who underwent PTCA because of AMI is associated with improved quality of life in several parameters. Confirmation of this finding requires further investigation.

08

## APPLICATION OF CONTINUOUS AUTOTRANSFUSION SYSTEM DURING LIVER TRANSPLANTATION

Mándli T., Forró M.

*Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary*

### Purpose

The advantages and disadvantages of continuous autotransfusion during liver transplantation are investigated in our study compared with blood saving and traditional cell saving techniques.

### Methods

Patients were divided into three groups in this retrospective study; Group 1 ( $n = 14$ ): continuous autotransfusion was applied; in Group 2 ( $n = 14$ ): no blood saving technique used; in Group 3 ( $n = 14$ ): Haemonetics cell saver was used. Age, body weight, diagnosis, Child-Pugh score, level of haemoglobin and clotting factors, activated clotting time (ACT), duration of hepatectomy, blood replacement therapy, post-operative respiration time, treatment time and mortality were examined.

### Results

In Group 1 the number of Child B patients was significantly higher than Child C patients ( $p < 0.05$ ). The initial values of haemoglobin were significantly lower in Groups 1 and 3 ( $89 \pm 19$  vs.  $103 \pm 17$  vs.  $90 \pm 16.8$  g/l;  $p < 0.03$ ). During hepatectomy in Group 1 lower haemoglobin values were detected than in the other two groups ( $96 \pm 7$  vs.  $104 \pm 16$  vs.  $106 \pm 16.6$  g/l;  $p < 0.05$ ). The quantity of total blood utilisation (donor + autotransfusion) was significantly higher in Group 3 than Group 2 and in Group 1 than Group 2 ( $21.06 \pm 11.2$  vs.  $11.07 \pm 3.8$  vs.  $30.71 \pm 18$  U;  $p < 0.001$ ). Comparing the values of ACT in each group during operation periods no significant difference was found. Treatment time on the ICU of the patients in Group 3 was significantly longer than in the other two groups ( $11.08 \pm 7.8$  vs.  $9.17 \pm 3.5$  vs.  $26.62 \pm 14.6$  days;  $p < 0.03$ ).

### Conclusion

We found that applying CATS is advantageous during liver transplantation, as the device reduces donor blood requirement. No significant complication was observed.

09

## EXPERIENCE IN SELECTION OF LIVER TRANSPLANTATION RECIPIENTS IN ANAESTHETIC ASPECT BASED ON THE FIRST 100 CASES

Forró M., Mándli T., Gondos T.

*Department Of Transplantation and Surgery, Semmelweis University, Budapest, Hungary*

### Purpose

Analysing preoperative parameters were for predict the outcome of liver transplantation.

### Methods

Patients were divided retrospectively into two groups: Group 1. uncomplicated cases ( $n = 50$ ), Group 2.: patients with severe complications (infection, rejection, organ failures etc.) ( $n = 29$ ). Cases with primary surgical complications (bleeding, thrombosis of hepatic artery, problems of bile duct etc.) and acute retransplantations were excluded ( $n = 21$ ). Age, BMI, Child-Pugh score, incidence of concomitant diseases, perioperative lab data, central venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), systemic vascular resistance (SVR), requirement of intraoperative transfusion, treatment time in ICU, duration of mechanical ventilation and haemodynamic monitoring, need of cardiac support, incidence of perioperative infections, MOF score and mortality were compared between the two groups.

### Results

Lower level of preoperative haemoglobin ( $104 \pm 27$  vs.  $121 \pm 21$  g/l  $p = 0.003$ ), PCWP ( $16.8 \pm 9.6$  vs.  $12.6 \pm 5$   $p = 0.02$ ), higher requirement of intraoperative transfusion ( $12.6 \pm 5$  vs.  $16.8 \pm 9.6$  U  $p = 0.02$ ), longer ventilation time ( $31.3 \pm 32$  vs.  $50 \pm 42$  days  $p = 0.03$ ) longer staying in ICU, ( $7.8 \pm 2.5$  vs.  $28.3 \pm 22.9$  days  $p = 0.0003$ ), higher frequency of cardiac monitoring ( $15/50$  vs.  $23/29$  cases  $p = 0.0001$ ), higher MOF score ( $0.24 \pm 0.5$  vs.  $2.65 \pm 1.76$   $p < 0.002$ ), and lower mortality ( $2$  vs.  $56.3\%$   $p = 0.0001$ ) were found in Group 2 than Group 1. Remaining parameters were not showed any significant differences.

### Conclusion

It was found mortality and morbidity of liver transplantation are lower in case the recipients are well-hydrated and have good cardiac compensation ability.

## SECTION: INFECTION

10

### INFECTIONS VERSUS COLONIZATION AND IMPLICATIONS FOR ANTIBIOTIC THERAPY

Romand J. A.

*Surgical Intensive Care, University Hospitals, Geneva, Switzerland,  
jacques-andre.romand@hcuge.ch*

No abstract available.

11

### FUTURE PERSPECTIVES OF THE SELECTIVE DECONTAMINATIONS OF THE DIGESTIVE TRACT WITH EMPHASIS ON THE CONTROL OF THE EMERGENCE OF RESISTANCE IN THE CRITICALLY ILL

Zandstra D. F.

*Afdeling Intensive Care, Onze Lieve Vrouwe Gasthuis, Amsterdam,  
The Netherlands, zandstra@pop3.olvg.nl*

No abstract available.

12

### CATHETER-RELATED INFECTIONS IN THE ICU, WITH SPECIAL EMPHASIS ON PREVENTION

Eggimann P.

*Medical Intensive Care Unit, University Hospitals of Geneva, Switzerland,  
philippe.eggimann@hcuge.ch*

Catheter-related infection remains a leading cause of nosocomial infections, particularly in intensive care units (ICUs). It includes colonization of the device, skin exit-site infection and device – or catheter-related bloodstream infection. The latter represents the most frequent life-threatening associated complication of central venous catheter use and is associated with significant patient morbidity, mortality and extra hospital costs. The incidence of catheter-related bloodstream infection ranges from 2 to 14 episodes per 1000 catheter-days. On average microbiologically-documented device-related bloodstream infections complicate 3 to 5 per 100 central venous line uses, but they only represent the visible part of the iceberg and most clinical sepsis are nowadays considered to be catheter-related.

We briefly review the pathophysiology of these infection, highlighting the importance of the skin insertion site and of intravenous line hub as principal sources of colonization. Principles of therapy are shortly re-

viewed. The most recent preventive approach are presented in more details, including the possible benefit of recently developed impregnated catheters and the positive impact of educational programs and/or global preventive strategy based on strict application of preventive measures and on a careful control of all factors associated with catheter-related infection.

Preliminary data from our institution showing a positive long term impact of these measures will be discussed. This may help clinicians to determine the eventual necessity to incorporate them in their own practice.

13

### VENTILATOR-ASSOCIATED PNEUMONIA: NEVER ENDING STORY

Ševčík P.

*Department of Anaesthesiology and Intensive Care Medicine, St. Ann's Hospital, Brno, Czech Republic*

#### Introduction

The human body consists from approximately  $10^{14}$  cells. Most of them, 90 %, are microorganisms. In other words, only 10 % of human body cells are of eucaryotic type. In adult, almost 1 kg of microorganisms, most of them bacteria, is present, particularly in the gut. In normal situation, 99.9 % of bacteria in the large intestine are anaerobes. In critically ill patient the ecology of intestinal flora changes significantly and plays important role in the development of nosocomial infections. Nosocomial pneumonia is the second most common nosocomial infection and the most common nosocomial infection in intensive care units. Compared to most hospitalized patients, rates of nosocomial pneumonia are 10- to 20-fold higher in intensive care unit patients, and 7- to 21-fold higher in the intubated patients. Therefore, intubated and artificially ventilated patients in intensive care units are in the highest risk of nosocomial pneumonia<sup>9</sup>. Most of the published studies report the incidence rate of the ventilator-associated pneumonia (the number of cases of ventilator-associated pneumonia per 100 hospitalized patients). The incidence of ventilator-associated pneumonia (VAP) ranges from 9 % (some pediatric ICUs) to more than 50 % in patients with ARDS. These rates fail to adjust for the duration of ventilation and are therefore difficult to interpret. Device-associated incidence density rates of VAP, that is, the number of cases of VAP per 1000 ventilator-days, are reported only for small amount of studies and range from 10 to 30 per 1000 ventilator days<sup>5, 6</sup>. In our study done in middle 90 s (261 patients, general medical-surgical ICU, APACHE II score  $21.76 \pm 7.15$ ) we observed 18.2 VAP per 1000 ventilator days, or, VAP developed in 24.2 % of ventilated patients<sup>12</sup>. On average, VAP rates are 9.3 times higher than nonventilator-associated pneumonia rates, ranging from 2.6 times higher in respiratory ICUs to 19 times higher in burn ICUs<sup>9</sup>.

Nosocomial pneumonia is not only common, but also deadly. Estimates of its crude mortality range from 28 to 37 %. In our study, the mortality of patients with nosocomial pneumonia was significantly higher (39.3 %) than the mortality of patients without pneumonia (16.1 %,  $p < 0.01$ ). Some have argued that these high crude mortality

rates merely reflect the severity of patients underlying illnesses. However, several studies have shown that a large proportion of the mortality (approximately 30 % for intubated patients) is directly attributable to the pneumonia<sup>17</sup>. VAP caused by antibiotic-resistant bacteria was associated more closely with excess hospital mortality<sup>10</sup>.

In addition to increasing mortality, nosocomial pneumonia has an important economic impact<sup>2</sup>. Intubated ICU patients require mechanical ventilation for 18 to 22 more days. They stay 10 to 13 days longer in the hospital<sup>17</sup>. In our study, patients with pneumonia stay on average 11 day longer in ICU. It is estimated in USA that healthcare providers in DRG system lose \$ 5800 per case of nosocomial pneumonia because of uncompensated extra costs<sup>3</sup>.

### Pathophysiology

Soon after admission, hospital-acquired bacteria appear in gastric secretions, the oropharynx, and the endotracheal tube<sup>15</sup>. Nasogastric intubation and supine body position allow bacteria-laden secretions to reflux into the endotracheal tube. These colonizing bacteria usually come from the patients themselves rather than from the mechanical ventilator.

Usual community pathogens such *Streptococcus pneumoniae*, *Haemophilus influenzae*, methicillin-sensitive *Staphylococcus aureus*, *Moraxella catarrhalis* may be responsible for early onset nosocomial pneumonia, multiresistant Gram-negative bacilli (*Pseudomonas*, *Enterobacteriaceae*), Gram-positive cocci (MRSA) or fungi are responsible for late onset nosocomial pneumonia.

### Definition and diagnosis of nosocomial pneumonia

Nosocomial pneumonia (NP) is difficult to define. It may be defined as an infection of lung parenchyma that was neither present nor incubating at the time of hospital admission. The criteria for nosocomial pneumonia diagnosis are clinical and include fever, cough, purulent sputum, in combination with radiological evidence of a new or progressive pulmonary infiltrate, a suggestive Gram's stain, and positive cultures of sputum, tracheal aspirate, pleural fluid, or blood. Although clinical criteria together with cultures of tracheal specimens may be sensitive for bacterial pathogens, they are not specific, especially in patients with artificial ventilation. Conversely, positive blood or pleural fluid cultures have very low sensitivity but are generally quite specific for nosocomial pneumonia<sup>13</sup>.

Much of misdiagnosis of VAP arises from the inaccuracy of traditional diagnostic criteria. In the previously healthy outpatient the findings of fever, leukocytosis, purulent respiratory secretions, and new radiographic lung infiltrates have identified pneumonia well<sup>18</sup>. However, in the long-term intubated critically ill patient, purulent lower respiratory secretions occur commonly. Radiographic infiltrates may represent for example atelectasis, pulmonary edema, or post-operative changes. In one study, the positive predictive value of a chest radiograph done in supine position was only 35 % for pneumonia in ICU patients<sup>11</sup>. No radiological signs successfully predicted pneumonia if the ARDS was present<sup>19</sup>.

Important part of the diagnosis of VAP is microbiological examination. Most investigations have focused on quantitative cultures. The methods to obtain samples from the lower respiratory tract range from simple endotracheal aspiration to more invasive bronchoscopic procedures, such as protected aspiration, brushing or bronchoalveolar lavage (BAL). Endotracheal aspiration is most commonly used, but it is the method with the greatest degree of contamination by upper respiratory flora. The specificity of endotracheal aspirates is only 30 to 60 % (ref.<sup>16</sup>). In most studies, protected catheter aspirate and protected

specimen brush have shown much greater specificity and sensitivity than endotracheal aspiration (60–100 %). The sensitivity of BAL is 80–100 %, probably because of the large area of lung sampled, the specificity is comparable with protected catheter aspiration or brushing. BAL provides the most accurate information for the identification of pneumonia prevalence in ICU<sup>4</sup>. A strategy based on bronchoscopy and BAL by direct examination generally leads to a rapid and appropriate treatment of nosocomial pneumonia in ventilated patients<sup>14</sup>. On the other hand, three studies have found no improvement in survival for patients with VAP diagnosed clinically compared with the use of bronchoscopically obtained lower airway cultures using bronchoalveolar lavage or protected specimen brush samples<sup>10</sup>.

### Risk factors

Many aspects of a patient's health status may predispose him or her to nosocomial pneumonia. These include old age, poor nutrition, chronic diseases such as chronic obstructive pulmonary disease and neuromuscular disease. Acute changes in health, such as decreased consciousness, impaired airway reflexes, aspiration, injury, particularly to the head or chest, may also increase risk of pneumonia. Investigators have identified several therapeutic measures as important risk factors for nosocomial pneumonia – endotracheal intubation (particularly performed in emergency), long-term mechanical ventilation, thoracic and/or upper abdominal surgery, nasogastric tube placement, recumbent position of the patient, treating patients with antacids or H2 receptor antagonists, antibiotics. Intensivists cannot change patient's underlying illnesses; however, they may help prevent more severe infections by decreasing unnecessary antibiotic use<sup>17</sup>.

### Preventive measures

Education of healthcare workers is essential part of the control program<sup>13</sup>.

Body position – semirecumbent position may reduce aspiration of oropharyngeal secretions.

Oral intubation has been shown to decrease the incidence of VAP and hospital mortality compared with nasal intubation<sup>7</sup>.

Reducing the duration of tracheal intubation has been associated with lower rates of VAP.

Subglottic secretion drainage may reduce the incidence of nosocomial pneumonia.

New techniques are undergoing development to prevent biofilm formation on endotracheal tubes, which have been implicated in the pathogenesis of VAP<sup>1</sup>.

Changing ventilator circuits – not every day but in 3- to 7-day intervals. Stress ulcer prophylaxis – agents that do not raise gastric pH are advocated (sucralfate).

Selective decontamination of digestive tract (SDD) is matter of discussion. Some investigators have reported an increase in highly antibiotic resistant Gram-negative bacteria, others have noted greater patient colonization with Gram-positive cocci<sup>17</sup>.

### Antibiotic treatment

The optimal antibiotic treatment of VAP is unknown. In general, when a decision is made to treat VAP, antibiotics with demonstrable *in vitro* activity against the causative bacteria should be used. Unnecessary antibiotic treatment should be avoided to limit the emergence of resistance<sup>10</sup>. Ibrahim *et al.* demonstrated that 7 days of antibiotic treatment is as effective as 14 days of treatment in patients with VAP<sup>8</sup>. Several clinical studies have found that anaerobic bacteria are un-

common in the lower airway of patients with VAP or aspiration pneumonia occurring in the hospital setting. This may explain the lack of greater efficacy among antibiotic regimens with intrinsic anaerobic activity for patients with VAP<sup>10, 17</sup>.

## Conclusion

Nosocomial pneumonia remains a challenge for intensivists and infection-control team. Many of the factors that increase patient's risk of pneumonia are unalterable (underlying diseases, age, essential medical procedures), but some of them are preventable. Knowing the risk factors for nosocomial pneumonia may help intensivists prevent future cases. It is possible to reduce pneumonia rates by educating health-care personnel about the importance of such simple measures as hand washing or body position. Clinicians practicing in the intensive care unit should support the development and routine implementation of interventions aimed at preventing VAP and encouraging rational use of antibiotic therapy<sup>10, 17</sup>.

## References

- Adair CG, Gorman SP, Feron BM et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. *Intensive Care Med* 1999; 25: 1072–1076.
- Artigas AT, Dronda SB, Vallés EC et al. Risk factors for nosocomial pneumonia in critically ill trauma patients. *Crit Care Med* 2001; 2: 304–309.
- Boyce JM, Potter-Bynone G, Dziobek L et al. Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. *Arch Intern Med* 1991; 151: 1109–1114.
- Cook DJ, Brun-Buisson C, Guyatt GH et al. Evaluation of new diagnostic technologies: bronchoalveolar lavage and the diagnosis of ventilator-associated pneumonia. *Critical Care Med* 1994; 22: 1314–1322.
- Fagon J-Y, Chastre J, Domart Y et al. Nosocomial pneumonia receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. *Am Rev Respir Dis* 1989; 139: 877–884.
- George DL. Epidemiology of nosocomial ventilator-associated pneumonia. *Infect Control Hosp Epidemiol* 1993; 14: 163–169.
- Holzappel L, Chastang C, Demingon G et al. A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients: Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1999; 159: 695–701.
- Ibrahim EH, Kollef MH. Improving antibiotic utilization for the treatment of ventilator-associated pneumonia using a clinical guideline. *Chest* 2000; 118: 112 S.
- Keita-Perse O, Gaynes RP. Surveillance and its impact. In: Jarvis WR (ed). *Lung Biology in Health and Disease – Volume 150 – Nosocomial Pneumonia*. Marcel Dekker, Inc., New York 2000: 39–52.
- Kollef MH. What's new about ventilator-associated pneumonia. *Anaesthesiology* 2001; 94: 551–553.
- Lefcoe MS, Fox GA, Leasa DJ et al. Accuracy of portable chest radiography in the critical care setting. Diagnosis of pneumonia based on quantitative cultures obtained from protected brush catheter. *Chest* 1994; 105: 885–887.
- Ševčík P. Nozokomiální infekce v intenzivní medicíně. Habilitační práce. (Nosocomial infections in intensive care medicine. Dissertation). Masaryk University, Brno 1996: 94 pp.
- Tablan OC, Anderson LJ, Arden NH et al. Guideline for prevention of nosocomial infection. *Respir Care* 1994; 39:1191–1236.
- Timsit JF, Cheval C, Gachot B et al. Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia. *Intensive Care Med* 2001; 27: 640–647.
- Torres A, el-Ebiary M, González J et al. Gastric and pharyngeal flora in nosocomial pneumonia acquired during mechanical ventilation. *Am Rev Respir Dis* 1993; 148: 352–357.
- Torres A, Martos A, de la Bellacasa JP et al. Specificity of endotracheal aspiration, protected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. *Am Rev Respir Dis* 1993; 147: 952–957.

- Wiblin RT. Nosocomial pneumonia. In: Wenzel RP (ed). *Prevention and Control of Nosocomial Infections*. 3<sup>rd</sup> ed. Williams & Wilkins, Baltimore 1997: 807–819.
- Wollschlaeger CM, Khan FA, Khan A. Utility of radiography and clinical features in the diagnosis of community-acquired pneumonia. *Clin Chest Med* 1987; 8: 393–404.
- Wunderink RG, Woldenberg LS, Zeiss J et al. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. *Chest* 1992; 101: 458–463.

## 14

### FREQUENCY OF GRAMNEGATIVE BACTERIAL PATHOGENS IN BLOODSTREAM INFECTIONS IN THE CZECH REPUBLIC

Kolář M., Láta T., Marek O., Čermák P., Berta E., Blahut L.

*Department of Microbiology, University Hospital, Olomouc  
Department of Anesthesiology and Intensive Care Medicine, University Hospital, Olomouc, Czech Republic*

## Aim of the study

To determine the incidence of gramnegative bacterial pathogens in bloodstream infections in the Czech Republic.

## Material and methods

The study was organized in twelve hospitals in the Czech Republic in the months June – October, 2001. The criteria for the participation were the location of facilities and their size, so that the study covered the whole area of the country and equal numbers of small and big (university type) hospitals were involved. The length of study was five months. Maximum number of strains from one facility was one hundred successive gramnegative isolates from blood, corresponding to the criteria of choice.

## Results

During the period of observation, 831 bacterial strains (i. e. clinical cases) were registered (one strain = one patient with unequivocal bacterial bloodstream infection). In the total, 584 strains (70 %) were isolated in the group of big hospitals, and 247 strains (30 %) in the small hospitals. The most frequently, the strains of *Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* were identified as etiologic agents (66 %). The incidence of other bacterial strains was lower than 7 %. A statistically significant difference ( $p = 0.05$ ) was registered at *Escherichia coli* strains, the frequency of which was higher by 10 % in the group of small hospitals. As for *Acinetobacter sp.* strains, their incidence was lower in the small facilities. *Stenotrophomonas maltophilia* strains were isolated in big hospitals only.

## Conclusions

In spite of the increasing incidence of grampositive bacteria (staphylococci and enterococci), gramnegative bacteria are to be considered as very dangerous pathogens causing bloodstream infections, namely in relation to the possibility of endotoxin reaction, more frequent development of sepsis and higher mortality of patients. The results show that among the gramnegative bacterial pathogens, the strains of

*Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* were the most frequently identified ones.

Working Group (other coworkers): D. Burgetová, M. Dovalová, B. Heini-geová, B. Horová, E. Chmelařová, H. Křemečková, Y. Lovečková, O. Nyč, V. Petkov, B. Prokūpková, M. Štolbová

## 15

### BACTERIAL AND MYCOTIC INFECTIONS AFTER OESOPHAGUS CARCINOMA OPERATIONS

Sobanska D., Stryjski A., Mazurek J., Stryjska M.

*Department of Anesthesiology and Intensive Care of Greatpoland  
Cancer Center Poznan, Poland  
Railway Outpatient Clinic Poznan, Poland*

#### Introduction

Esophageal carcinoma belongs to the diseases of predominantly unfavourable prognosis. The first symptoms such as difficult or painful swallowing appear relatively late, the disease being already in advanced stage. This neoplasm occurs in elderly patients, tobacco smokers and people with heavy alcohol intake. Alcohol and nicotine are common risk factors which contribute to postoperative complications.

#### The purpose of the study

The aim of the study is to assess an effectiveness of prophylaxis as well as antibacterial and antimycotic treatments in patients of ITD subjected to oesophagus carcinoma operations.

#### The subjects studied

The subjects studied were 31 patients aged 45–76 (59 on the average, 5 female and 26 male) after oesophagus carcinoma operation, treated in ITD of Greatpoland Cancer Center. The ASA of these patients was classified as III. As an indicator of a nourishment condition an albumine content was taken, the standard value of which is  $>3.5$ , as well as total number of lymphocyte (cll) per  $1 \text{ mm}^3$  of peripheral blood (standard  $> 1500 \text{ mm}^3$ ). For every patient bacteriological and mycological assays were made by culture method and all were administered preventive antibiotic: Metronidasol 0.5 g 3 times a day for 3 days, Biotaxym 1.0 g 4 times a day or Netromycyne 0.3 g 1 time a day. To patients with clinical or laboratory symptoms of mycosis Diflucan 0.2 g 1 time a day was given.

#### Results

In 18 (58 %) patients after operative procedures a decrease of the albumine content was observed. In 9 (19 %) persons *Candida albicans* was cultured (also in these with bacterial infections). 12 patients (39 %) revealed bacterial infection and in their bacteriological cultures *Escheria coli*, *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Staphylococcus auricularis*, *Staphylococcus warneri*, *Staphylococcus haemolyticus*, *Haemophilus parainfluenzae*, *Streptococcus pyogenes*, *Enterobacter cloacae*, *Streptococcus faecalis* and *Streptococcus aga-*

*lactine* were found. Occurrence of the infection contributed to eventration in 1 (3 %) patient. In 3 (9 %) patients pneumonia was recognized in spite of intensive motor and respiratory rehabilitation.

#### Conclusions

The patients subjected to operational treatment of esophageal carcinoma showed a decreased lymphocyte number (48 %) and albumine content (58 %). These developments facilitated the occurrence of mycotic (19 %) and bacterial (39 %) infections despite the antibiotic prophylaxis and antimycotic treatment.

## 16

### CAN BIOIMPEDANCE MEASUREMENT OF EXTRACELLULAR WATER HELP TO ESTIMATE THE DISTRIBUTION VOLUME OF ANTIBIOTICS IN SEVERE CAPILLARY LEAK SYNDROME?

Balík M.<sup>1</sup>, Kolář M.<sup>1</sup>, Šedivý J.<sup>2</sup>, Hendl A.<sup>3</sup>

<sup>1</sup> *Department of Anaesthesiology and Intensive Care, University Hospital Královské Vinohrady, Šrobárova 50, Prague 10, 100 34, Czech Republic, balik@fnkv.cz*

<sup>2</sup> *Department of Clinical Pharmacology, Institute for Clinical and Experimental Medicine, Prague*

<sup>3</sup> *Department of Kinesiology, Charles University, Faculty of Physical Education and Sport, Prague*

#### Introduction

The authors were looking for correlation between distribution volume of the antibiotics assessed from the pharmacokinetic model and bioimpedance measured extracellular water (ECW) in septic mechanically ventilated patients with capillary leak syndrome.

#### Methods

13 patients were treated with vancomycine (van) and 12 with netilmycine (net) more than 48 h. The initial doses of the antibiotics were corrected according to the renal functions. Patients with presence of ascites, pleural effusion or treated with renal replacement therapy were excluded. Serum concentrations were measured before, 1 h and 4 h after the antibiotic infusion. Fast distribution compartment (V<sub>1</sub>), slow distribution compartment (V<sub>d</sub>-area) and total body clearance (Cl) were measured. At the moment of the drawing of the third blood sample the total body multi-frequency bioimpedance analysis at 1, 5, 50 and 100 kHz was performed, the volume of ECW, TBW and ECW/TBW ratio were calculated. The protocol was repeated after 24 h.

#### Results

Significant relationship was revealed for V<sub>d</sub>-area of van and ECW/TBW ( $r = 0.73$ ,  $p < 0.0001$ ). Cl of van correlated with ECW ( $r = 0.56$ ,  $p < 0.003$ ) as well as with ECW/TBW ( $r = 0.60$ ,  $p < 0.002$ ). V<sub>d</sub>-area of net correlated with ECW/TBW ( $r = 0.41$ ,  $p < 0.05$ ). V<sub>1</sub> of net correlated with ECW ( $r = 0.41$ ,  $p < 0.05$ ) and with ECW/TBW ( $r = 0.46$ ,  $p < 0.03$ ). In 11 patients (84.6 %) on van and in 7 patients on net (58.3 %) the toxic levels were reached requiring reduction of the dosage.



## Conclusion

Bioimpedance measurement can help to estimate the increased distribution volume and clearance in particular of vancomycin in severe sepsis with capillary leak syndrome. The correlation between the ratio ECW/TBW and Vd-area and CI of van and between ECW/TBW and V1 of net represents probably better penetration of van into the tissues in comparison to net. The antibiotics are distributed poorly into the extravascular space and routine treatment may lead to significant overdose. The next steps should be directed towards monitoring of the tissue level of the antibiotics.

## Reference

1. Patel RV, Peterson EL, Silverman N, Zarowitz BJ: Estimation of total body and extracellular water in post-coronary artery bypass graft surgical patients using single and multiple frequency bioimpedance, *Crit Care Med*, 1996, 24: 1824–8.

17

## HEMORRHAGIC FEVER WITH RENAL SYNDROME IN THE DOLENJSKA REGION OF SLOVENIA – A 10 YEAR SURVEY

Kapš R.<sup>1</sup>, Starič S.<sup>1</sup>, Furlan P.<sup>1</sup>, Avšič-Županc T.<sup>2</sup>

- <sup>1</sup> General Hospital Novo mesto, Šmihelska 1, 8000 Novo mesto, Slovenia
- <sup>2</sup> Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana, Slovenia

Authors describe the investigation of clinical findings for larger series of patients with hemorrhagic fever with renal syndrome (HFRS) who were infected with Dobrava virus. From 1985 to 1995, 38 patients with serologically confirmed HFRS were hospitalised at the regional hospital in Novo mesto in the Dolenjska region of Slovenia. On the basis of results of serological examination, 24 patients had Dobrava virus infection, and 14 patients had Puumala virus infection. Complete clinical data were available for 31 patients. Eleven patients underwent hemodialysis for treatment of acute oliguric or anuric renal failure. Four patients, all infected by Dobrava virus, had signs of shock and severe bleeding. Three severely ill Dobrava virus-infected patients died of hemorrhagic complications. We have demonstrated that Dobrava and Puumala virus coexist in a single region of endemicity and are capable of causing HFRS with significant differences in severity.

18

## CRYPTOCOCCUS NEOFORMANS ON ICU – CASE REPORTS

Zvoníček V.<sup>1</sup>, Ondrovčík P.<sup>1</sup>, Sas I.<sup>1</sup>, Novák I.<sup>2</sup>, Šrámek V.<sup>1</sup>

- <sup>1</sup> Clinic of Anaesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czech Republic.
- <sup>2</sup> ICU, Medical Department I, University Hospital Pilsen, Czech Republic

Cryptococcal infection affects usually immunocompromised patients<sup>1–3</sup>.

## Methods

We reviewed medical records of 3 patients with cryptococcal meningoencephalitis hospitalized during 2000–2001 in 2 different ICUs.

1. Immunocompromised patient 7 weeks after uncomplicated liver transplantation.
2. Nonimmunocompromised patient.
3. Meningoencephalitis after penetrating head trauma.

## Results

Lung as the principal route of entry of infection and CNS dissemination was documented in case 2. In case 3 direct entry of cryptococcus into CNS tissue was suspected.

Clinical picture of infection varied in our cases, meningeal symptomatology was always present, in two cases changes in gray matter on brain MR images were found. In two patients the disease was diagnosed by microscopic analysis of CSF, in one cryptococcal antigen in CSF was detected. The diagnosis of infection was revealed relatively late in the course of disease and this may explain the fatal outcome in 2 cases.

## Conclusion

Cryptococcal meningoencephalitis may occur in immune competent patients. Direct microscopic detection of cryptococcus in CSF may help to reveal the cryptococcal meningitis early in the course of disease and may potentially improve the outcome.

## References

1. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. *Clin Infect Dis*. 2000 Apr; 30(4): 710–8.
2. Singh N, Husain S. Infections of the central nervous system in transplant recipients. *Transpl Infect Dis*. 2000 Sep; 2(3): 101–11.
3. The AIDS Patient. In: Cunha BA, Infectious diseases in critical care medicine. New York: Marcel Dekker, Inc. 1998: 617–618.

## SECTION: METABOLISM

19

### ENERGY METABOLISM IN CRITICALLY ILL PATIENTS: LACTATE IS A MAJOR SUBSTRATE

Leverve X.

*Laboratoire de Bioénergetique Fondamentale et Appliquée, Université Joseph Fourier, Grenoble, France, Xavier.Leverve@ujf-grenoble.fr*

Lactic acid, which is mostly present in biological fluids as its dissociated cationic form (lactate<sup>-</sup>), is widely distributed among the pathways involved in the intermediary metabolism of living systems. While, from the physiologist point of view, it is one of the most crucial intermediate of carbohydrate and non-essential aminoacid metabolisms, for most physicians it is merely considered as a marker of bad prognosis significantly related to high mortality rate in acutely ill patients. Although several works in the literature have shown the safety, and sometimes the usefulness, of administration of exogenous lactate, it is very often considered as a highly “toxic” compound. Even in sport physiology the “lactic threshold” as marker demonstrating a sharp switch from aerobic to anaerobic metabolism is very popular and lactate increase is often believed as the cause of side effects observed after exhausting exercise. Of course it is clear that high lactate infusion is actually safe, even in very sick patients, it is indeed a metabolite like glucose, aminoacids, fatty acids or ketones. Nevertheless, lactate is often intuitively considered as “*the devil in metabolism*” by many physicians or scientists, this resulting probably from confusion between cause and consequence.

Lactate is alternatively consumed and produced in the body, as it is the case for every intermediate involved through the vast circuit of the intercellular and interorgan metabolic interplay. This notion is actually the basis of the concept of “*milieu intérieur*” as described by the French physiologist Claude Bernard more than a century ago. Hence, when released from one cell, lactate can be considered as a wastage product, but when taken up by another cell, it becomes a very useful substrate. In fact, the extent of lactate turnover *in vivo* in man is of similar order of magnitude than that of glucose, alanine or glutamine, *i. e.* it is amongst the highest recycling rates in intermediary metabolism. Therefore, the main question remains as to understand precisely the role of lactate as one of the main actors of the energetic homeostasis in both physiological and pathological conditions.

Lactate is actually a metabolic “*cul de sac*” because it is metabolized by one single enzyme, lactate dehydrogenase. But, since the first description many decades ago by Cori, of an interorgan glucose-lactate recycling, it is clear that lactate has a real physiological meaning. The role energetic shuttle is classically considered between organs responsible for a net lactate release and the liver. Every organ is able to release lactate since all cells do contain the different enzymes allowing the conversion of glucose into lactate, pancreatic  $\beta$ -islets is an exceptional since they are deficient in lactate dehydrogenase. However quantitatively, muscle and red blood cells are probably the main tissues in physiological conditions other organs, as the lung for instance, could be of importance in pathological states. If the liver is often regarded as main organ for lactate disposal because of its prominent role in the gluconeogenesis, the kidney, although recognized for a long time as gluconeogenic organ as well, has been probably underestimated. Moreover, it was recently shown that even during the anhe-

patic phase occurring during liver transplantation, plasma lactate was maintained at a higher but constant value indicating that liver is not mandatory for lactate clearance.

Besides its role as redox and carbon shuttle between organs involved in the global energy metabolism, it appears also that lactate possesses also some specific effects, probably related to precise physiological functions. Different interesting works have emphasized a role of lactate in the brain as a protective substrate not only in animal studies but also in humans. The description of coordinated glucose and lactate metabolisms between neurons and astrocytes in relation to neuron excitation has revealed a new and fascinating side of brain lactate metabolism. Concerning heart metabolism and cardiovascular function, it has been recently shown that lactate improves cardiac function in a model of hemorrhagic shock and sodium-lactate infusion in humans increases cardiac output not only in postoperative patients, but also in cardiogenic shock.

Hence, our view of lactate will probably change in the near future, this metabolite instead of being only considered as a marker of severity in critically ill patients might be used as a substrate for specific purposes.

20

### EARLY ENTERAL NUTRITION IN CRITICALLY ILL PATIENTS: WHERE IS A BENEFIT?

Novák I., Rokyta R. jr., Matějovič M., Kroužecký A.

*ICU, Medical Department I, University Hospital Pilsen, Czech Republic, novaki@fnplzen.cz*

**Key words:** Nutrition / Enteral nutrition / Intensive care / Critical illness

#### Abstract

Enteral nutrition (EN) is preferred mode of feeding in critically ill patients unless obvious contraindications such as ileus or active gastrointestinal bleeding are present. Severe protein-calorie malnutrition, which develops very quickly, is a major problem in many intensive care (ICU) patients, due to the increased catabolic state often associated with acute severe illness. Early and complete nutritional support is thus an important part of patient's management. EN has gained considerable popularity, due to its favourable and protective effects on the digestive tract, its lower cost and decreased morbidity compared to parenteral nutrition. However, clinicians caring for ICU patients are often faced with contradictory data and difficult decision-making when having to determine the optimal timing and modalities of EEN administration, estimation of patient requirements and choice of formulas. Especially the timing of initiation and the dose of EEN in circulatory compromised patients is a matter of controversy.

#### Introduction

Severe protein-calorie malnutrition, which develops very quickly, is a major problem in many intensive care (ICU) patients, due to the increased catabolic state often associated with acute severe illness. Hypermetabolic, critically ill patients rapidly mobilize lean tissue, re-

leasing large amount of amino acids into the circulating pool for distribution to the liver, intestine, bone marrow, and injured or healing tissues. Enteral nutrition (EN) is the currently recommended technique of artificial nutrition in critically ill patients. EN has many advantages over parenteral nutrition such as maintenance of gut mucosal barrier function<sup>1</sup>, reduction of incidence of nosocomial infection<sup>2</sup>, better tolerance to carbohydrates, and reduced systemic inflammatory response (SIRS) to inflammation or infection<sup>3</sup>. Hepatosplanchnic region (gastrointestinal tract and liver) plays pivotal role in the pathophysiology and pathogenesis of shock states. EN activates a series of physiological responses involving the digestive, cardiovascular, respiratory and immune systems. Progress in intensive care has allowed prolonged survival of patients suffering from protracted catabolic disease such as sustained sepsis and multiple organ dysfunction (MODS). Hence, severe malnutrition, slowing down recovery and increasing ICU and hospital stay, is often present in such patients<sup>4</sup>. A growing body of evidence suggests that, in the presence of a functional gut, nutrition should be administered by the enteral route whenever possible (concept of early enteral nutrition is to start during 48 hours after admission). Indeed, it is becoming increasingly clear that the consequences of enteral nutrition (EN) go beyond the supply of energy and proteins to the body, other beneficial effects including modulation of the host's immune response and the provision of fuel and protein to maintain gut integrity and possibly prevent bacterial translocation<sup>5</sup>. In healthy subjects the digestion and absorption of nutrients induce typical hemodynamic changes, consisting of an increase in both cardiac output and mesenteric blood flow<sup>6, 7</sup>. The timing of initiation and the dose of EEN in circulatory compromised patients is a matter of controversy<sup>8</sup>. In terminal cardiac failure the decreased cardiac output leads to splanchnic hypoperfusion and malnutrition, the so-called cardiac cachexia<sup>9</sup>. The purpose of this review is to focus on the assessment of the early systemic and splanchnic hemodynamic and metabolic changes in conjunction with EEN.

### Rationale for enteral nutrition

Nutritional support for critically ill patients should be considered as an integral component of treatment.

#### **Decisive factors for commencing of nutritional support**

1. Route of feeding
  2. Timing
  3. Composition of feeding
  4. Amount of feeding
  5. The way of delivery (continuous vs. bolus)
- The concept, that early enteral feeding should be preferred, whenever possible is gaining growing acceptance<sup>10</sup>. During last two decades nutritional support has emerged as a vital component of the management of critically patients.

#### **The hazards of parenteral nutrition compared to enteral nutrition<sup>11, 12</sup>**

1. Immune compromise
2. Increased rate of infections
3. Overfeeding
4. Increase length of stay
5. Costs

Indeed, complete bypass of the gut leads to adverse structural and functional modifications of the mucosal barrier, which can be reversed by enteral feeding<sup>13</sup>. This favourable effect stems from factors such as the stimulation of epithelial cell metabolism by direct contact with nutrients, increased in mucosal blood flow, and secretion of enterotrophic

gastrointestinal hormones such as gastrin and enteroglucagon<sup>14</sup>. Preventing mucosal atrophy is certainly an important goal, as animal studies indicate that the associated increase in gut permeability can induce translocation of bacteria from the gut lumen to the circulation<sup>15</sup>, although there is no evident and convincing proof of such an occurrence in critically ill patients<sup>16</sup>. Many critically ill, injured, and post-operative patients develop gastroparesis with abnormalities in intestinal motility. This phenomenon is responsible for limitation of ability to tolerate gastric feeding. However, it is now recognized that small bowel function and the ability to absorb nutrients remains intact, despite critical illness and the presence of gastroparesis<sup>8</sup>. In patients with intolerance of gastric feeding is possible to introduce the post pyloric feeding. It has been suggested that EEN may reduce septic and non-septic complications<sup>10</sup>.

### Failure of gut barrier

Failure of the gut barrier function after injury may result in increased intestinal permeability with the risk of bacterial and endotoxin translocation as has been showed in both animal and human studies. An increase in intestinal permeability has been shown in patients with severe injuries and burns, ischemia – reperfusion, after cardiac surgery, and in those receiving only parenteral nutrition. EEN decreased intestinal permeability in some groups of critically ill. Pape studied gut permeability in multiply injured patients with respect to the development of multiple organ failure (MOF). Two groups were defined according to MOF score (threshold 10 points) as to whether MOF developed (group 1; n = 11, four deaths) or did not (group 2; n = 21, no death). Gut permeability was determined from the ratio of urinary excretion of enterally administered lactulose and mannitol. Serum elastase concentrations were also determined. Gut permeability was abnormal during the entire study. Severe injury led to increased intestinal permeability, which was related to a systemic inflammatory response<sup>17</sup>. Roumen has shown in patients after elective or emergency aortic aneurysm repair a significant increase in intestinal permeability by a dual sugar absorption test, with lactulose and mannitol as markers. It has been suggested that this is mainly due to reperfusion injury rather than the ischemic period of the intestine itself<sup>18</sup>. Hadfield reported the study comparing the effects of TPN and EN on GIT function. Twenty-four critically ill patients were randomly allocated to receive TPN or EN. The ratio between urinary recovery of lactulose and L-rhamnose (L/R) was used to measure GIT mucosal permeability. In the EN group, the L/R ratio displayed a progressive, significant fall. In the TPN group, no significant change in the L/R ratio occurred. This study demonstrated that GIT dysfunction is evident in critically ill patients and suggested that loss of GIT mucosal integrity is reversed by the institution of EN<sup>19</sup>. As Fink pointed out that a variety of pre-mucosal and post-mucosal factors might influence the urinary excretion of an enterally administered probe (e. g. intestinal transit time, glomerular filtration rate). Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients<sup>20</sup>. Adams has proven that hemorrhagic shock-induced lung injury depends on gut injury and mesenteric lymph appears to be the route by which gut-derived toxic factors exit the gut to cause lung injury<sup>21</sup>. Endothelial cell injury by polymorphonuclear neutrophils respiratory burst after trauma and hemorrhagic shock predisposes subjects to acute respiratory distress syndrome and multiple organ failure. In animal model mesenteric lymph injured endothelial cell and lymph duct ligation before trauma or hemorrhagic shock prevented pulmonary injury. Mesenteric lymph mediates post shock PMN dysfunction<sup>22</sup>.

## Translocation in human subjects

Translocation as a pathogenic mechanism is well established, but still the number of publications actually demonstrating this mechanism in human subjects is few. The classic publication demonstrates a prevalence of 5 % in patients without distal intestinal obstruction or inflammatory bowel disease undergoing explorative laparotomy<sup>23</sup>. A relationship is also described between translocation, in patients undergoing laparotomy, and the risk of developing postoperative complications<sup>24</sup>. In patients with distal intestinal obstruction or with inflammatory bowel disease the incidence is higher<sup>23, 25</sup>. In neonates the immature intestine probably allows for translocation. At least, there is evidence that translocation and septicemia occurs in infants requiring long-term parenteral nutrition<sup>26</sup>. Also in intestinal transplantation there are a number of risk factors involved, which makes translocation a highly likely event. In a report of intestinal transplantation in children similar bacteria are reported in sequel cultures as well as in blood and liver biopsies<sup>27</sup>. Patients with liver insufficiency also show signs of bacterial translocation, the extent of which correlates with the degree of cirrhosis according to the Child-Pugh classification<sup>28</sup>.

## Translocation and nutrition

There is a considerable amount of data from humans showing that patients who could not be provided nutrition by the enteral route have more organ failures in the intensive care unit, have a less favourable prognosis and have a higher frequency of septicemia, in particular involving bacterial species from the intestinal tract. However, there is very little evidence that this is connected with translocation or bacterial species in humans. When interpreting studies comparing enteral and parenteral nutrition one must keep in mind that failure to provide nutrition by the enteral route in many cases is related to an impaired intestinal function due to the underlying disease. Therefore, in many studies comparing enteral and parenteral nutrition, the underlying disease may contribute, to a substantial degree, to the prevalence of translocation. There is considerable evidence that bacteria of enteral origin are present in the blood, but their way into the blood is not well described. Furthermore, as pointed out in two recent overviews the evidence that parenteral nutrition in itself is associated with bacterial translocation in man is weak<sup>29, 30</sup>. Animal studies have shown that long-term total parenteral nutrition leads to intestinal mucosal atrophy, however, this contrasts with human studies in which this relationship is less clear<sup>23, 32</sup>. Furthermore, there is very little documentation from humans to support the hypothesis that enteral nutrition inhibits translocation. Also, animal data are not convincing. The high incidence of sepsis from gut origin in premature neonates is suggested to be reduced by parenteral or enteral nutrition containing a high concentration of glutamine<sup>33</sup>.

## Risk of early enteral nutrition

Controversy persists as to the optimal means of providing nutritional support. The aim of MacFie's study was to compare enteral nutrition (EN) and parenteral nutrition (TPN) in terms of adequacy of nutritional intake, septic and no septic morbidity, and mortality. This was a prospective pragmatic study, whereby the route of delivery of nutritional support was determined by the attending clinician's assessment of gastrointestinal function. Patients considered to have inadequate gastrointestinal function were given TPN (group 1), while those deemed to have a functioning gastrointestinal tract received EN (group 2). Patients in whom there was reasonable doubt as to the adequacy of intestinal function were randomised to receive either TPN (group 3) or EN (group 4). A total of 562 patients were included in the study. Gastro-

intestinal function on entry into the study was considered inadequate in 267 patients who were given TPN (group 1) and adequate in 231 whom received EN (group 2). There was clinical uncertainty about the adequacy of gut function in 64 patients (11.4 %) who were randomised to receive either TPN (group 3, 32 patients) or EN (group 4, 32 patients). The incidence of inadequate nutritional intake was significantly higher in group 4 compared with group 3 (78 % versus 25 %). Complications related to the delivery system and other feed-related morbidity were significantly more frequent in both EN groups compared with the respective TPN groups. EN was associated with a higher overall mortality in both nonrandomised and randomised patients. There were no significant differences observed in the incidences of septic morbidity between patients receiving TPN and those given EN. EN is associated with a higher incidence of inadequate nutritional intake, complications related to the delivery system, and other feed-related morbidity than TPN. There is no evidence from this study to support a difference between the two modalities in terms of septic morbidity. Patients, in whom there is reasonable doubt as to the adequacy of gastrointestinal function, should be fed by the parenteral route<sup>29</sup>.

## EEN is contraindicated

### Absolute

1. Non functional gut: anatomic disruption, obstruction, gut ischemia, toxic megacolon
2. Generalized peritonitis
3. Severe shock states

### Relative

1. Expected short period of fast, except in severely injured patients
2. Abdominal distension during EN
3. Localised peritonitis, intraabdominal abscess, severe pancreatitis
4. Patients with terminal disease
5. Extremely short bowel (less than 30 cm)

There is clinical consensus that severe hemodynamic instability is a contraindication to EN, based on idea that feeding the hypoperfused gut might result in worsening of gut ischemia. The main weak point of this hypothesis is how to define hemodynamic instability. Revelly assessed the hemodynamic and metabolic adaptations to EN in patients with hemodynamic compromise. This prospective study compared fasted with continuous EN condition. Nine patients requiring hemodynamic support by catecholamines (dobutamine and/or norepinephrine) 1 day after cardiac surgery under cardiopulmonary bypass were enrolled. Isoenergetic EN via a postpyloric tube while catecholamine treatment remained constant. Baseline (fasted) condition was compared to continuous EN condition. The introduction of EN in these postoperative patients increased cardiac output and splanchnic blood flow, while the metabolic response indicated that nutrients were utilized. These preliminary results suggest that the hemodynamic response to early EN may be adequate after cardiac surgery even in patients requiring inotropes<sup>8</sup>. Rokytka studied the influence of low dose postpyloric EEN on hepatosplanchnic perfusion and energy metabolism in medical critically ill patients with severe sepsis and/or septic shock (8 mechanically ventilated). In our study was concluded that the initiation of low dose postpyloric EN in septic patients requiring low dose norepinephrine does not compromise hepatosplanchnic blood flow<sup>34</sup>. On the other side early high calorie enteral feeding might lead to a mismatch between oxygen delivery and oxygen consumption of the intestine. EN generates a dose and substrate dependent increase on intestinal oxygen consumption whereas overall organ perfusion is markedly diminished<sup>35</sup>.

Functional intestinal complaints occur frequently but generally respond to alteration of the infusion rate or tube feeding formula. Occasionally,

however, non-specific signs of intestinal disturbance progress to a syndrome of abdominal distension, hypotension, and hypovolemic shock resulting in extensive small bowel necrosis. Schunn has reported that small bowel necrosis is a rare but highly morbid complication associated with postoperative jejunal tube feeding<sup>36</sup>. Early high calorie enteral feeding might lead to a mismatch between oxygen delivery and oxygen consumption of the intestine. Kles tested the hypothesis in a rat model that delivery of enteral nutrients to the hypoperfused jejunum increases oxidative demand beyond that available, thereby exacerbating intestinal hypoxia. The results indicated that provision of metabolizable nutrients to the hypoperfused intestine exacerbates hypoxia and potentially leads to intestinal ischemia<sup>37</sup>. Tappenden proved in rat model that the provision of luminal nutrients exacerbates the loss of gastrointestinal barrier function during hypoxia<sup>38</sup>. Although early enteral nutrition is an important intervention after trauma, care must be taken to ensure adequate intestinal perfusion.

Nonocclusive bowel necrosis (NOBN) is a rare, but potentially fatal complication, related to EEN in acutely stressed patients. Marvin showed that NOBN developed in 0.3 % of trauma patients. Onset occurred in the second week in patients who have had a period of EN tolerance. Clinical findings resembled bacterial sepsis with tachycardia, fever, and leukocytosis. Gastrointestinal specific signs were not consistent or occurred late<sup>39</sup>. Gastric carbon dioxide tonometry may detect a vulnerable subgroup of patients<sup>40</sup>. There are 3 major components, which could explain aetiology of NOBN (fig. 1):

1. Metabolic stress
2. Dysmotility of intestine
3. Dysmicrobia with bacterial colonization




Fig. 1 Adapted by Marvin<sup>39</sup> with permission

## Methods to treat or prevent gut ischemia/reperfusion injury

The main task at the beginning of treatment is to reach hemodynamic stability and restore adequate perfusion on regional level as soon as possible. Microcirculatory recruitment is crucial for the fate of critically ill. The first step in the therapeutic management (volume resuscitation) is followed by ischemia/reperfusion injury. Mechanisms of injury are not so far fully explained. It has been proposed i. e. damage from oxygen free radicals, neutrophil-derived enzymes, platelet-activating factor, and protein kinase C and/or mucosal cell dysfunction caused by cytokines or lipid mediators. Treatments tend to focus on minimizing injury by reducing the duration or severity of the ischemic event. There are two principle routes how to treat the effects of ischemia/reperfusion injury:

## Intravenous route

Intravenous treatment is familiar for intensivists. Pyruvate has been shown to be protective in numerous in vitro and in vivo models of oxidant-mediated cellular or organ system injury. In an effort to take advantage of the ability of pyruvate to scavenge reactive oxygen species while avoiding the problems associated with the instability of pyruvate in solution. Sims has used a simple derivative, ethyl pyruvate and assessed in animal model if ethylpyruvate would be protective. Treatment of rats with either pyruvate solution or ethylpyruvate solution significantly ameliorated the development of intestinal mucosal hyperpermeability during the reperfusion. Treatment with ethyl pyruvate solution also significantly decreased the extent of histological mucosal damage after mesenteric reperfusion<sup>41</sup>. Additional approaches have included hypothermia, prostaglandin E and pharmacological modulation of blood flow by using diltiazem, nitric oxide donors (arginine), or angiotensin-converting enzyme inhibition. Sympathetic and angiotensinergic activation reduce splanchnic oxygen delivery during hypovolemia, which may lead to failure of the intestinal mucosal barrier. Hypovolemia preferentially increased mesenteric sympathetic outflow and caused vigorous angiotensinergic activation. Aneman demonstrated that treatment with enalaprilate prevented the reduction of mesenteric oxygenation and duodenal mucosal alkaline secretion in pig model<sup>42</sup>. Von Ritter has showed the effects of several free radical scavengers and antioxidant enzymes on neutrophil-mediated changes in mucosal permeability. Manganese-loaded desferrioxamine (a superoxide dismutase mimetic), PZ51 (a glutathione peroxidase analogue), desferrioxamine (an iron chelator), or dimethylsulfoxide (a hydroxyl radical scavenger) significantly attenuated mucosal damage. The results of the study indicated that neutrophilic oxidants are responsible for a major portion of the mucosal permeability changes<sup>43</sup>. Xia has studied superoxide dismutase (a free-oxygen radical scavenger), leupeptin (a protease inhibitor) and verapamil to evaluate their efficacy in maintaining cellular integrity in the gut of thermally burned rats whose fluid resuscitation had been delayed. Data indicated that intestinal reperfusion injury in burned rats could be effectively modulated with superoxide dismutase or leupeptin therapy<sup>44</sup>. Intravenous administration of a total parenteral nutrition (TPN) solution results in small intestinal gut-associated lymphoid tissue (GALT) atrophy, lowers small intestinal immunoglobulin A (IgA) levels, and impairs upper respiratory tract secretory IgA-mediated mucosal immunity. Kudsk demonstrated that addition of 2 % glutamine, a specific lymphocyte fuel, prevents deleterious effects of TPN on gut-associated lymphoid tissue and IgA while preserving IgA-mediated upper respiratory immunity to influenza virus and preserves respiratory immunity and improves survival to a *Pseudomonas pneumonia*<sup>45</sup>.

## Intraluminal route

Intraluminal treatments also have shown promise. These approaches have several advantages including delivery of the active agent directly to the mucosal cells. Maintenance of gut barrier function and integrity is essential in preventing the translocation of bacteria and endotoxin into the portal circulation and mesenteric lymphatics. In addition, intraluminal therapy may be delivered at concentration higher than that tolerated in the circulation with fewer systemic side effects. Intraluminal sodium pyruvate decreased mucosal injury<sup>46</sup>. Schleiffer has proved that intraluminal L-arginine decreased reperfusion injury and this phenomenon was explained by increasing blood flow through a nitric oxide-mediated mechanism<sup>47</sup>. Multiple human and experimental studies emphasized the importance of enteral feeding in treating the effects of ischemic gut injury including different specialised formulas of immunomodulation enteral diet. Marik and Zaloga in their meta-analysis con-

firmed that EEN was associated with a significantly lower incidence of infections and a reduced length of hospital stay. There were no significant differences in mortality or non-infectious complications between the two groups of patients<sup>10</sup>. Caparros demonstrated that critically ill patients fed a high-protein diet enriched with arginine, fibre, and antioxidants had a significantly lower catheter-related sepsis rate than patients fed a standard high-protein diet. There were no differences in mortality or ICU and hospital length of stay<sup>48</sup>.

### Monitoring of enteral nutrition

Introduction of feeding protocol is cost-effective and improves nutritional parameters as well as outcome<sup>49</sup>. Tolerance of EN should be monitored and the most often method is measurement of gastric aspirate volume. A gastric aspirate volume of 150 ml after 6 hours is considered to be safe. No evidence – based recommendations can be made on which prokinetic agent is to be preferred. Cisapride, metoclopramide, and erythromycin are all effective in promoting gastric emptying in critically ill. Postpyloric feeding should be considered in cases of intragastric intolerance despite prokinetic agents. Endoscopic placement is most reliable. NOBN is an unusual complication in ICU patients. Most of cases occurred in patients where enteral nutrition was started in a delayed fashion, and full-dose EN was tolerated for several days prior to the development of NOBN. The type of enteral formula could play a role. Mostly patients with NOBN received a polymeric diet. Some as a safer alternative in these patients has proposed TPN.

### Conclusion

Present evidence strongly suggests that, in ICU patients, enteral nutrition should be preferred to parenteral nutrition whenever possible, due to its favourable trophic effects on the intestinal mucosa, reduced rate of complications and lower costs. Data is slowly accumulating that in some patients a reduced rate of complications and length of hospital stay can result from the use of immunomodulating enteral formulas, but further studies into this promising development should be performed before their widespread can be recommended. But EN generates complications either related to mechanical or to metabolic effects. Abdominal pains, nausea, vomiting and diarrhoea following enteral feeds infusion may occur, especially when infusion rate is greater than 50 ml/hour. There is necessary to stress the fact, that early enteral nutrition can have also complications. The most serious complication is nonocclusive bowel necrosis. The onset occurs in the second week in high-acuity patients who have had a period of EN tolerance. Clinical findings resemble bacterial sepsis with tachycardia, fever, and leukocytosis. Gastrointestinal specific signs are not consistent or occur late.

### Acknowledgement

*Supported by a grant IGA MZ NB/6728-3*

### References

- Alverdy J. The effect of nutrition on gastrointestinal barrier function. *Semin Respir Infect* 1994; Dec 9(4): 248–55.
- Moore F, Feliciano D, Andrassy RJ. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. *Ann Surg* 1994; 216: 172–183.
- Lowry SF, Fong Y. Determine whether 1 week of total parenteral nutrition (TPN) in healthy subjects alters systemic responses to a subsequent dose of endotoxin. *Ann Surg* 1996; 223: 107–108.
- Giner M, Laviano A, Meguid MM, Gleason JR. In 1995 a correlation still exists between malnutrition and poor outcome in critically ill patients still exists. *Nutrition* 1996; 12: 23–29.
- Frost P, Bihari D. The route of nutritional support in the critically ill: physiological and economical considerations. *Nutrition* 1997; 13: 58S–63S.
- Siderly MB, MacDonald IA, Fullwood L. Cardiovascular responses to high fat and high – carbohydrate in young subjects. *Am J Physiol*, 1991; 261: H1430–H1436.
- Sieber C, Beglinger C, Jager K, Stalder GA. Intestinal phase of superior mesenteric artery blood flow in man. *Gut* 1992; 33(4): 497–501.
- Revelly JP, Tappy L, Berger MM, Gersbach P, Cayeux C, Chiolerio R. Early metabolic and splanchnic responses to enteral nutrition in postoperative cardiac surgery patients with circulatory compromise. *Intensive Care Med* 2001; 27(3): 540–547.
- Anker SD, Rauchhaus M. Heart failure as a metabolic problem. *Eur J Heart Fail* 1999; (2): 127–131.
- Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. *Crit Care Med* 2001; 29(12): 2264–2270.
- Heyland DK, MacDonald S, Keefe L, Drover JW. Total parenteral nutrition in the critically ill patient: a meta-analysis. *JAMA* 1998; 23: 2013–2019.
- Minard G, Kudsk KA. Nutritional support and infection: does the route matter? *World J Surg* 1998; 22(2): 213–219.
- Buchman AL, Moukarzel AA. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. *JPEN* 1995; 19: 453–460.
- Lew JL, Rombeau JL. Effects of enteral nutrients on the critically ill gut. In: Wilmore D, Carpentier Y (ed). *Metabolic support of the critically ill patient*. Springer-Verlag. Berlin, Heidelberg, New York, 1993; pp 175–197.
- Deitch EA, Specian RD, Berg RD. Endotoxin-induced bacterial translocation and mucosal permeability: role of xanthine oxidase, complement activation, and macrophage products. *Crit Care Med* 1991; 19: 785–791.
- Wernerman J, Hammarqvist I. Bacterial translocation: effects of artificial feeding. *Cur Opin Clin Nutrition Metab Care* 2002; 5: 163–166.
- Pape HC, Dwenger A, Regel G. Increased gut permeability after multiple trauma. *Br J Surg* 1994; 81(6): 850–852.
- Roumen RM, van der Vliet JA, Wevers RA, Goris RJ. Intestinal permeability is increased after major vascular surgery. *J Vasc Surg*. 1993; 17(4): 734–737.
- Hadfield RJ, Sinclair DG, Houldsworth PE, Evans TW. Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. *Am J Respir Crit Care Med* 1995; 152: 1545–1548.
- Fink MP. Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients. *Intensive Care Med* 2002; 28: 103–104.
- Adams CA Jr, Magnotti LJ, Xu DZ, Lu Q, Deitch EA. Acute lung injury after hemorrhagic shock is dependent on gut injury and sex. *Am Surg* 2000; 66(10): 905–912; discussion 912–913.
- Adams JM, Hauser CJ, Adams CA Jr, Xu DZ, Livingston DH, Deitch EA. Entry of gut lymph into the circulation primes rat neutrophil respiratory burst in hemorrhagic shock. *Crit Care Med* 2001; 29(11): 2194–2198.
- Sedman PC, Macfie J, Sagar P. The prevalence of gut translocation in humans. *Gastroenterology* 1994; 107: 643–649.
- O'Boyle CJ, MacFie J, Mitchell CJ. Microbiology of bacterial translocation in humans. *Gut* 1998; 42: 29–35.
- Deitch EA. Simple intestinal obstruction causes bacterial translocation in man. *Arch Surg* 1989; 124: 699–701.
- Pierro A, Saene HKF, Jones MO. Clinical impact of abnormal gut flora in infants receiving parenteral nutrition. *Ann Surg* 1998; 227: 547–552.
- Cicalese L, Sileri P, Green M. Bacterial translocation in clinical intestinal transplantation. *Transplant* 2001; 71: 1414–1417.
- Cirera I, Bauer TM, Navasa M. Bacterial translocation of enteric organisms in patients with cirrhosis. *J Hepatol* 2001; 34: 32–35.
- MacFie J. Enteral versus parenteral nutrition: the significance of bacterial translocation and gut-barrier function. *Nutrition* 2000; 16: 606–610.
- Jeejeebhoy K. Total parenteral nutrition: potion or poison. *Am J Clin Nutr* 2001; 74: 160–163.
- Sedman PC, MacFie J, Palmer MD. Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans. *Br J Surg* 1995; 82: 1663–1667.
- Guedon C, Schmitz J, Lerebours E. Decreased brush border hydrolase activities without gross morphologic changes in human intestinal mucosa after prolonged total parenteral nutrition of adults. *Gastroenterology* 1986; 90: 373–378.
- Neu J, Roig JC, Meetze WH. Enteral glutamine supplementation for very low birth weight infants decreases morbidity. *J Pediatr* 1997; 131: 691–699.

34. Rokyta R Jr, Matejovic M, Krouzecky A, Novak I. Effects of early postpyloric enteral nutrition on hepatosplanchnic hemodynamics and metabolism in severe sepsis. *Intensive Care Med* 2001; 27,suppl 2, S202.
35. Siregar H, Chou CC. Relative contribution of fat, protein, carbohydrate, and ethanol to intestinal hyperemia. *Am J Physiol* 1982; 242(1): G27–31.
36. Schunn CD, Daly JM. Small bowel necrosis associated with postoperative jejunal tube feeding. *J Am Coll Surg*. 1995; 180(4): 410–416.
37. Kles KA, Wallig MA, Tappenden KA. Luminal nutrients exacerbate intestinal hypoxia in the hypoperfused jejunum. *J Parenter Enteral Nutr* 2001; 25(5): 246–253.
38. Tappenden K. Provision of phosphorylatable substrate during hypoxia decreases jejunal barrier function. *Nutrition* 2002; 18: 168–172.
39. Marvin RG, McKinley BA, McQuiggan M, Cocanour CS, Moore FA. Nonocclusive bowel necrosis occurring in critically ill trauma patients receiving enteral nutrition manifests no reliable clinical signs for early detection. *Am J Surg* 2000; 179(1): 7–12.
40. Rokyta R Jr, Novak I, Matejovic M, Hora P, Nalos M, Sramek V. Impact of enteral feeding on gastric tonometry in healthy volunteers and critically ill patients. *Acta Anaesthesiol Scand* 2001; 45: 564–569.
41. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. *Crit Care Med* 2001; 29(8): 1513–8.
42. Aneman A, Pettersson A, Eisenhofer G, Friberg P, Holm M, von Bothmer C, Fandriks L. Sympathetic and renin-angiotensin activation during graded hypovolemia in pigs: impact on mesenteric perfusion and duodenal mucosal function. *Shock* 1997; 8 (5): 378–84.
43. von Ritter C, Grisham MB, Hollwarth M, Inauen W, Granger DN. Neutrophil-derived oxidants mediate formyl-methionyl-leucyl-phenylalanine-induced increases in mucosal permeability in rats. *Gastroenterology* 1989; 97(3): 778–80.
44. Xia ZF, Hollyoak M, Barrow RE, He F, Muller MJ, Herndon DN. Superoxide dismutase and leupeptin prevent delayed reperfusion injury in the rat small intestine during burn shock. *J Burn Care Rehabil* 1995; 16: 111–117.
45. Li J, King BK, Janu PG, Renegar KB, Kudsk KA. Glycyl-L-glutamine-enriched total parenteral nutrition maintains small intestine gut-associated lymphoid tissue and upper respiratory tract immunity. *J Parenter Enteral Nutr* 1998; 22(1): 31–36.
46. Cicalese L, Subbotin V, Rastellini C, Stanko RT, Rao AS, Fung JJ. Preservation injury and acute rejection of rat intestinal grafts: protection afforded by pyruvate. *J Gastrointest Surg*. 1999; 3(5): 549–554.
47. Schleiffer R, Raul F. Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia. *Gut* 1996; 39(2): 194–198.
48. Caparros T, Lopez J, Grau T. Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. *J Parenter Enteral Nutr* 2001; 25(6): 299–308; discussion 308–309.
49. Hedberg AM, Lairson DR, Aday LA, Chow J, Suki R, Houston S, Wolf JA. Economic implications of an early postoperative enteral feeding protocol. *J Am Diet Assoc* 1999; 7: 802–807.

## 21

## CONTINUOUS HEMOFILTRATION AS A TOOL FOR CONTROL OF HOMEOSTASIS: RENAL SUPPORT OR RENAL REPLACEMENT?

Gašparović V.

*Department of Internal Medicine Emergency and Intensive Care Medicine, Zagreb, Croatia, vgaspardo@altavista.net*

No abstract available.

## 22

## CATHETER RELATED SEPSIS AND METABOLIC COMPLICATIONS IN TPN PATIENTS

Phelan D.

*Department of Intensive Care Mater, University Hospital, Dublin, Ireland, dphelan@mater.ie*

No abstract available.

## 23

## EFFECTS OF EARLY POSTPYLORIC ENTERAL NUTRITION ON HEPATOSPLANCHNIC HEMODYNAMICS AND METABOLISM IN SEVERE SEPSIS

Rokyta R. jr., Matějovič M., Kroužeký A., Novák I.

*ICU, Medical Department, Charles University Hospital Pilsen, Czech Republic*

### Introduction

The administration of enteral nutrition (EN) during states of acute stress and/or circulatory compromise is controversial due to the possible onset of the imbalance between the hepatosplanchnic oxygen and/or energy demand and supply. Recently, the "adequate" central and splanchnic hemodynamic responses to isoenergetic EN have been demonstrated in post-cardiac surgery patients requiring inotropes and/or vasopressors [1]. However, there are no such data in critically ill septic patients. Therefore, we studied the effects of early EN on hepatosplanchnic hemodynamics and metabolism in patients with severe sepsis.

### Methods

Eight mechanically ventilated medical ICU patients (mean age  $64 \pm 10$  years) fulfilling the following criteria were studied: (1) severe sepsis or septic shock (2) no enteral feeding before the study. Data were collected at the fasting state (BL1; 90 min of stable hemodynamics), after 120 min of postpyloric EN (EN; 40 ml bolus, then 40 ml/h continuously; Survimed®), and 120 min after EN-cessation (BL2). In addition to systemic hemodynamics (arterial and PA catheters), arterial and hepatic venous (HV) blood gases, lactate (L), pyruvate (P) and glucose levels were measured. Hepatosplanchnic blood flow (HSBF, steady state indocyanine green technique) was estimated using hepatic vein catheter. Gastric mucosal  $\text{PCO}_2$  ( $\text{PgCO}_2$ ) was determined by air tonometry (Tonocap) and gastric mucosal to arterial  $\text{PCO}_2$  difference ( $\text{PCO}_2$  gap) was calculated.

### Results

All patients remained stable over the study with no change in norepinephrine dose (6 patients, mean dose  $0.2 \pm 0.4$  ug/kg/min). Data are median, 25<sup>th</sup> and 75<sup>th</sup> percentiles (RM ANOVA on ranks, Dunn's test,  $p < 0.05$ , \*EN vs BL1, \*BL2 vs EN).

	BL1	EN	BL2
MAP (mmHg)	83 (74;91)	80 (74;82)	83 (77;90)
Cardiac index (l/min/m <sup>2</sup> )	3.1 (2.8;3.3)	3.3 (2.9;3.7)*	3.1 (2.5;3.3)*
HSBF (l/min/m <sup>2</sup> )	1.36 (0.85;1.60)	1.51 (1.09;1.74)*	1.21 (0.87;1.47)*
HSBF/cardiac index (%)	42 (31;49)	43 (38;49)	42 (32;45)
Splanchnic VO <sub>2</sub> (l/min/m <sup>2</sup> )	68 (59;89)	74 (68;85)	63 (57;75)*
S <sub>HV</sub> O <sub>2</sub> (%)	54 (48;61)	62 (46;65)	53 (43;64)
Hepatic venous L/P ratio	7.4 (6.9;8.9)	8.8 (7.2;9.5)	8.4 (7.8;10.5)
PCO <sub>2</sub> gap (kPa)	1.1 (0.6;1.1)	0.7 (0.7;1.0)	1.0 (0.7;1.1)

## Conclusion

Our data show that the administration of low dose postpyloric enteral nutrition in medical ICU patients with severe sepsis and/or septic shock leads to the parallel increase of systemic and hepatosplanchnic blood flow. In addition, neither total hepatosplanchnic nor gastric mucosal energy balance deteriorated during enteral feeding. These results suggest that the initiation of low dose postpyloric enteral nutrition may not be harmful even in septic patients requiring norepinephrine.

## References

1. Revelly JP et al. *Intensive Care Med* 2001; 27: 540–547.

## Acknowledgement

Supported by a grant IGA MZ NB/6728-3

## 24

## MONITORING OF THE RESIDUAL RENAL FUNCTIONS DURING CONTINUOUS RENAL REPLACEMENT THERAPY – THE APPLICATION OF THE ANALYSIS OF CYSTATIN C AND NATRIURETIC PEPTIDES

Balík M.<sup>1</sup>, Jabor A.<sup>2</sup>, Kolář M.<sup>1</sup>, Hendl A.<sup>3</sup>

<sup>1</sup> Department of Anaesthesiology and Intensive Care, University Hospital Královské Vinohrady, Prague

<sup>2</sup> Department of Clinical Biochemistry, Hospital Kladno, Czech Republic

<sup>3</sup> Department of Kinanthropology, Charles University, Prague, Czech Republic

## Introduction

The reason for the decrease of urine output (Vu) following the start of continuous venovenous hemodiafiltration (CVVHDF) has not been clarified yet. The renoprotective properties of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were described. The sensitive marker of glomerular filtration is cystatin C (cysC).

## Methods

ANP levels (normal < 14 pmol/l) and BNP levels (normal < 5.3 pmol/l) were analysed in 13 and cysC levels (normal < 0.99 mg/l) were analysed in 16 ventilated patients, all treated with CVVHDF (blood flow 120 ml/min, dialysis 1000 ml/h, hemofiltration 500 ml/h). Creatinine clearance (Ccr) was monitored before therapy. Samples were drawn before and after 24 h and 48 h of CVVHDF both from the ports proximal and distal to the filter. Arteriovenous concentration differences (A-Vdiff.) reflecting sieving, adsorption or both were calculated. Furosemide was reduced to 1 mg/kg/day after commencing of CVVHDF. Left ventricular dysfunction (LVD) was defined as LV ejection fraction below 40 %. Patients were divided according to the Vu after 48h of treatment into the groups with Vu < 3000 ml/24 h and groups which retained Vu > 3000 ml/24 h.

## Results

The levels of ANP were significantly higher in the group with decreasing diuresis (48.66–26.83 pmol/l, n = 5, Vu 930+/-1245 ml/24 h) than in the group with increasing diuresis (13.79–8.96 pmol/l, n = 8, Vu 4998.8+/-1260 ml/24 h, p < 0.004). Similar difference was found for BNP: (267.86–356.22 vs 111.0–100.85, p < 0.01). Levels of both peptides were grossly elevated in comparison to controls (n = 10, p < 0.0001). The significant correlations were revealed for ANP and Vu (r = -0.40, p < 0.02) and for BNP and Vu (r = -0.43, p < 0.007). Ccr measured before the therapy was not different between the groups. Average AVdiff (%) of ANP was -3.68+/-48.72 and of BNP was -4.04+/-23.68. The differences between cardiac and non-cardiac patients did not reach significance either for ANP or for BNP. The levels of both peptides predicted survival (BNP 114.24+/-143.81 vs 278.47+/-287.18 (p < 0.005) of non-survivors, ANP 11.34+/-16.34 vs 29.57+/-19.90 (p < 0.0002) of non-survivors). There were 7 patients with increasing diuresis (average 4857.1+/-1460 ml/24 h) in the cysC study, in 9 patients the volume of urine decreased (average 546.7+/-945 ml/24 h). Ccr taken before treatment was not different between the groups. Average AVdiff (%) of cysC was +5.73+/-15.57. Significant correlation between cysC and Vu was found in particular for the cysC levels below 4.0 mg/l (r = -0.76, p < 0.002). cysC levels were significantly higher in nonsurvivors (3.67+/-1.29 vs 2.77+/-1.10, p < 0.002).

## Conclusions

The elimination of cysC, ANP and BNP by the CVVHDF is negligible. The levels of cysC and natriuretic peptides are inversely related to Vu. Whether cysC could be used as an indicator of successful weaning from CVVHDF needs to be confirmed by further study. The levels of cysC, ANP and BNP levels predict survival of patients treated with CVVHDF. ANP and BNP levels did not correlate with LVD which may be caused by their elevation due to renal failure.



## ACUTE RENAL FAILURE REQUIRING RENAL REPLACEMENT THERAPY AFTER CARDIAC SURGERY

Král J.<sup>1</sup>, Šetina M.<sup>1</sup>, Králová I.<sup>2</sup>, Tesařík R.<sup>2</sup>

<sup>1</sup> Department of Cardiac Surgery

<sup>2</sup> Department of Anaesthesiology and Intensive Care, Hospital České Budějovice, Czech Republic

### Background

Acute renal failure (ARF) requiring renal replacement therapy (RRT) occurs in the postoperative period and is an important risk factor for an early mortality. The purpose of this study was to assess the incidence of ARF, to determine whether there is an association of ARF with the type of surgery and to give some characteristics of the patients requiring RRT after cardiac surgery.

### Patients and methods

One thousand patients who underwent coronary artery bypass grafting (CABG) or valve surgery with or without bypass grafting from May 2000 to December 2001 were evaluated to determine the association between ARF sufficient to require RRT and operative mortality, with and without adjustment for comorbidity – preoperative renal function, presence of diabetes.

### Results

A total of 823 of the 1000 patients underwent isolated CABG surgery, the remaining 177 patients underwent valve surgery with or without bypass grafting. ARF requiring RRT occurred in 33 (3.3 %) patients. ICU mortality was 48.5 % in these patients. Of the CABG patients 1.9 % developed ARF requiring RRT – mortality 43.7 %, mean duration of RRT was 10.8 days. Of the valve surgery patients 9.6 % developed ARF requiring RRT – mortality 52.9 %, mean duration of RRT was 5.7 days. 16 of RRT patients had preoperative serum creatinine level of less than 130 micromol/l – mortality 50 %. 17 of RRT patients had preoperative creatinine level of 130 micromol/l or greater – mortality 47 %. Additional characteristics of RRT patients (mean values): age of survivors (17 patients) – 71.9 years, non-survivors (16 patients) – 78.2 years; preoperative serum creatinine level: survivors 151 micromol/l, non-survivors 131 micromol/l; presence of diabetes: survivors – 3 patients, non-survivors – 3 patients; duration of cardiopulmonary bypass: survivors – 110 min, non-survivors – 148 min; duration of RRT: survivors – 8.5 days, non-survivors – 7.3 days.

### Conclusion

The development of ARF requiring RRT is associated with a high mortality following cardiac surgery. We have described perioperative variables, which may be useful in stratifying risk for the development of ARF and mortality.

## References

- Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, Landolfo K. (1999) Acute renal failure following cardiac surgery. *Nephrol Dial Transplant* 14(5), 1158–62.
- Ostermann ME, Taube D, Morgan CJ, Evans TW. (2000) Acute renal failure following cardiopulmonary bypass: a changing picture. *Intensive Care Med* 26(5), 565–71.
- Lawman SH, Cohen SL, Batson SD. (2002) Acute renal failure after cardiothoracic surgery: a review of three years experience. *Blood Purif* 20(3), 293–5.

## LOW URINE OUTPUT IN ACUTE RENAL DYSFUNCTION DIAGNOSIS IN LONG TERM ICU PATIENTS

Suk P., Hruša J., Zvoníček V., Šrámek V.

Department of Anaesthesia and Intensive Care, St. Ann's University Hospital, Brno, Czech Republic

### Introduction

Low urine output (UO) has been recently suggested to define acute renal dysfunction/failure (ARI/ARFS) in addition to urea/creatinine levels<sup>1</sup>. We tested how inclusion of UO would change the incidence of ARI/ARFS in long term ICU patients.

### Methods

Medical records of long term ICU patients (> 3 days) hospitalised in 2000 were analysed for UO and urea/creatinine levels on daily basis for the whole ICU stay. Furosemide medication was also recorded. Values given as means ± SD (range).

### Results

Out of 189 admissions in 2000, 90 patients (62 males, 28 females) were hospitalised > 3 days. Medical records of 84 patients were available for analysis (age of 59 years (16–85)), APACHE II on admission  $25.4 \pm 7.7$ ). Altogether 1196 ICU days were analysed. Thirty nine ICU days when 7 patients required renal replacement therapies were recorded. Out of remaining 1157 ICU days complete data set (i. e. urine output, urea and creatinine levels) was obtained in 340 cases because creatinine was not performed on daily basis. Based on renal metabolites, ARI/ARFS was present on 62 ICU days (18.2 %). Inclusion of UO led to 14 additional ICU days of ARI/ARFS. In 2 ICU days more severe form of dysfunction (ARFS) would be classified based on UO than renal metabolites. In all but one patient an episode with low UO was recorded when no furosemide was given.

### Conclusion

When diuretics are not given, inclusion of low urine output into an acute renal dysfunction definition increases the number of ARI/ARFS patients.

### Reference

1. Belomo R et al. (2001) Acute renal failure: time for consensus. *Intensive Care Med* 27, 1685–8.

27

## HAEMORRHAGIC HYPOVOLEMIA AND SOME OF ITS MARKERS IN EXPERIMENTAL AND CLINICAL MEDICINE

Studená A.<sup>1</sup>, Bračoková I.<sup>2</sup>, Firment J.<sup>1</sup>

<sup>1</sup> Department of Anaesthesiology and Intensive Medicine,

<sup>2</sup> Department of Physiology, Medical Faculty of Safarik University and the University Hospital, Košice, Slovak Republic

The most expressive clinical signs of the first phase of haemorrhagic hypovolaemia are: hypotension, tachycardia, tachypnoe and rapid re-organisation of the energy-producing metabolic system. Clinical useful markers for assessing the quantity of blood and state of patient are still and widely discussed. The aim of this study was to define some clinically useful markers of the phase of blood loss by comparing some variables immediately after experimental blood loss at experimental animals in patients with haemorrhagic shock at the Department of anaesthesiology and intensive medicine.

### Methods

The acute experiments were performed on 20 cats, anaesthetized by pentobarbital, applied intraperitoneally (40 mg/kg). Haemorrhagic hypovolaemia was induced by removal of 20–30 % of the blood volume. The clinical group consisted of 12 patients in the intensive care unit, mostly some hours after bleeding and therapy. We assess such variables as blood pressure, heart rate, breathing, arterial and venous blood gases, arterial lactate concentration, some haematological variables and blood glucose level. In patients the parameters of internal environment were analysed from capillary blood samples.

### Results

In experimental animals immediately after the blood loss (up to 30 %) there was paradox of metabolic acidosis with hypoxemia in venous blood and signs of respiratory alkalemia in arterial blood together with significant increasing of number of erythrocytes, leucocytes, haematocrit ratio, concentration of haemoglobin, lactate and glucose level. There were nearly normal blood pressure with tachycardia, in capillary blood signs of metabolic acidosis, signs of haemodilution and significant increasing of number of leucocytes and concentration of blood glucose in patients few hours after the bleeding and therapy.

### Conclusion

Our findings in experimental animals compared with those in patients account for the fact that in the first phase of haemorrhagic hypovolaemia venous blood most accurately reflects the acid base state, and as the markers could be better to use arterio-venous differences of pH, pO<sub>2</sub>, pCO<sub>2</sub>, lactate concentration as well as leukocyte count and blood glucose concentration.

### References

1. Kula, R., Holý, V., Koutun, J., Májek, M.: Kritériá úspešnosti liečby šoku. *Anesteziologie a neodkladná péče*. 7, 1996,3, p. 105–110.
2. Marzi, J.: Der hämorrhagische Shock. *Anaesthetist*, 1996, 45, p. 976–992.
3. Ševčík, P., Husa, P.: Šok, sepse, multiorgánové selhání. In.: Ševčík, P., Černý, V., Vítovec, J. et al.: *Intenzivní medicína*. Galén Praha, 2000, p. 84–103.

28

## FLUID AND ELECTROLYTE DISTURBANCE RESULTING IN TONIC-CLONIC SEIZURES, RESPIRATORY AND RENAL FAILURE (A CASE REPORT)

Adorján K., Donáth K.

Hospital and Central Clinic of the Hungarian Railways, Budapest, Hungary

The case of a man aged 31 is reported, who was admitted to hospital, having lost consciousness after a few days' history of coughing, having temperature, hiccups and vomiting. After admission two grand mal type epileptic seizures had been observed, and he lapsed into a coma. Investigations concerning his physical and neurological status, the laboratory analysis of the cerebrospinal fluid, the chest x-ray and abdominal ultrasound scan did not reveal any abnormality. According to the CT scan, a slight cerebral oedema was present. His blood tests showed considerable hyponatraemia, hypochloreaemia, hypokalaemia and azotaemia. The blood gas analysis indicated a marked metabolic alkalosis, hypercapnia and hypoxaemia. In his longer-term history a sutured duodenal perforation was known.

Following admission to the ICU the patient was intubated, mechanical ventilation was commenced and he received sodium and potassium supplementation and antibiotic. An excessive amount of gastric contents drained through the gastric tube. After 24 hours of treatment the serum Na<sup>+</sup>, K<sup>+</sup> and Cl<sup>-</sup> concentrations returned to the normal range, he gradually regained consciousness and was extubated, subsequently receiving oxygen through a face mask, although the metabolic alkalosis and hypercapnia still persisted until the end of the third day. Urine output improved, the azotaemia gradually ceased. On the third day the clinical and radiological symptoms of pneumonia appeared on the left side, which responded to the treatment employed within a week. The gastroscopy performed on the fourth day showed a deformed, oedematous, eroded bulbus duodeni with a constricted lumen, it stated stenosis duodeni and suggested that it required surgical intervention later.

We considered this case worthy to be reported because of the severe fluid and electrolyte disturbance leading to a derangement of consciousness, seizures, respiratory and renal failure.

## THE DIAGNOSIS AND THERAPY OF HEPARIN INDUCED THROMBOTIC THROMBOCYTOPENIA SYNDROME IN A CZECH GENERAL ICU

Balík M.<sup>1</sup>, Plašil P.<sup>1</sup>, Stehlíková M.<sup>2</sup>

<sup>1</sup> Department of Anaesthesiology and Intensive Care, University Hospital, Prague

<sup>2</sup> Institute of Haematology and Blood Transfusion, Prague, Czech Republic

### Objective

HITS is a allergic drug reaction with consequent thrombocytopenia and thrombosis. Up to 2.7–3.0 % of patients receiving unfractionated heparin (UFH) develop HITS. Thrombocytopenia is severe in type II, disease often associates with DIC, thrombosis or embolisations.

### Methods

The laboratory diagnosis can be made by the antigen assays (ELISA). Functional assays exploit the ability of HIT-Ig to activate platelets. The results of serotonin release assay (SRA) may confirm or exclude the initial diagnosis made by the antigen assays. We developed method to measure radioactive serotonin release in HITS sera by high performance liquid chromatography (HPLC) – fluorimetric detection. Patients who developed thrombocytopenia during UFH therapy were tested for antigen ELISA assay and functional SRA with HPLC detection.

### Results

The authors present two case studies:

Case I: Patient was admitted for multiple trauma including thoracic, spinal and pelvic trauma. CVVHDF with heparin anticoagulation was initiated on the 4<sup>th</sup> day, there was gradual trombocyte drop, repeated transfusion requirements, perirenal hematoma progression, repeated GIT bleeding. The epoprostenol anticoagulation was started, and later the patient was switched to citrate anticoagulation. All the tests for HITS were highly positive. On the 34<sup>th</sup> day the antiaggregation with aspirin was started. The patient was weaned from ventilator and on 50<sup>th</sup> day transferred to nephrology dept. for nonheparin IHD.

Case II: Patient suffered multiple trauma in Bayern quickly developing bronchopneumonia, sepsis, renal insufficiency and thrombocytopenia. The heparin antibodies were detected. The fall of thrombocyte count stopped on hirudin. On the 4<sup>th</sup> day the patient was moved to our ICU. For sings of septic activation of coagulation and impossibility of hirudin administration the refugium ultimum therapy with reviparin was initiated. Trombocyte level gradually raised to 200th/uL on the 8<sup>th</sup> day. Patient was extubated and discharged on the 20<sup>th</sup> day.

### Discussion

The only choice of treatment in Czech Republic up to now was to try LMWH or antiaggregation therapy with aspirin which puts a patient at risk of bleeding. Recently lepirudin (Refludan) was registered, another choice would be danaparoid. One patient was succesfully treated with reviparin and the question is thus the validity of the used diagnostic testing for HITS. The anticoagulation of choice for the patients indicated to CRRT seems to be citrate. Prostacyclin (epoprostenol) may be used safely but it has not been registered in Czech Republic yet.

## SECTION: CARDIOVASKULAR DYNAMICS

30

### ARGININE VASOPRESSIN IN VASODILATORY SHOCK

Hasibeder W., Dünser M., Mayr A., Friesenecker B.

*Division of General and Surgical Intensive Care Medicine, Department of Anesthesiology, University of Innsbruck, Austria, walter.hasibeder@uibk.ac.at*

We report on physiological and pharmacological aspects of arginine vasopressin (AVP), and summarize current clinical knowledge with a continuous AVP infusion in critically ill patients suffering from catecholamine-resistant vasodilatory shock of different etiologies. During the last years, several investigations impressively demonstrated that AVP can successfully stabilize hemodynamics even in advanced vasodilatory shock. In view of presented experimental evidence and current clinical experience, a continuous AVP infusion ( $1\text{--}4\text{ Uxh}^{-1}$ ) can be considered as a supplement to vasopressor catecholamines in order to preserve cardiocirculatory homeostasis in advanced vasodilatory shock. Because data on adverse side effects are still limited, AVP should be reserved for patients in whom adequate hemodynamic stabilization cannot be achieved with conventional vasopressor therapy, or obvious side effects of catecholamines promote further significant hemodynamic deterioration. For the same reasons, AVP should not be used as a single, alternative vasopressor agents instead of catecholamine vasopressors. Future prospective studies will be necessary to define the exact role of AVP in the therapy of vasodilatory shock.

31

### HEMODYNAMIC GOALS IN SEPTIC SHOCK

Černý V.

*Department of Anesthesiology and Intensive Care, Charles University, Faculty of Medicine  
University Hospital Hradec Králové, Czech Republic, cerny@fnhk.cz*

#### Introduction

Septic shock is characterized by hypotension, usually accompanied by signs of altered tissue perfusion as a oliguria, reduced capillary refill and altered consciousness. During sepsis, organ perfusion should be restored as a first and most important goal of any therapeutic approach.

#### Major goals of therapy

- Restoring organ perfusion, normalization of cellular metabolism and therefore reversal organ dysfunction
- Adequate cardiac filling

- Adequate cardiac output
- Adequate mean blood pressure
- Adequate mixed venous saturation of oxygen

#### Fluids

##### Key points

- Septic shock is associated with hypovolemia (absolute and relative)
- Fluids should be the first step in restoring organ perfusion
- Giving fluids should be titrated to the clinical and hemodynamic endpoints
- There is a ongoing controversy regarding the choice of “best fluid strategy”
- Colloids and crystalloids are equal in restoring tissue perfusion, however the larger amount of crystalloids (approx. twice to four times) is required compared to colloids
- Colloids may be preferred due to more rapid effect on restoring or increasing plasma volume.
- There is ongoing debate about usefulness of using albumin in this setting

#### Vasopressor and inotropic support

##### Key points

- Vasopressor therapy should be employed whenever fluids are inadequate in restoring organ perfusion and targeted blood pressure
- Vasopressor therapy should be always given after volume replacement, however in life threatening hypotension maintaining perfusion pressure is essential even in presence of hypovolemia, which must be corrected as fast as possible
- Norepinephrine is a preferred agent in restoring blood pressure
- Dobutamin is preferred agent for inotropic support

#### Criteria for effectiveness

- Restoring organ perfusion (increase of urine output, adequate skin perfusion, increased capillary refill)
- Increase of cardiac output
- Increase of blood pressure
- Increase of  $\text{SvO}_2$
- Decrease of blood lactate level

32

### MYOCARDIAL DYSFUNCTION IN SEPSIS AND MOF

Voga G.

*Medical ICU, General Hospital, Celje, Slovenia,  
gorazd.voga@guest.arnes.si*

No abstract available.

## STEROIDS IN SEPTIC SHOCK

Briegel J.

*Klinikum Grosshadern, Ludwig-Maximilian Universität München, Germany, josef.briegel@ana.med.uni-muenchen.de*

A series of clinical trials on the use of corticosteroids for the treatment of sepsis gave negative results. Two meta-analyses led to the conclusion that glucocorticoids for sepsis do not improve survival and may even be harmful<sup>1,2</sup>. Trials with high doses of glucocorticoids showed adverse effects with a trend to increased overall mortality, with an increased mortality due to secondary infections and with adverse effects on respiratory, hepatic and renal function. Although the precise mechanisms are not completely understood, the dose and the duration of the intervention may account for the negative results of the glucocorticoids trials in sepsis.

Glucocorticoids interact with the host response at virtually all levels exerting suppressive and permissive effects on the immune response. In a dose dependent manner, corticosteroids inhibit the synthesis of many pro-inflammatory mediators such as cytokines, phospholipase A<sub>2</sub> and cyclooxygenase. At physiological concentrations of glucocorticoids, the synthesis of antiinflammatory mediators such as the Interleukins 4 and 10 or the Interleukin-1-receptor antagonist is not altered or even increased<sup>3</sup>. There is evidence that pharmacological doses of glucocorticoids exert suppressive effects on immune reactions thus threatening an effective host defense. Although immunological data are lacking, the adverse effects observed in the negative glucocorticoid trials were attributed to a prolonged and nonspecific immunosuppressive effect of high doses of corticosteroids when given in the first 24 hours after onset of sepsis or ARDS<sup>4</sup>.

The role of the endogenous glucocorticoid hydrocortisone has been completely neglected in designing the high-dose steroid trials. Cortisol acts as a conductor in the orchestra of various immune reactions. In response to infections cortisol induces suppressive as well as permissive effects on the immune response thus counteracting overshooting immune reactions<sup>5</sup>. There is a body of evidence that the adrenocortical function is impaired and that this impairment appears to correlate with the degree of systemic inflammation<sup>6</sup>. The diagnosis of relative adrenocortical insufficiency is still a source of an ongoing debate and research. The short corticotropin stimulation test is widely used for its assessment. However, the appropriate cutoff value for the diagnosis of relative adrenocortical insufficiency is difficult to determine. Using the different cutoff values proposed in literature, Bouachour found an incidence of relative adrenocortical insufficiency ranging from 6.25 to 75 % in one study group of septic shock patients<sup>7</sup>. A recent study of Annane in a large group of patients with septic shock concluded that a cortisol increment of less than 9 µg/dL may be indicative for an inappropriate adrenocortical function. Combined with a basal cortisol level of more than 34 µg/dL a blunted cortisol response is indicative for a high 28-day mortality rate (81 %) (ref.<sup>8</sup>).

With respect to these data the substitution of cortisol by stress doses of hydrocortisone appears to be a rationale therapeutic approach. In normal volunteers stress doses of hydrocortisone reduced the clinical response to endotoxin and attenuated the appearance of circulating

pro-inflammatory cytokines<sup>9,10</sup>. Low-dose hydrocortisone infusion in patients with sepsis attenuated the systemic inflammatory response as judged by temperature, heart rate, mean arterial pressure and inflammatory markers such as phospholipase A<sub>2</sub> and C-reactive protein<sup>11</sup>. Two double-blind single center studies have demonstrated that stress doses of hydrocortisone reverse septic shock as defined by cessation of vasopressor therapy<sup>12,13</sup>. The data provided evidence that earlier shock reversal was associated with an improved morbidity but not mortality. In a recent french multicenter trial it has been demonstrated that stress doses of hydrocortisone (50 mg every 6 hours for five days) significantly reduces overall mortality in patients with septic shock (D. Annane, personal communication).

Summarizing the present data, there is evidence that glucocorticoids may have a place in the treatment of septic shock. However, the use of glucocorticoids should be restricted to low doses of hydrocortisone and to patients in vasopressor-dependent septic shock. A large multicenter trial (CORTICUS) is on the way to evaluate the effectiveness of stress doses of hydrocortisone on survival in patients with septic shock. The project, which is supported by the European Commission, will further clarify the role of stress doses of hydrocortisone in the treatment of septic shock. The high-dose steroid trials, undertaken more than 10 years ago, may have failed because of inappropriate dosage regimen and target populations.

## References

1. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: A meta-analysis. *Crit Care Med* 1995; 23: 1294–1303.
2. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MAD et al. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. *Crit Care Med* 1995; 23: 1430–1439.
3. Briegel J, Kilger E, Schelling G. Stress doses of hydrocortisone in septic shock: Beyond the hemodynamic effects. In: Vincent J-L, editor. 1999 Yearbook of Intensive Care and Emergency Medicine. Berlin; Heidelberg; New York: Springer, 1999: 189–198.
4. Giroir BP. Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. *Crit Care Med* 1993; 21: 780–789.
5. Sapsolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. *Endocr Rev* 2000; 21(1): 55–89.
6. Tayek JA, Atienza VJ. Pituitary-adrenal axis function in systemic inflammatory response syndrome. *Endocrine* 1995; 3: 315–318.
7. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. *Intensive Care Med* 1995; 21(1): 57–62.
8. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. *JAMA* 2000; 283(8): 1038–1045.
9. Santos AA, Scheltinga MR, Lynch E, Brown EF, Lawton P, Chambers E et al. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. *Arch Surg* 1993; 128: 138–144.
10. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y et al. Glucocorticoid therapy alters hormonal and cytokine response to endotoxin in man. *J Immunol* 1993; 150: 1999–2006.
11. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. *Clin Invest* 1994; 72: 782–787.
12. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998; 26(4): 645–650.
13. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999; 27(4): 723–732.

34

## NON-INVASIVE HAEMODYNAMIC MONITORING IN INTENSIVE CARE AND ANESTHESIA

Illias W.

*Ho-Med Handelsges. M.b.H., Vienna, Austria*

No abstract available.

35

## INFLUENCE OF THE DEGREE OF TRICUSPID REGURGITATION ON CARDIAC OUTPUT MEASUREMENTS BY THERMODILUTION

Balík M.<sup>1</sup>, Páchl J.<sup>1</sup>, Hendl J.<sup>2</sup><sup>1</sup> *Department of Anaesthesiology and Intensive Care, University Hospital, Prague 10, balik@fnkv.cz*<sup>2</sup> *Department of Kinesiology, Charles University, Faculty of Physical Education and Sport, Prague, Czech Republic*

### Introduction

The authors were studying the influence of different grade of tricuspid regurgitation (TR) on accuracy of cardiac output (CO) measurement by thermodilution.

### Methods

27 patients were separated into three groups. All patients were initially investigated by transesophageal echocardiography (TEE) (multiplanar probe, Omniplane, Hewlett-Packard) and later the pulmonary artery catheter (PAC) was inserted for continuing haemodynamic instability. All patients with higher than the 1<sup>st</sup> degree of aortic regurgitation were excluded. There were 8 patients with no or the 1<sup>st</sup> degree of TR graded according to color doppler criteria, the second group consisted of 9 patients with the 2<sup>nd</sup> degree of TR. The third group included 10 patients with the 3<sup>rd</sup> degree of TR. All patients were measured twice simultaneously by TEE and PAC for cardiac output. At least three pulsions were measured using continuous doppler for velocity-time integral (VTI) at the level of aortic valve and at least six VTI were averaged in case of stroke volume (SV) variation in atrial fibrillation. Aortic valve area (AVA) was measured by planimetry twice and results were averaged. SV was calculated multiplying VTI with AVA and heart rate. Simultaneous PAC measurement was carried out applying three 10 ccm boluses of iced saline.

### Results

The mean difference between TEE measurement and PAC measurement was 514.1+/-541.3 ml/min in the first group of patients ( $r = 0.96$   $p < 0.0001$ ). The mean difference of 837.8+/-976.1 ml/min was found in the second group of patients ( $r = 0.92$   $p < 0.0001$ ). The difference between

the two modes of CO measurement was 1893.0+/-1143.9 ml/min in the third group ( $r = 0.69$   $p < 0.001$ ).

### Conclusion

The difference in the third group is probably caused by inadequately low values of CO measured by thermodilution. The inaccuracy of CO measurement in the group of patients with the 3<sup>rd</sup> degree of TR can be misleading for further therapy. It can cause more significant inaccuracy in another calculated parameters like pulmonary and systemic vascular resistances and stroke work indexes of left and right ventricle.

### Reference

1. Perrino AC, Harris SN, Luther MA (1998) Intraoperative Determination of Cardiac Output Using Multiplane Transesophageal Echocardiography, *Anesthesiology* 89, 350–357.

36

## PAPILLARY MUSCLE RUPTURE WITH SEVERE ACUTE MITRAL REGURGITATION – RARE COMPLICATION OF ACUTE MYOCARDIAL INFARCTION. OUR EXPERIENCE WITH THREE CONSECUTIVE PATIENTS

Bělohávek J., Škulec R., Pšenička M., Linhart A., Aschermann M.

*Department of Medicine II, Faculty General Hospital, Charles University Prague, U nemocnice 2, Prague 2, Czech Republic*

The mortality of patients with cardiogenic shock (CS) following acute myocardial infarction (AMI) remains frustratingly high, despite modern pharmacological and interventional therapeutical approaches. The progressive hemodynamic deterioration in patients suffering from AMI is usually caused by severe left ventricular systolic dysfunction as a consequence of large regions affected by necrosis or ischaemia. These patients account for about 10 % of all admitted for AMI and their mortality is as high as 60–80 %. The special subset of CS patients comprises patients presenting with mechanical complications of AMI, mainly the severe acute mitral regurgitation (SAMR), ventricular septal rupture and ventricular free wall rupture or tamponade (8 %, 6 % and 2,7 %, respectively, of all CS patients). Papillary muscle rupture causing severe acute mitral regurgitation paradoxically occurs frequently in patients with relatively small areas of affected myocardium and well preserved systolic function of the left ventricle.

There have been 3 small series of patients suffering from SAMR comprising 22–33 patients during the period of 10 to 22 years published in recent literature. We report on 3 consecutive patients who were treated in our institution during the last 9 months. All of them survived.

We stress aggressive therapeutical approach with the need of initial stabilization, organ support (mechanical ventilation, intraaortic balloon countepulsation, eventually continuous renal replacement therapy) and early surgical intervention. Successful initial management offers excellent long-term prognosis for early survivors.

## References

1. Yehezkiel K et al. (1992) Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow up of 22 patients. *Mayo Clin Proc* 67, 1023–1030.
2. Tavakoli R et al. (2002). Surgical management of acute mitral valve regurgitation due to post-infarction papillary muscle rupture. *J Heart Valve Dis* 11, 22–26.
3. Qiang C et al (2002) Mitral valve surgery for acute papillary muscle rupture following myocardial infarction. *J Heart Valve Dis* 11, 27–31.

## 37

### RELATIONSHIPS BETWEEN CONVENTIONAL HEMODYNAMIC AND BLOOD VOLUME MONITORING DURING AND AFTER ORTHOTOPIC LIVER TRANSPLANTATION

Fazakas J., Gondos T., Horovitz P.

*Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary*

#### Purpose

Liver transplantation program started at Semmelweis University in 1995. Our purpose was to evaluate the standard hemodynamic and the newer blood volume monitoring technique in patients undergone orthotopic liver transplantation (OLTx), especially to analyse the correlations among different pressure, volume and flow parameters.

#### Methods

The relationships among intravascular filling pressures, preload volume and flow parameters ( $n = 130$ ) and their changes ( $n = 110$ ) were analysed in 8 liver transplanted patients underwent conventional and volumetric hemodynamic monitoring. The conventional hemodynamic monitoring consisted of Swan-Ganz catheterization to assess filling pressures (CVP, PCWP) and cardiac index (CI). The blood volume monitoring technique consisted of a fiberoptic catheter for thermo-dye dilution (COLD System, Pulsion Medizintechnik) to assess the intrathoracic and global enddiastolic volume (ITBVI, GEDVI) and CI. All patients had received the same surgical and anaesthesiological technique. Measurements were obtained during anaesthesia and in the first five post-operative days. Statistical analysis was performed with Statview program.

#### Results

Preload pressure values showed significant correlation (CVP-PCWP,  $r = 0.78$ ); but the correlation between the intravascular pressure and volume parameters were poor (PCWP-GEDVI, ITBVI,  $r = 0.02$ ). The correlation coefficient between the intrathoracic volume parameters was very high (GEDVI-ITBVI,  $r = 0.97$ ). The relationships between the changes of CI and volumetric preload parameters were more significant ( $\Delta$  GEDVI- $\Delta$  CI,  $r = 0.61$ ;  $\Delta$  ITBVI- $\Delta$  CI,  $r = 0.64$ ) than between the changes of preload pressure parameters and CI, ( $\Delta$  PCWP- $\Delta$  CI,  $r = 0.25$ ;  $\Delta$  CVP- $\Delta$  CI,  $r = 0.28$ ). Doing multiple regression ana-

lysis to evaluate influencing factors of CI, the multiple correlation coefficients was higher using COLD system ( $r = 0.92$ ) compared to the parameters measured by Swan-Ganz catheter ( $r = 0.57$ ).

#### Conclusion

We found that COLD system gives more adequate information from the hemodynamic status of the patient, than the more invasive Swan-Ganz catheterization. Volumetric preload parameters correlated significantly better with the changes of CI, than the conventional pressure preload parameters.

## 38

### DIAGNOSIS OF SHOCK DUE TO MASSIVE PULMONARY EMBOLISM

Krivec B., Voga G., Skale R., Parežnik R., Podbregar M., Gabršček L.

*Department of Intensive Internal Medicine, General Hospital Celje, Celje, Slovenia*

#### Study objective

To evaluate the value of transesophageal echocardiography (TEE) as an initial diagnostic method in patients with unexplained shock.

#### Setting

Medical ICU in 800-bed hospital.

#### Patients and methods

Forty consecutive shocked patients with congested jugular veins without clinical signs of pulmonary congestion. Both ventricles, atrial septum, main pulmonary artery (MPA), right pulmonary artery (RPA) and left pulmonary artery (LPA) were examined by single plane (24 patients) and multiplane TEE (16 patients).

#### Measurement and results

Twenty-seven patients had isolated right ventricular dilatation. Global right ventricular hypokinesis was present in 26 and segmental akinesis in one patient. Nineteen thrombemboli were visualized in RPA, 6 in LPA and 3 in MPA. Ten patients had predominant left ventricular dysfunction and 3 had cardiac tamponade. According to pulmonary scintigraphy or autopsy, sensitivity of TEE for diagnosis of massive pulmonary embolism (MPE) in patients with right ventricular dilatation and shock was 90 % and specificity was 100 %.

#### Conclusion

In contrast to transthoracic echocardiography, TEE is an accurate and definite bedside diagnostic tool in patients with unexplained nonhypovolemic shock and can directly visualize central thrombemboli in shocked patients with MPE.

## SECTION: SYSTEMIC INFLAMMATION AND SEPSIS

39

### GOAL-DIRECTED THERAPY IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK: DOES IT EXIST?

Radermacher P.

Section Anaesthesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinik für Anaesthesiologie, Ulm, Germany, peter.radermacher@medizin.uni-ulm.de

No abstract available.

40

### SEPSIS, SEPTIC SHOCK AND MULTIPLE ORGAN DYSFUNCTION: NEW THINKING ABOUT THEIR PATHOPHYSIOLOGY

Matějovič M., Rokyta R. jr., Kroužeký A., Novák I.

ICU, Medical Department, Charles University Hospital Plzeň, Czech Republic, matejovic@fnplzen.cz

**Key words:** Sepsis / Septic shock / Multiple organ dysfunction / Nitric oxide / Peroxynitrite / PARS / Endothelial dysfunction / Coagulation / Fibrinolysis

Sepsis is a highly complex pathophysiological state representing a major challenge to physicians. The most common cause of death in patients with sepsis/septic shock is deterioration of the function of multiple organs, termed multiple organ dysfunction syndrome (MODS). This brief review addresses the recent important issues concerning the downstream and relatively late effectors of acute inflammation. Among these, a complex interplay of nitric oxide, oxidative stress and PARS pathway is emerging as one of key mechanisms involved in the development of organ dysfunction in various acute pathological conditions including septic shock. In addition, since the endothelium represents both mechanism and target in the pathogenesis of septic shock and multiorgan dysfunction, the basic aspects of the microvascular endothelial response to inflammatory and hemostatic stress are also discussed.

#### Introduction

Recent 1998 data from the Centers for Disease Control show that sepsis is the 11<sup>th</sup> leading cause of death overall. In addition, Angus and colleagues<sup>1</sup> projected the incidence of sepsis to increase 1.5 % per annum due to growth in predisposed segments of the population. The most common cause of death in patients with sepsis/septic shock is deterioration of the function of multiple organs, termed multiple organ dysfunction syndrome (MODS). Unfortunately, therapy of these syndromes still remains largely supportive. Consequently, the implication of an understanding of the complex pathophysiology of septic shock and

organ dysfunction are critical to the development of mechanism-based therapeutic strategies. Clinical trials, however, using so-called “immuno-therapy” failed to produce a significant improvement in the treatment of sepsis over the past 20 years. This failure suggest either that multiple mediators must be targeted or that the morbidity of sepsis results from the downstream consequences of cytokine activity<sup>2</sup>. This brief review addresses the recent important issues concerning these downstream and relatively late effectors of acute inflammation. Among these, a complex interplay of nitric oxide, oxidative stress and PARS pathway is emerging as one of key mechanisms involved in the development of organ dysfunction in various acute pathological conditions including septic shock. In addition, since the endothelium represents both mechanism and target in the pathogenesis of septic shock and multiorgan dysfunction, the basic aspects of the microvascular endothelial response to inflammatory and hemostatic stress are also discussed.

#### Cardiovascular failure in septic shock

The circulatory failure associated with septic shock is characterized by severe hypotension as a result of low peripheral vascular resistance, hyporeactivity of the vasculature to vasoconstrictor agents (vasoplegia), myocardial dysfunction, maldistribution of microcirculatory blood flow, and reduced tissue oxygen extraction. Previous explanation for this hemodynamic pattern in septic shock included down-regulation of adrenoceptors, metabolic acidosis, injury to vascular cells due to severe hypotension or effects of many different circulating mediators such as prostaglandins. Although the underlying mechanism of sepsis-induced hypotension seems to be very complex and not yet completely understood, the present evidence suggest that three probably closely interacting major pathways are involved in this loss of peripheral vascular tone.

#### 1. The role of nitric oxide (NO) and reactive nitrogen/oxygen species (RNOS)

Several lines of evidence support the view that the overproduction of NO by inducible nitric oxide synthase (iNOS) contributes significantly to the circulatory failure in septic shock. First, pharmacologic inhibition of iNOS have been documented to improve or reverse hypotension both in rodents and larger mammals models of endotoxemia or sepsis<sup>3-6</sup>. Second, mice in which iNOS gene has been inactivated by gene targeting (iNOS-knockout mice) exhibited only a minor fall in blood pressure when challenged with endotoxin<sup>7,8</sup>. Finally, the inhibition of NO production maintained blood pressure and enabled a reduction of vasopressor support in human studies<sup>9</sup>. However, a randomized, placebo-controlled, multicentre phase III trial was recently halted because of significantly worse survival among patients receiving non-selective NOS inhibitor; the mechanisms of this adverse effect remain to be elucidated<sup>10</sup>. Hence, non-selective NOS inhibition – although increasing blood pressure – seems unlikely to find a role in the management of human septic shock. By contrast, results from preclinical studies with selective iNOS inhibitors are promising and require further evaluation. Several possible mechanisms account for NO-mediated hypotension. Not only NO itself (via cGMP-mediated smooth muscle relaxation), but also its downstream biological effects may play a pathophysiological role in sepsis-induced vasodilatation<sup>6</sup>. Growing body of evidence suggests that peroxynitrite (ONOO<sup>-</sup>), a highly toxic reactive species formed from NO and superoxide (O<sup>-</sup>), is capable of inducing endothelial dysfunction and vascular hyporeactivity<sup>11</sup>. Recently, Takakura



et al. proposed that cardiovascular hyporeactivity to catecholamines in septic shock may be due in part to ONOO<sup>-</sup>-induced inactivation of  $\alpha$ -adrenoreceptors<sup>12</sup>. The potential important role of RNOS in the pathophysiology of circulatory failure in septic shock was also recently demonstrated by Macarthur et al.<sup>13</sup>. They showed that superoxide can deactivate catecholamines resulting in loss of their activity. Moreover, administration of superoxide dismutase mimetic to a rat model of endotoxic shock restored the vasopressor response to norepinephrine<sup>13</sup>. Finally, NO may also exert its vasodilatory effects by activation of potassium channels (see below) in the plasma membrane of vascular smooth muscle cells<sup>14</sup>, underscoring the complexity of NO-mediated vascular effects.

## 2. The role of activation of ATP-Sensitive Potassium Channels

The key role in the regulation of vascular tone plays the membrane potential of vascular smooth muscle cells. Hyperpolarization closes calcium channels thereby decreasing the cytosolic calcium concentration resulting in relaxation. ATP-sensitive potassium channels ( $K_{ATP}$  channels) markedly influence the membrane potential of vascular smooth muscle cells. The opening of  $K_{ATP}$  channels, triggered by decreased cellular ATP content or increased intracellular concentrations of lactate or hydrogen ion, promotes vasodilatation by hyperpolarizing the membrane and preventing the influx of calcium into the vascular cells<sup>15–17</sup>. Inhibition of these  $K_{ATP}$  channels using antidiabetic drug sulfonylurea reversed hypotension in rodent models of endotoxic shock<sup>16</sup>. As mentioned above, apart from metabolic causes,  $K_{ATP}$  channels might also be activated by NO<sup>14</sup>.

## 3. The role of vasopressin

Vasopressin, a peptide hormone, is an essential component of cardiovascular homeostasis. During the initial phase of septic shock the levels of vasopressin are increased. However, later in the course of septic shock, the plasma levels of vasopressin are inappropriately low<sup>18</sup>. This deficiency of vasopressin seems to be another crucial player in the pathogenesis of vasodilatory shock. Indeed, in patients with septic shock infusion of low doses of exogenous vasopressin (to only restore the vasopressin deficiency) caused a significant vasopressor response<sup>18</sup>. Although the exact mechanism explaining the low vasopressin levels remains to be elucidated, the depletion of neurohypophyseal stores of vasopressin has recently been demonstrated<sup>19</sup>. Concerning the mechanism of action of vasopressin, it is amazing that vasopressin is able to inactivate  $K_{ATP}$  channels as well as decrease synthesis of iNOS<sup>20</sup>.

Hence, circulatory failure in septic shock involves a complex interplay of several interacting mechanisms. The exact understanding how these vasoregulatory pathways are linked and how they work may help to develop an effective and safety therapeutic approach for patients in refractory septic shock.

### Organ dysfunction in septic shock – impaired cellular energetics as a final common pathway – the role of cytopathic hypoxia and endothelial cell dysfunction.

Several overlapping mechanisms including a cascade of bacterial factors, inflammatory mediators, endothelial injury, microcirculatory failure and disturbed hemostasis have been proposed to explain the development of MODS. Among these, (1) **the hypoxic component** resulted from an inadequate oxygen supply to tissues, and (2) **direct cytotoxic effects** of various mediators are believed the key elements in the pathophysiology of MODS in sepsis/septic shock.

**The hypoxic component.** Tissue hypoxia is a crucial factor in the pathophysiology of MODS. In sepsis, the oxygen delivery at which supply dependency develops may be higher than expected – so called patho-

logical oxygen-supply dependency<sup>21</sup>. Moreover, an imbalance between regional oxygen demand and delivery may occur despite adequate perfusion and oxygen kinetics at the level of the whole organism. This is particularly true in case of hepato-splanchnic area<sup>22</sup>.

**Direct cytotoxic effects.** A growing body of evidence indicates that alterations in cellular energy metabolism independent of oxygen availability, termed **cytopathic hypoxia**<sup>23</sup>, may be a critical component in the genesis of organ dysfunction in sepsis. A number of pathogenic mechanisms have been proposed, including inhibition of key mitochondrial enzymes involved in either the tricarboxylic acid (TCA) cycle or the electron transport chain, uncoupling of oxidative phosphorylation, diminished delivery of a key substrate (i. e. pyruvate) into the TCA cycle or activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS) (ref.<sup>23</sup>). Accumulating data support the view that NO-related pathway (both direct and indirect) is, at least partly, responsible for impaired cellular bioenergetics in sepsis. As mentioned above, many biological actions of NO are mediated through the guanylyl cyclase/cGMP system. In addition to cGMP-related pathway, the potential cytotoxic effects of NO includes a number of cGMP-independent actions such as the inhibition of key mitochondrial enzymes<sup>24</sup>. Realization that overproduction of NO from iNOS could be the final common pathway in the pathogenesis of sepsis-induced tissue injury formed the basis for novel therapeutic strategies. It must be stressed, however, that NO is not only an ugly molecule in sepsis<sup>25</sup>. It is generally assumed that NO produced by eNOS has protective effects, whereas excess NO production by iNOS contributes to the development of tissue injury. However, even iNOS-generated NO may be beneficial under some circumstances. This paradox is best demonstrated in sepsis, where NO has a dual role, ranging from vasoregulation and cell signaling to direct cellular toxicity. Thus, depending on the type of insult, the tissue type, the level and duration of iNOS expression, and the redox stress, NO can be either cytoprotective or cytotoxic, acting either pro- or anti-inflammatory<sup>25–27</sup>.

The second important mechanism which has been suggested to play a major role in the cellular and tissue damage associated with the overproduction of NO is formation of peroxynitrite (ONOO<sup>-</sup>). Peroxynitrite is even more cytotoxic than NO and may exert several toxic effects<sup>11, 26</sup>, including inhibition of mitochondrial respiration<sup>11, 28</sup> and increased microvascular permeability<sup>29</sup>. The deleterious effects of peroxynitrite are mediated both directly or indirectly, implicating DNA damage and subsequent activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS), a pathway increasingly recognized as a major mechanism of NO/peroxynitrite-induced cytotoxicity<sup>30–32</sup>. Activation of this nuclear enzyme depletes the intracellular stores of its substrate nicotinamide adenine dinucleotide, slowing the rate of glycolysis, mitochondrial electron transport and adenosine triphosphate formation. This process triggers failure of cellular energetics, leading to cell dysfunction and necrosis. The experimental data suggests that this “PARS suicide mechanism” is involved in many of fundamental disturbances of endotoxic shock, including endothelial dysfunction<sup>30</sup>, loss of vascular energetic and contractile failure<sup>33</sup>, pulmonary endothelial and intestinal mucosal hyperpermeability<sup>34, 35</sup>, and impairment of mitochondrial respiration<sup>36</sup>. Moreover, once upregulated, PARS is able to activate multiple pro-inflammatory cascades, resulting in progressively amplifying the inflammatory response<sup>32, 37</sup>. Pharmacological inhibition of PARS has been shown effective in protecting tissue injury in various shock and inflammatory conditions, and may therefore represent a promising and very potent therapeutic tool.

**The endothelial cells** with their total surface exceeding 1000 m<sup>2</sup> represent the key (if not the most important) target organ for the action of inflammatory mediators<sup>38</sup>. During inflammation, endothelium becomes **activated** due to changes in endothelial cells phenotype. This results in increased expression and release of endothelial adhesion mole-

cules<sup>38</sup>. In sepsis/septic shock, however, the exposure of endothelium to cytokines and their downstream effectors described above results in profound alterations in many of physiological endothelial function (endothelial **dysfunction**) (ref.<sup>38, 39</sup>). These changes encompass altered balance between endothelial vasoactive compounds (i. e. NO, carbon monoxide, endothelins, prostacyclin) resulting in loss of vascular tone and microvascular perfusion heterogeneity, expression of adhesion molecules, production of cytokines and RNOS, and imbalance between pro- and anticoagulant mechanisms<sup>40</sup>.

The latter mechanism has recently gained particular importance<sup>41, 42</sup>. The excessive inflammation and associated endothelial dysfunction lead to release of tissue factor (from endothelial cells and mononuclear), a key mediator linking inflammation and coagulation, which in turn triggers the extrinsic coagulation cascade and accelerates the production of thrombin<sup>43</sup>. This procoagulant state is normally balanced by the production of endogenous anticoagulant factors, such as antithrombin III, activated protein C and tissue factor pathway inhibitor. However, these modulators are consumed in sepsis and their levels become deficient<sup>44</sup>. In this context, a critical point in **the loss of pro-anticoagulant balance** is ascribed to the endothelial surface proteins thrombomodulin and endothelial protein C receptor (EPCR). These proteins, under normal conditions, activate the protein C possessing antithrombotic, profibrinolytic and anti-inflammatory properties<sup>41</sup>. If the endothelial injury is present, the functions of these regulating proteins are impaired<sup>44</sup>.

Furthermore, studies have shown that pro-inflammatory mediators causing endothelial dysfunction not only produce the pro-coagulant properties of endothelial cells, but also suppress the fibrinolytic capacity of the endothelium, resulting in marked **imbalance between coagulation and fibrinolysis**<sup>45, 46</sup>. Suppressed fibrinolysis means that the capacity of fibrinolytic system to remove formed microthrombi and maintain microvascular blood flow is impaired. The reasons for the diminished fibrinolysis in sepsis include a decrease in tissue-type plasminogen activator (t-PA, produced by endothelial cells), increased activity of plasminogen activator inhibitor (PAI-1, produced by endothelial cells and platelets) and thrombin activatable fibrinolysis inhibitor (TAFI), and formation of plasmin-antiplasmin (PAP) complexes<sup>47</sup>. Hence, the inflammation-induced shift of endothelial cell phenotype to a prothrombotic state may promote the widespread formation of microvascular thrombi, resulting in microcirculatory failure and tissue hypoxia<sup>48</sup>. This apparent cross-talk between the inflammation network and coagulation pathway suggest that activation of coagulation may amplify the uncontrolled inflammatory response, ultimately leading to multiorgan dysfunction. The clinical significance of this new paradigm on the pathophysiology of sepsis and organ dysfunction continue to be delineated. Results of recently completed phase III study with activated protein C are promising.

## Conclusion

There are many diseases in the medicine that require multiple agents for successful treatment. They include, for example, combined immunosuppression for transplanted organs; diuretics, ionotropes and vasodilators for patients with heart failure; multiple antibiotics for polymicrobial infection or combined chemotherapy for cancer treatment. Because of enormous complexity of the pathophysiology of sepsis and related multiorgan dysfunction, it is likely that similar combined and sequential targeting of several principal mechanisms may be needed to yield clinical success when treating sepsis and multiple organ dysfunction. In this context, every effort made to identify a single pathophysiological pathway may help to put together the final picture of "sepsis puzzle".

## Acknowledgement

*This work was supported by a research grant IGA MZ ČR ND 6837-3/2001.*

## References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001; 29: 1303–10.
2. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. *Crit Care Med* 2001; 29 (Suppl): S99–S106.
3. Wray GM, Milliar CG, Hinds CJ, Thiemermann C: Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. *Shock* 5: 329–335, 1998.
4. Matejovic M, Radermacher P, Tutgekin I, Stehr A, Theisen M, Vogt J, Wachter U, Ploner F, Georgieff M, Träger K. Effects of selective iNOS inhibition on gut and liver O<sub>2</sub> – exchange and energy metabolism during hyperdynamic porcine endotoxemia. *Shock* 2001; 16: 203–10.
5. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. *New Horiz* 1995; 3: 2–32.
6. Shah AM. Inducible nitric oxide synthase and cardiovascular disease. *Cardiovascular research* 2000; 45: 148–155.
7. MacMicking JD, Nathan C, Hom G et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell* 1995; 81: 641–650.
8. Hollenberg SM, Broussard M, Osman J, Parillo JE. Increased microvascular reactivity and improved survival in septic mice lacking inducible nitric oxide synthase. *Circ Res* 2000; 86: 774–779.
9. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor N<sup>G</sup>-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. *Crit Care Med* 1999; 27: 913–922.
10. Grover R, Lopez A, Lorrente J, Steingrub J, Bakker J, Williatts S, McLuckie A, Takala J. Multi-center, randomized, placebo controlled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. *Crit Care Med* 1999; 27: A33.
11. Szabó C: The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. *Shock* 6: 79–88, 1996.
12. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S. Modification of alpha-1 adrenoreceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. *Crit Care Med* 2002; 30: 894–899.
13. Macarthur H, Westfall T, Riley D, Misko T, Salvemini D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. *PNAS* 2000; 97: 9753–8.
14. da Silva Santos JE, Terluk MR, Assereuy J. Differential involvement of guanylyl cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats. *Shock* 2002; 17: 70–76.
15. Landry DW, Oliver JA. The ATP-sensitive K channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. *J Clin Invest* 1992; 89: 2071–4.
16. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. *Horm Metab Res* 1996; 28: 496–507.
17. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. *New Engl J Med* 2001; 345: 588–595.
18. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilatation of septic shock. *Circulation* 1999; 95: 1122–1125.
19. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. *Crit Care Med* 2002; 30: 497–500.
20. Umino T, Kusano F, Muto S et al. AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. *Am J Physiol* 1999; 276: F433–F441.
21. De Backer D, Vincent JLV. VO<sub>2</sub>-DO<sub>2</sub> relationship are altered in some critically ill patients. *Semin Respir Crit Care Med* 1995; 16: 394–402.
22. De Backer D, Creteur J, Noordally O, Smail N, Gulbis B, Vincent JL. Does hepato-splanchnic VO<sub>2</sub>/DO<sub>2</sub> dependency exist in critically ill septic patients? *Am J Respir Crit Care Med* 1998; 157: 1219–1225.
23. Fink MP. Cytopathic hypoxia: mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. *Critical Care Clinics* 2001; 17: 219–237.
24. Brown GC: Nitric oxide and mitochondrial respiration. *Biochimica et Biophysica Acta* 1411: 351–369, 1999.
25. Radermacher P, Matejovic M, Brückner UB: Liver dysfunction: Nitric oxide, Carbon Monoxide, and Reactive Oxygen Species. In: Evans TW and Fink MP

- (eds): Mechanisms of Organ Dysfunction in Critical Illness. Springer-Verlag Berlin Heidelberg 2002; pp 301–314.
26. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? *Pharmacology & therapeutics* 2001; 91: 179–213.
  27. Li J, Billiar TR: Nitric oxide. Determinants of nitric oxide protection and toxicity in liver. *Am J Physiol* 1999; 275: G1069–G1073.
  28. Zingarelli B., Day BJ, Crapo JD, Salzman AL, Szabó C: The potential role of peroxynitrite in the vascular contractile and cellular energy failure in endotoxemic shock. *Br J Pharmacol* 1997; 120: 259–267.
  29. Greenacre S, Ridger V, Wilsoncroft P, Brain SD. Peroxynitrite: a mediator of increased microvascular permeability? *Clin Exp Pharmacol Physiol* 1996; 24: 880–88261. Szabó C.
  30. Szabó C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxin shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. *J Clin Invest* 1997; 100: 723–735.
  31. Cuzzocrea S, Zingarelli B, Costantino G, Sottile A, Teti D, Caputi AP. Protective effect of poly (ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. *Crit Care Med* 1999; 27: 1517–1523.
  32. Liaudet L. Poly(adenosine 5'-diphosphate) ribose polymerase activation as a cause of metabolic dysfunction in critical illness. *Curr Opin Clin Metab Care* 2002; 5: 175–184.
  33. Zingarelli B, Salzman AL, Szabó C. Protective effects of nicotinamide against nitric oxide-mediated delayed vascular failure in endotoxemic shock: potential involvement of polyADP ribosyl synthetase. *Shock* 1996; 5: 258–264.
  34. Szabó A, Salzman AL, Szabó C. Poly (ADP-ribose) synthetase activation mediates pulmonary microvascular and intestinal mucosal dysfunction in endotoxemic shock. *Life Sci* 1998; 63: 2133–2139.
  35. Taner AS, Cinel I, Ozer L et al. Poly (ADP-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge. *Shock* 2001; 16: 159–162.
  36. Szabó C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. *Free Radical Biol Med* 1996; 21: 855–869.
  37. Yang Z, Zingarelli B, Szabó C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. *Shock* 2000; 13: 60–66.
  38. Vallet B, Wiel E, Talbère-Rodière PA. Endothelial cell dysfunction and abnormal tissue perfusion. In: Evans TW and Fink MP (eds): Mechanisms of Organ Dysfunction in Critical Illness. Springer-Verlag Berlin Heidelberg 2002; pp 175–190.
  39. Hack CE, Zeerleder S. The endothelium in sepsis: source of and target for inflammation. *Crit Care Med* 2001; 29 (Suppl): S21–S27.
  40. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. *Crit Care Med* 2001; 29 (Suppl): S36–S41.
  41. Vincent JL. Microvascular endothelial dysfunction: renewed appreciation of sepsis pathophysiology. *Critical Care* 2001; 5: S1–S5.
  42. Bernard G, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344: 699–711.
  43. Gando S, Nanzaki S, Sasaki S et al. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. *Crit Care Med* 1998; 26: 2005–2009.
  44. Esmon T. Role of coagulation inhibitors in inflammation. *Thromb Haemost* 2001; 86: 51–6.
  45. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. *Semin Thromb Hemost* 1998; 24: 33–44.
  46. Levi M, van der Poll T, ten Chate H et al. The cytokine mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. *Eur J Clin Invest* 1997; 27: 3–9.
  47. Thijs LG. Coagulation abnormalities in critical illness. In: Evans TW and Fink MP (eds): Mechanisms of Organ Dysfunction in Critical Illness. Springer-Verlag Berlin Heidelberg 2002; pp 376–393.
  48. Vallet B. Microthrombosis in sepsis. *Minerva Anesthesiol* 2001; 67: 298–301.

## GASTROINTESTINAL TRACT RESUSCITATION IN CRITICALLY ILL PATIENTS

Träger K., Radermacher P.

*Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinik für Anästhesiologie, Ulm, Germany*

Particular research interest has focused on the resuscitation on the gastrointestinal tract in the recent past: on the one hand, this organ system is regarded to be the “motor of multiple organ failure”<sup>1</sup> representing both a *mechanism* and a *target*. On the other hand the gut has been attributed the role of the “canary of the body”<sup>2</sup>, i. e. a sentinel organ which is particularly susceptible to derangements of blood flow and/or oxygen and substrate supply due to its particular micro-circulatory anatomy, and may therefore promote a vicious circle resulting from the translocation of endotoxin and/or live bacteria and ultimately leading to organ dysfunction<sup>3</sup>.

The gastrointestinal tract is characterized by a number of particular features which interfere with every resuscitative measure:

1. The blood supply is unique in the body, inasmuch it comprises both a *serial* and a *parallel* vascular bed providing for blood flow to the most important organ, the liver. This vascular bed belongs both to the high pressure as well as to the low pressure vascular net. Since in general access to the portal vein is prohibited for obvious anatomical reasons oxygen and/or substrate kinetics can only yield net balances for the whole hepato-splanchnic region i. e. gut and liver taken together. Therefore discrimination between these organs is normally impossible.
2. Liver blood flow of which about 75–80 % is supplied by the portal vein and only 20–25 % by the common hepatic artery has an inter-dependent regulation, inasmuch changes in the portal venous blood flow are compensated for by compensatory variations in hepatic arterial perfusion in order to maintain total blood flow. This phenomenon is known as the *hepatic arterial buffer response*<sup>4</sup>.
3. The total blood flow to the hepato-splanchnic region accounts for about 20–25 % of cardiac output, while the oxygen uptake in this region contributes approximately 25–30 % to the whole body oxygen consumption. Consequently the regional oxygen extraction is normally higher than the systemic one resulting in the well-known hepatic venous-mixed venous hemoglobin oxygen saturation gradient of  $\approx 5$  in normal healthy volunteers.
4. Because of the central synthetic role of the liver functional changes cannot only be described by blood flow and oxygen exchange rates but have to take into account the numerous organ specific metabolic pathways, some of which being highly oxygen dependent (gluconeogenesis, protein synthesis) (ref.<sup>5</sup>). This phenomenon is further underscored by the intrahepatic metabolic compartmentation resulting from the different localization of metabolic activity within the periportal and perivenous region<sup>6</sup>.

The strategies primarily aim at the augmentation of blood flow and oxygen/substrate supply by using fluids, vasoactive drugs or epidural anesthesia, but nutritional and metabolic support are considered as well as the role of antioxidant supplementation<sup>7</sup>.

### Regional Blood Flow

Augmentation of blood flow to the hepato-splanchnic system certainly is the primary aspect in the resuscitation of the gastrointestinal tract. It should be noted that depending on the underlying physiologic status

the response of the regional circulation may differ substantially from that of total cardiac output. For example, the infection- and sepsis-induced increase in cardiac output for instance is mostly affiliated with a parallel rise of the regional blood flow<sup>8</sup>, but this increase in blood flow may not necessarily match the oxygen demands which may result in increased regional oxygen extraction and, consequently, a rise of the hepatic venous-mixed venous hemoglobin oxygen saturation gradient which may even be used as a diagnostic parameter indicating pathologic regional oxygen uptake/supply dependency<sup>9</sup>.

### Hypovolemia

It is trivial that the redistribution of cardiac output to the vital organs brain and heart during hypovolemia – such as changing from the recumbent to the erect position<sup>8</sup> – induces a substantial fall in the blood flow to the hepato-splanchnic organs<sup>8</sup> resulting from increased regional vascular resistance. It should be kept in mind, however, that this splanchnic vasoconstriction does not resume after hypovolemia is corrected<sup>10</sup>. By contrast, optimizing the intravascular filling by perioperative plasma volume expansion was associated with reduced incidence of gastric mucosal acidosis and postoperative morbidity and complications in patients undergoing cardiac surgery<sup>11</sup>. Covert hypovolemia probably is also responsible for the drop in hepato-splanchnic blood flow associated with epidural anesthesia, because when appropriately used epidural anesthesia not only increased colonic mucosal blood flow but also improved the gastric mucosal-arterial PCO<sub>2</sub> gap and the small bowel motility and degree of dilatation as determined by ultrasound techniques in patients with peritonitis<sup>12</sup>.

### Mechanical Ventilation

Intermittent positive pressure ventilation, in particular with a PEEP, increases mean intrathoracic pressure and, consequently, the “downstream”-pressure of the hepatic-circulation due to the rise of the (non-transmural) right atrial pressure. Therefore the hepato-splanchnic blood flow declines, in particular in the portal vein<sup>13</sup>. It must be underscored, however, that hepato-splanchnic blood is not affected or even increases when the PEEP level is titrated to the lung pressure-volume curve, i. e. respecting the lower inflection point of the static compliance curve<sup>14</sup>. Finally, ventilation in the prone position, a routine maneuver to improve pulmonary gas exchange may also jeopardize gastrointestinal energy balance: of 12 patients ventilated in the prone position for acute lung injury and who developed increased intraabdominal pressure. 9 ones showed an increased gastric mucosal-arterial PCO<sub>2</sub> gap. Those patients in whom the intraabdominal pressure remained unchanged, however, the PCO<sub>2</sub> gap was unaffected confirming data reported by Sugrue et al. on the relation between intraabdominal pressure and mucosal acidosis<sup>15</sup>. Inappropriate weaning from mechanical ventilation, however, may also compromise the gastrointestinal perfusion: It is well-known that exercise is associated with an increase of cardiac output at the expense of the perfusion in the gastrointestinal tract<sup>8</sup>. “Breathing as an exercise”<sup>16</sup> may mimic this situation and thus lead to a reduced gastric mucosal perfusion such as demonstrated in patients who could not be weaned from the respirator using Laser Doppler flowmetry<sup>17</sup>.

### Vasoactive Drugs

Catecholamines are most commonly used to increase cardiac output and regional blood flow, and in fact, infusing adrenaline or noradrenaline increased hepato-splanchnic blood flow in volunteers in a dose-dependent manner as a function of their  $\beta$ -adrenergic receptor agonist properties<sup>18</sup>. Nevertheless, it must be underscored that “not all cate-

cholamines are created equal”<sup>19</sup>: Adrenaline not only impaired hepato-splanchnic blood flow and oxygen exchange when compared to a combination of noradrenaline and dobutamine, but also compromised hepato-splanchnic lactate clearance<sup>20</sup>, which may be of particular importance since hyperlactatemia in the critically ill is primarily caused by impaired lactate removal in the liver<sup>21</sup>. Moreover, in contrast to this catecholamine combination adrenaline also increased the lactate/pyruvate ratios<sup>22</sup> indicating at least transiently aggravated cytosolic redox state<sup>23</sup>. Finally, adding dobutamine to noradrenaline in septic shock improved gastric mucosal perfusion as assessed with Laser Doppler flowmetry as well as intramural acidosis when compared to noradrenaline or adrenaline alone<sup>24</sup>. Dobutamine alone also compared favorably in this respect with dopamine<sup>25</sup>, and unlike doxamine lowered the lactate/pyruvate ratios in noradrenaline-dependent patients with septic shock<sup>26</sup>. In fact, the beneficial effects of doxamine on the gastrointestinal tract remain controversial: although this substance has been reported to “protect the hepato-splanchnic organs”<sup>27</sup>, in part due to increased regional microcirculatory blood flow<sup>28</sup>, this effect has been questioned in the recent past: Kiefer et al. could not confirm the preferential rise of the hepato-splanchnic blood flow attributed to doxamine when it was added in noradrenaline-dependent patients with septic shock<sup>29</sup>, and no beneficial effect on any parameter of regional metabolism and energy balance was found either<sup>30</sup>. Furthermore, the gastric mucosal-arterial PCO<sub>2</sub> gap even worsened despite increased regional blood flow when incremental infusion rates of doxamine were administered in patients treated with continuous i. v. dobutamine<sup>31</sup>. Nevertheless, the exogenous  $\beta$ -adrenergic receptor stimulation seems to be pivotal in inotrope-dependent patients with septic shock: replacing noradrenaline by the pure  $\alpha$ -agonist phenylephrine considerably reduced the regional blood flow and thereby impaired the hepato-splanchnic metabolic performance although no change in systemic hemodynamics or gas exchange had occurred<sup>32</sup>. Interestingly, a “splanchnic-directed”, i. e. pHi-guided therapy in trauma patients had already previously suggested the potential importance of  $\beta$ -mimetics for the resuscitation of the gastrointestinal tract: combining folate and mannitol with the infusion of low-dose *isoproterenol* significantly reduced the number of organ failures and subsequently ICU and hospital length of stay<sup>33</sup>. In addition to catecholamines non-adrenergic compounds may also be considered to improve the blood flow to the hepato-splanchnic organs, the most studied being prostacyclin (or its stable analogue iloprost) and N-acetylcysteine.

Prostacyclin, a vasodilator prostaglandin with platelet-aggregation inhibiting and cytoprotective properties is well-known to increase hepatic blood flow in healthy volunteers<sup>34</sup>, and we could confirm this effect infusing iloprost in noradrenaline-dependent patients with septic shock. It is noteworthy that beyond increasing blood flow prostacyclin or iloprost also seem to beneficially influence gut and liver energy balance and metabolic performance: Lehmann et al. recently reported that  $1 \text{ ng} \times \text{kg}^{-1} \times \text{min}^{-1}$  improved plasma indocyanine-green clearance as measured using thermal-dye double-indicator dilution in a comparable group of patients without any detectable effect on systemic hemodynamics<sup>35</sup>.

N-acetylcysteine has become the treatment of choice for paracetamol intoxication-related liver failure due to its glutathione replenishing and, hence, antioxidant effects, as well as to its vasodilator properties as a sulfhydryl donor regenerating the Endothelial Derived Relaxing Factor<sup>36</sup>, in particular during episodes of hyperoxic ventilation<sup>37</sup>. In patients with septic shock requiring vasopressors to maintain adequate blood pressure it increased hepato-splanchnic blood flow and improved both the gastric mucosal-arterial PCO<sub>2</sub> gap and the conversion of lidocaine to monoethylglycinexylidide, a parameter of the cytochrome P450 system located in the perivenous hepatocytes<sup>38</sup>.

## Nutritional And Metabolic Support

Nutritional and metabolic support for the gastrointestinal tract comprises several aspects, i. e. the supplementation of glutamine, arginine as the precursor molecule of nitric oxide,  $\omega$ -3 polyunsaturated fatty acids, trace elements and antioxidants, all of which probably being most efficient when used in combination. Clearly, preferring the enteral over the parenteral route is of utmost importance in this context, in part certainly as a result of the increase in regional blood flow affiliated with the enteral administration of calories<sup>39</sup>. It has to be kept in mind, however, that this increased blood flow is the physiologic adaptive response to the rise in oxygen demands associated with enteral intake<sup>39</sup>, and up to now no bedside monitoring is available to discriminate between the supportive and stressful effects of enteral nutrition. While the beneficial role of enteral nutrition *per se* seems to be unequivocal this issue is not definitely settled for the "key nutrient" supplementation. Two recent meta-analyses reviewing 23 clinical trials including a total of 2.491 patients concluded that this nutritional strategy reduces overall hospital stay of critically ill patients, in particular after surgical interventions, but does not influence mortality<sup>40, 41</sup>. Moreover, enteral feeding supplemented with antioxidants and fish-oil lipids improved pulmonary gas exchange and thereby reduced the duration of mechanical ventilation and ICU stay in patients with acute respiratory failure, possibly due to the anti-inflammatory properties of the  $\omega$ -3-fatty acids<sup>42</sup>. Finally, an antioxidant-supplemented enteral nutrition comprising vitamin C and E, selenium and N-acetylcysteine reduced both infectious complications and organ failure<sup>43</sup> in trauma patients similar to the effects of trace element supplementation in burn patients<sup>44</sup>. Glutamine supplementation, however, only exerted significant beneficial effects when administered parenterally: Powell-Tuck *et al.*<sup>45</sup> could not confirm the improved hospital outcome described previously<sup>46</sup>, and length of hospital stay was significantly reduced in the surgical patients only<sup>45</sup>. By contrast, in patients receiving enteral glutamine supplementation mortality was strictly the same as in those given a standard feed<sup>47</sup>.

## Conclusions

A variety of therapeutic strategies has been investigated for the resuscitation of the gastrointestinal tract. Among the different approaches volume expansion and vasoactive drugs, either catecholamines or non-adrenergic substances, primarily aim at the augmentation of blood flow and oxygenation and thereby energy balance but may also allow to improve the metabolic performance. Moreover, the potentially profound effects of clinical routine measures in day-to-day ICU practice such as mechanical ventilation and weaning from the respirator need to be taken into account for their impact on the hepato-splanchnic system. Finally, integrating nutritional and metabolic support by combining different substrates and antioxidants adds to the therapeutic orchestra aimed at this organ system.

## References

1. Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple organ failure syndrome. The gastrointestinal tract: the "motor" of MOF. *Arch Surg* 1986; 121:196–208.
2. Dantzer DR. The gastrointestinal tract – the canary of the body? *JAMA* 1993; 270:1247–8.
3. Chievelly-Williams S, Hamilton-Davies C. The role of the gut in major surgical postoperative morbidity. *Int Anesthesiol Clin* 1999; 37: 81–110. An elegant review of the pathophysiology, monitoring and treatment of the gut.
4. Jakob SM, Takala J. Importance of the splanchnic circulation. *Int J Intensive Care* 1999; 6: 42–6.
5. Träger K, Brinkmann A, Georgieff M, Radermacher P. Therapeutische Beeinflussung des Hepato-Splanchnikusgebiets bei Traum und Sepsis. Mehr als  $\text{VO}_2/\text{DO}_2$  Verhältnisse? *Anaesthesist* 2000; 49: 451–54.
6. Gumucio JJ. Hepatocyte heterogeneity: the coming of age from the description of a biological curiosity to a partial understanding of its physiological meaning and regulation. *Hepatology* 1989; 9: 154–60.
7. Pastores SM, Katz DP, Kvetan V. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. *Am J Gastroenterol* 1996; 91: 1697–710.
8. Bradley ES. Variations in hepatic blood flow in man during health and disease. *N Engl J Med* 1949; 12: 456–61.
9. DeBacker D, Creteur J, Noordally O *et al.* Does hepato-splanchnic  $\text{VO}_2/\text{DO}_2$  dependency exist in critically ill septic patients? *Am J Respir Crit Care Med* 1998; 157: 1219–25.
10. Edouard AR, Degremont AC, Duranteau J *et al.* Heterogeneous regional vascular responses to simulated transient hypovolemia in man. *Intensive Care Med* 1994; 20: 414–20.
11. Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. *Arch Surg* 1995; 130: 423–9.
12. Spackman DR, McLeod ADM, Prineas SN *et al.* Effect of epidural blockade on indicators of splanchnic perfusion and gut function in critically ill patients with peritonitis: a randomised comparison of epidural bupivacaine with systemic morphine. *Intensive Care Med* 2000; 26: 1638–45.
13. Winsö O, Biber B, Gustavsson B *et al.* Portal blood flow in man during graded positive end-expiratory pressure ventilation. *Intensive Care Med* 1986; 12: 80–5.
14. Kiefer P, Nunes S, Kosonen P, Takala J. Effect of positive end-expiratory pressure on splanchnic perfusion in acute lung injury. *Intensive Care Med* 2000; 26: 376–83.
15. Sugrue M, Jones F, Lee A *et al.* Intra-abdominal pressure and gastric intramucosal pH: is there an association? *World J Surg* 1996; 20: 988–91.
16. Pinsky MR. Breathing as exercise: The cardiovascular response to weaning from mechanical ventilation. *Intensive Care Med* 2000; 26: 1164–6.
17. Bocquillon N, Mathieu D, Neviere R *et al.* Gastric mucosal pH and blood flow during weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999; 160: 1555–61.
18. Bearn AG, Billing B, Sherlock S. The effect of adrenaline and noradrenaline on hepatic blood flow and splanchnic carbohydrate metabolism in man. *J Physiol* 1951; 115: 430–41.
19. Carpati CM, Astiz ME, Rackow EC. Optimizing gastric mucosal perfusion: all catecholamines may not be created equal. *Crit Care Med* 1997; 25: 1624–5.
20. Meier-Hellmann A, Reinhart K, Brede DL *et al.* Epinephrine impairs splanchnic perfusion in septic shock. *Crit Care Med* 1997; 25: 399–404.
21. Levraut J, Ciebiera JP, Chave S *et al.* Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. *Am J Respir Crit Care Med* 1998; 157: 1021–6.
22. Lévy B, Bollaert PE, Charpentier C *et al.* Comparison of nor-epinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism and gastric tonometric variables in septic shock: a prospective, randomized study. *Intensive Care Med* 1997; 23: 282–7.
23. Lèverve XM. From tissue perfusion to metabolic marker: assessing organ competition and co-operation in critically ill patients? *Intensive Care Med* 1999; 25: 890–2.
24. Duranteau J, Sitbon P, Teboul JL *et al.* Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. *Crit Care Med* 1999; 27: 893–900.
25. Neviere R, Mathieu D, Chagnon JL *et al.* The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. *Am J Respir Crit Care Med* 1996; 154: 1684–8.
26. Lévy B, Nace L, Bollaert PE *et al.* Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock. *Intensive Care Med* 1999; 25: 942–8.
27. Smithies M, Yee TH, Jackson L, Beale R, Bihari D. Protecting the gut and the liver in the critically ill: effects of dopexamine. *Crit Care Med* 1994; 22: 789–95.
28. Temmesfeld-Wollbrück B, Szalay A, Mayer K *et al.* Abnormalities of gastric mucosal oxygenation in septic shock: partial responsiveness to dopexamine. *Am J Respir Crit Care Med* 1998; 157: 1586–92.
29. Kiefer P, Tugtekin I, Wiedeck H *et al.* Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock. *Am J Respir Crit Care Med* 2000; 161: 775–9.
30. Kiefer P, Tugtekin I, Wiedeck H *et al.* Effect of a dopexamine-induced increase in splanchnic blood flow on hepatic metabolic activity in patients with septic shock. *Shock* 2001; 15: 427–31.

31. Meier-Hellmann A, Bredle DL, Specht M *et al.* Dopexamine increases splanchnic blood flow but decreases gastric mucosal pH in severe septic patients treated with dobutamine. *Crit Care Med* 1999; 27: 2166–71.
32. Reinelt H, Radermacher P, Kiefer P *et al.* Impact of exogenous  $\beta$ -adreno-receptor stimulation on hepato-splanchnic oxygen kinetics and metabolic activity in septic shock. *Crit Care Med* 1999; 27: 325–31.
33. Barquist E, Kirtan O, Windsor J *et al.* The impact of antioxidant and splanchnic-directed therapy on persistent uncorrected gastric mucosal pH in the critically injured trauma patient. *J Trauma* 1998; 44: 355–60.
34. Scheeren T, Radermacher P. Prostacyclin (PGI<sub>2</sub>): new aspects of an old substance in the treatment of critically ill patients. *Intensive Care Medicine* 1997; 23: 146–58.
35. Lehmann C, Taymoorian K, Wauer H *et al.* Effects of the stable prostacyclin analogue iloprost on the plasma disappearance rate of indocyanine green in human septic shock. *Intensive Care Med* 2000; 26: 1557–60.
36. Kiefer P, Vogt J, Radermacher P. From mucolytic to antioxidant and liver protection: New aspects in the intensive care unit career of *N*-acetylcysteine. *Crit Care Med* 2000; 28: 3935–6.
37. Reinhart K, Spies CD, Meier-Hellmann A *et al.* *N*-acetylcysteine preserves oxygen consumption and gastric mucosal pH during hyperoxic ventilation. *Am J Respir Crit Care Med* 1995; 151: 773–9.
38. Rank N, Michel C, Haertel C *et al.* *N*-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: Results of a prospective, randomized, double-blind study. *Crit Care Med* 2000; 28: 3799–807.
39. Brundin T, Branstrom R, Wahren J. Effects of oral vs. i. v. glucose administration on splanchnic and extrasplanchnic O<sub>2</sub> uptake and blood flow. *Am J Physiol* 1996; 271: E496–504.
40. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systemic review of clinical outcome. *Crit Care Med* 1999; 27: 2799–805.
41. Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomised controlled clinical trials. *Ann Surg* 1999; 229: 467–77.
42. Gadek JE, DeMichele SJ, Karlstad MD *et al.* Effect of enteral feeding with eicosapentaenoic acid,  $\gamma$ -linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. *Crit Care Med* 1999; 27: 1409–20.
43. Porter JM, Ivatury RR, Azimuddin K, Swami R. Antioxidant therapy in the prevention of organ dysfunction syndrome and infectious complications after trauma: Early results of a prospective randomized study. *Am Surg* 1999; 65: 478–83.
44. Berger MM, Spertini F, Shenkin A *et al.* Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial. *Am J Clin Nutr* 1998; 68: 365–71.
45. Powell-Tuck J, Jamieson CP, Bettany GE *et al.* A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition. *Gut* 1999; 45: 82–8.
46. Griffiths RD, Jones C, Palmer TE. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. *Nutrition* 1997; 13: 295–302.
47. Jones C, Palmer TE, Griffiths RD. Randomized clinical outcome study of critically ill patients given glutamine-supplemented enteral nutrition. *Nutrition* 1999; 15: 108–15.

42

## GENETICS BEHIND SEPSIS

Trenkler Š.

*Department of Anaesthesiology and Intensive Medicine, Reimann Hospital, Prešov, Slovakia*

Clinical conditions of patients with sepsis vary dramatically. With similar infections some patients recover uneventfully whereas others develop septic shock and die. This variation may be ascribed to different degree of inflammatory response to infections, e. g. levels of TNF- $\alpha$ . However, a great variations in the TNF- $\alpha$  was noted despite the fact that the infection focus and the causative bacteria were similar. Genetic factors may determine host sensitivity to endotoxin by

modulating the production of TNF and other cytokines. The results of human genome projects has moved genetics into the medical mainstream and shifted emphasis from relatively rare single-gene disorders to common disorders of multifactorial causation, like sepsis. Stuber *et al.* demonstrated that the genomic polymorphism within the TNF locus influenced plasma TNF- $\alpha$  concentrations and the outcome of patients with severe sepsis. Tang and all. have shown that ICU patients with TNF2 allele do not have a higher chance of developing septic shock nor do they have higher baseline TNF- $\alpha$  levels after severe infections, but once septic shock develops, those patients are more likely to have higher plasma TNF- $\alpha$  levels and usually sustain a poor outcome. This suggest that subjects carrying the TNF2 allele are more likely in need of intensive care after surgical infection. The failure of recent clinical trials with anti-TNF antibodies may be related to the failure to identify the subgroup of patients who might benefit from such therapy (e. g. patients with TNF locus polymorphism). Another candidates for genetic determination of sepsis course are intron 2 for IL-1 receptor antagonist and gene for intracellular heat/shock proteins that are responsible for protection against cellular stress. The genes involved in inflammation are numerous as are genomic variations within most of these genes. Not only genes encoding proteins such as TNF, but all genes involved in signal transduction of inflammatory processes are important candidate genes for determining the extent of the individual's response to stress. Analysis and evaluation of these candidate genes will take enormous effort since new state-of-the-art tools of genetic epidemiology are difficult to apply. Critical care investigators have to integrate the stable, interconnected influence of thousands of gene polymorphism with acute changes in gene expression and translation induced by series of often unpredictable insults using the methods of functional genomics. But understanding of genetic determination of the inflammatory process will allow us to develop valuable diagnostic tools and new therapeutic approaches in severe sepsis. Genomic markers will allow us to stratificate the risk of septic patients to develop multiorgane failure. Future trials will be more successful if inclusion criteria will include genetics parameters. Genetics moves into the medical mainstream.

## References

- Tang GJ. and all.: Tumour necrosis factor gene polymorphism and septic shock in surgical infection. *Crit Care Med* 2000; 28: 2733–2736.
- Chung TP. and all.: Functional genomics of critical illness and injury. *Crit Care Med* 2002; 30: S51–S57.
- Stuber F. and all.: The role of genomic polymorphisms in sepsis. *Advances in Sepsis* 2001; 1: 58–64.

43

## DIFFERENTIATION BETWEEN LOCAL AND SYSTEMIC BACTERIAL INFECTION: THE VALUE OF PROCALCITONIN

Gabršček L., Voga G., Krivec B., Skale R., Parežnik R., Podbregar M.

*Intensive Care Unit, General Hospital Celje, Slovenia*

## Introduction

Bacterial infections with or without systemic inflammatory response represent common problem in critically ill patients. The presence of

systemic response should be assessed correctly and early in the course of infection because of its impact on prognosis and treatment. Procalcitonin (PCT) is a newer marker of bacterial infection with better diagnostic validity, monitoring and prognostic estimation of severe infection and sepsis.

### Methods and patients

Twenty six patients with microbiologically proven infection were included in prospective study in a 11 – bed medical intensive care unit. PCT, CRP, leukocyte count, SR and body temperature were determined at least two times during hospitalisation. Patients with local infection had clinical signs of infection with positive microbiological finding in any culture without bacteremia. Patients with local infections and positive blood culture represent the group with systemic infection.

### Results

In patients with positive blood cultures PCT concentrations were significantly higher than in group with negative blood cultures ( $p = 0.019$ ). The leukocyte count was significantly lower in the group with systemic infection compared to patients with negative blood culture ( $p = 0.0017$ ). Other markers did not differ significantly between both groups.

### Conclusions

Patients with bacterial infection and positive blood cultures had significantly higher PCT levels and lower leukocyte count. Other conventional markers of inflammation could not differentiate patients with local and systemic infection. Considering low leukocyte count non-specific for bacterial infection, determination of PCT is helpful for assessment of extension of bacterial infection in critically ill patients.

44

## THE SYSTEMIC AND REGIONAL PROCALCITONIN SERUM LEVEL CHANGES DURING AND AFTER LIVER TRANSPLANTATION

Fazakas J., Gondos T., Sárvári E., Varga M., Horovitz P.

*Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary*

### Purpose

Elevated procalcitonin (PCT) serum levels were observed in the early phase after liver transplantation (OLTx). The aim of this study was to analyse the systemic and regional changes of PCT serum level from the time of organ harvesting until the early postoperative phase of OLTx and to evaluate the prognostic value of the early postoperative PCT level changes in liver transplantation.

### Methods

The relationship among the changes of the inflammatory response parameters (especially PCT, measured by LUMitest, BRAHMS) and the APACHE II, SAPS II scores, liver function tests, renal function tests, cultures were studied in 62 patients who underwent liver transplantation. The systemic measurements were done during surgery: induc-

tion of anaesthesia, hepatectomy, anhepatic phase, after reperfusion, end of surgery ( $n = 40$ ), and in the first five postoperative days ( $n = 62$ ). The patients were divided in two groups: Group A ( $n = 32$ ) without and Group B ( $n = 29$ ) with major postoperative complications (hepatic artery thrombosis, renal or respiratory failure, severe coagulopathy). The regional measurements were done at the end of the anhepatic phase from the portal vein and during the hepatic reperfusion with own blood from the hepatic vein ( $n = 28$ ). Statistical analysis was performed with Wilcoxon signed rank test, paired t test and chi square test.

### Results

During organ preservation, hepatectomy and in the anhepatic phase the PCT levels were in normal range. There were no differences between the systemic and portal vein PCT levels. In 11/28 patients the hepatic vein PCT levels were higher than the systemic levels (1.27 vs. 0.16 ng/ml,  $p < 0.02$ ). Systemic elevations of PCT had begun 20 minutes after graft reperfusion (0.27 vs 1.04 ng/ml,  $p < 0.01$ ). The PCT level was elevated in both groups but, in Group B the level was significantly higher then in Group A (Group B: 30.6 vs. Group A: 4.8 ng/ml,  $p < 0.001$ ). There were also significant differences in the postoperative phase between the two groups in APACHE II and SAPS II scores ( $p = 0.05$ ) and ALAT, ASAT, LDH, serum bilirubin levels ( $p = 0.05$ ).

### Conclusion

The elevated hepatic vein PCT level suggests that the PCT may originate from the liver itself. The systemic elevation of PCT had begun immediately after the graft reperfusion without any signs of systemic infection. The postoperative changes of PCT may have prognostic value in the development of multiple organ failure.

45

## LUTEINIZING HORMONE, PROLACTIN AND TESTOSTERONE PLASMA LEVELS IN PATIENTS WITH SEPTIC SHOCK

Borkowski J.<sup>1</sup>, Jedynak M.<sup>1</sup>, Wolczynski S.<sup>2</sup>, Siemiatkowski A.<sup>1</sup>, Czaban S. L.<sup>1</sup>

<sup>1</sup> *Department of Anaesthesiology and Intensive Care,*

<sup>2</sup> *Department of Gynecological Endocrinology, Medical Academy in Białystok, Poland*

### Purpose of the study

Many researches show important disturbances in hormonal balance in patients with severe sepsis. There are a lot of factors, which are involved that process but the role of sex steroid hormones is unknown, specially, the role of testosterone, which is a one of the most important anabolic hormone. We hope that sex steroid hormones mechanism of action recognition in the septic shock could help in treatment such patients.

### Material and Methods

We studied plasma level of luteinizing hormone (LH), testosterone (TE) and prolactin (PRL) in patients with septic shock (group I;  $n = 20$ )

and in a control group (group II;  $n = 20$ ). The group I was divided into two subgroups: survivors (group IA,  $n = 10$ ) and nonsurvivors (group IB,  $n = 10$ ). Material for laboratory tests was taken at the moment of recognition of septic shock and in the 1<sup>st</sup>, 2<sup>nd</sup>, 5<sup>th</sup> and 10<sup>th</sup> day.

## Results

We noticed significant decreased in testosterone and LH plasma levels in the group I vs the group II and correlation between TE and LH plasma levels and survival. There were no significant changes in prolactin plasma level in the group I vs the group II and prolactin did not correlate with survival. Acute lung injury (ALI) was associated with higher PRL plasma level and was independent from the LH and TE plasma level. We also noticed incorrect pituitary down-regulation of the testosterone secretion.

## Conclusion

Our study showed that sex steroid hormones could be good prognostic factors of survival and complications of the septic shock. It could also give an impulse for supplementary treatment using exogenous hormones, especially testosterone.

## References

1. Voerman HJ, Groeneveld J, de Boer H et al: Time course and variability of the endocrine and metabolic response to severe sepsis. *Surgery* 1993, 114, 951–959.
2. Spratt DI, Cox P, Orav J et al: Reproductive axis suppression in acute illness is related to disease severity. *J Clin Endocrinol Metab* 1993, 76, 1548–1554.

46

## HYPERMYOGLOBINEMIA IN CRITICALLY ILL PATIENTS: WHAT DOES IT MEAN?

Kroužeký A., Matějovič M., Rokyta R. jr.,  
Bílek M., Novák I.

*ICU, Medical Department, Charles University Hospital Pilsen, Czech Republic*

## Introduction

Myoglobin is released from skeletal muscles in different quantities during various traumatic and non-traumatic conditions. Myoglobin is used in the clinical practice most often as a marker of acute myocardial damage. So far, there is no study describing the incidence and consequences of hypermyoglobinemia among medical critically ill patients. The aim of our prospective study was to assess hypermyoglobinemia incidence and to evaluate its relationship to severity of illness and the risk of acute renal failure as a part of multiple organ dysfunction syndrome (MODS).

## Methods

All consecutive patients admitted in the medical ICU ( $n = 310$ ) during 2001 were enrolled into the study. Admission myoglobin plasma level (immunoturbidimetry) was measured and collected in the integrated ICU database MIRO®. Values are medians (MED) and 95 % confidence

interval (CI); statistics: Mann-Whitney test, Spearman's coefficient of rank correlation, two-sample proportion test, and  $p < 0,05$ .

## Results

Patients characteristics: age 58 years, CI 55 to 61, female 127/male 183, APACHE II MED = 21, CI 20 to 22, 153 (47,7 %) pts were admitted with diagnosis severe sepsis/septic shock. Hypermyoglobinemia (MED 152, CI 102 to 1052) incidence was 68,5 %. Admission SOFA score correlated with myoglobinemia ( $r = 0,464$ , CI 0,374 to 0,546,  $p < 0,0001$ ). Admission myoglobin concentrations were significantly different between survivors and non-survivors in the whole group (MED 121 vs. 352,  $p < 0,001$ ) and also in the septic subgroup (MED 157 vs. 414,  $p < 0,001$ ). Acute renal dysfunction treated by renal replacement technique (RRT) developed in 81 pts (25,2 %) with significantly higher myoglobin compared to the rest of the whole group (MED 445 vs. 116,  $p < 0,001$ ).

## Conclusion

Hypermyoglobinemia occurs very frequently in medical ICU patients without signs of acute myocardial ischemia. In our group of ICU patients was incidence 68,5 %. Admission myoglobin concentrations differ significantly between ICU survivors and nonsurvivors and correlate with the severity of critical illness. Hypermyoglobinemia signals potential risk of acute renal dysfunction and evolution of MODS. Its pathophysiological relevance remains to be further elucidated.

47

## SERUM INTERLEUKIN-10 IN PATIENTS WITH ISOLATED ACUTE INTRACRANIAL LESIONS

Dziurdzik P.<sup>1</sup>, Krawczyk L.<sup>1</sup>, Jałowiecki P.<sup>1</sup>,  
Dudek-Dyczkowska D.<sup>1</sup>, Kondera-Anasz Z.<sup>2</sup>

<sup>1</sup> *Clinical Department of Anesthesiology and Intensive Therapy of Silesian Medical Academy, St. Barbara Provincial Hospital, Sosnowiec, Poland*

<sup>2</sup> *Chair, Department of Immunology and Serology, Silesian Medical Academy, Katowice, Poland*

## Rationale

Cerebral inflammation has been implicated in the development of brain oedema and secondary brain damage after traumatic and non-traumatic injury. This inflammatory response consists of mediators (cytokines, chemokines and adhesion molecules) followed by cells (neutrophils early after the onset of brain injury and then a later monocyte infiltration). IL-10 is considered to be the main anti-inflammatory cytokine, thus it may play a pivotal role in those processes. IL-10 is produced by activated T and B-cells, monocytes, macrophages and other cells. Its main biological activity includes suppression of lymphocyte and monocyte activation and suppression of pro-inflammatory cytokine production.



## Aim of the study

1) Determining IL-10 serum level and its pattern in patients with two types of isolated acute brain trauma. 2) Evaluation for possible prognostic value of serum IL-10 in those patients.

## Material/methods

Serum IL-10 levels in 29 ICU adult patients (teaching hospital) with traumatic brain injury (TBI, N = 18) and nontraumatic intracranial haemorrhage (SAH, N = 11) were detected using ELISA-technique on day "0", "1", "4", "7" (counted from the day of injury) as well as on ICU admission ("adm"). GCS and SAPS II scores were determined at the same moments. IL-10 levels between survivors (N = 17) and non-survivors (N = 12) were compared.

## Results

IL-10 was detectable in sera of all but one of the patients. Mean IL-10 level on ICU admission in all patients was 55.0 ( $\pm 86.7$ ) pg/ml. No statistically significant differences in IL-10 on any day between TBI and SAH as well as survivors and non-survivors groups were found (Fig 1). No correlation of IL-10 and GSC or SAPS II was stated. Significant fall of IL-10 from day "0", "1" and "adm" to day "4" and "7" in all patients was observed.

## Conclusions

Serum IL-10 in patients with acute brain injury is detectable independently of the nature of injury. It has a considerable high value deviation and in those patients it seems to have no prognostic values, although this is to be proven on greater number of cases.




Fig. 1 Mean serum IL-10 in TBI and SAH groups

## THE IMPACT OF OVERSEDATION ON SEPTIC SHOCK SEVERITY

Hruda J., Šrámek V.

*Department of Anaesthesia and Intensive Care, St. Ann's University Hospital, Brno, Czech Republic*

## Introduction

Septic shock is defined as hypotension of septic origin that is non-responsive to adequate volume resuscitation<sup>1</sup>. Nevertheless – on top of vasoparalysis – several additional factors may contribute to hypotension, e. g. oversedation may increase the vasopressor requirements.

## Methods

Study was approved by local ethics committee. Volume resuscitated ICU septic patients requiring norepinephrine to maintain adequate mean arterial pressure (MAP) ( $\geq 70$  mmHg in most cases) in whom oversedation (i. e. Ramsey score  $\geq 4$ ) during morning rounds was found were studied. When feasible (e. g. no head trauma) continuous analgosedation (sufentanil and midazolam) was decreased to 5–10 mg/hour and 1–2 mg/hour, respectively. Haemodynamics was recorded when Ramsey score reached 3. When MAP was higher than baseline the dose of norepinephrine (NE) was stepwise decreased in 10 minute intervals until baseline MAP was recorded for 10 min. Values are provided as means (range).

## Results

We provide results of 5 pilot patients. Baseline MAP was 80 (73–87) mmHg with continuous NE infusion of 5.6 (2.5–13.2) mg/min. In all 5 patients Ramsey score 3 was reached within 60 to 135 minutes with MAP of 105 (95–111) mmHg. This enabled reduction in NE doses by 2.5 and 3.3 mg/min in two and discontinuation of NE in three remaining patients. In 2 of 5 patients analgosedation was increased after completion of the study again due to pain (trauma patient) and ventilator interference (peritonitis patient).

## Conclusions

Oversedation leads to overestimation of severity of septic shock. This fact should be considered in septic shock diagnosis/stratification. In some ICU patients sedation at Ramsey score 3 is inadequate but might be if adequate analgesia was given.

## Reference

1. Bone RC, Balk RA, Cerra FB, et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101: 1644–55.

## SECTION: ACUTE RESPIRATORY FAILURE

49

### PATOPHYSIOLOGY OF ALI AND ARDS

Putensen C.

*Klinik und Poliklinik für Anästhesiologie und Intensivmedizin, Rheinisch-Friedrich-Wilhelms-Universität Bonn, Germany*

No abstract available.

50

### RESPIRATORY MECHANICS AT THE BEDSIDE

Nalos M., Růžicka J., Šrámek V., Novák I.

*St. Ann's University Hospital Brno, Czech Republic*

ARDS – acute respiratory distress syndrome is the most severe presentation of acute respiratory failure – ALI, characterized by bilateral inflammatory pulmonary oedema. Even though recently published results have shown decreasing mortality of ARDS patients it still remains relatively high 11–43 %. CT studies by Gattinoni et al. have shown that dependent dorsal parts of the lung in supine position are more injured than ventral parts, which are relatively free of interstitial oedema and amenable to ventilation. The lung thus behaves like a sponge, with hydrostatic forces causing dependent parts to be compressed by overlying pulmonary oedema. To ensure adequate oxygenation and normocapnia in mechanically ventilated patients with such grossly injured lung, originally PEEP set according to arterial oxygen saturation and large tidal volumes (10–12 ml/kg) have been advocated. However several animal studies have shown that this type of ventilation leads to alveolar overdistension and macroscopic (pneumothorax etc.) as well as microscopic (alveolar epithelial, endothelial) injury aggravating lung injury or even promoting it by maintaining the vicious cycle of inflammatory mediators production.

Results of Brazilian ARDS study and National Institute of Health ARDS Network Group have shown that so called protective ventilatory strategy in ARDS patients with tidal volumes adjusted to 6–8 ml/kg of body lean mass, higher PEEP of 10–20 cm H<sub>2</sub>O and correction of respiratory acidosis with bicarbonate can decrease morbidity and even mortality of ARDS patients by 22 % compared with traditional mechanical ventilation (12 ml/kg). However, even within the NIN ARDS Network, physicians tend to use tidal volumes higher and PEEP levels lower than those recommended. The mean tidal volume chosen by the attending physician being 10.3 ml/kg of predicted body weight or 8.6 ml/kg of measured weight for patients with ARDS (PaO<sub>2</sub>/FIO<sub>2</sub> of less than 200), and being not significantly different for ALI patients with PaO<sub>2</sub>/FIO<sub>2</sub> of 201 to 300. Plateau pressures were > 35 cm H<sub>2</sub>O in

26 % of patients and 78 % of patients with ARDS received PEEP of 10 cm H<sub>2</sub>O or less. This apparent reluctance to the use of strict protocol comes from the clinician's point of view as tidal volume reduction is associated with hypercapnia, which is associated with increased endogenous catecholamine production and might lead to increased cardiac output and increased shunt with the resulting decrease in oxygenation. Moreover high PEEP levels lead to increased incidence of barotrauma, extracellular water retention, might decrease gut perfusion and the metabolic capacity of the liver. Last but not least the use of very low tidal volumes leads to an increased need for sedation and/or muscle paralysis due to decreased patient tolerance of such ventilation, which is associated with other serious morbidities.

The measurement of respiratory mechanics enables us to get an insight into the individual patient's degree of lung and chest wall impairment. From the pathophysiologic point of view, bearing in mind the important results of the Brazilian and NIN ARDS Network trials, individually set ventilation based on respiratory mechanics measurement might be preferable to a strict ventilation protocol. Measurement and display of the dynamic respiratory mechanics provided by most of the current mechanical ventilators is of great value in most cases of acute lung injury. However measurement of static pressure volume (P–V) relationship is considered as the standard, although cumbersome, method for assessment of respiratory mechanics in ARDS patients. Recent trials underlined the importance of static P–V curve measurement for optimal ventilator settings. As there is still a discrepancy in the interpretation of lower inflection point of the P–V curve the importance of avoiding ventilation over the upper inflection (deflection) point of the static P–V curve is widely accepted.

We developed software able to control on breath-by-breath basis the mechanical ventilator (Adult Star™, Infrasonics, San Diego, USA) and to simultaneously read and process volume and pressure data from the ventilator output. This features enable one to deliver in chosen interval randomly selected test tidal volume (1 of 14 volumes in range of 2–14 ml/kg/body weight) under constant flow conditions with computer controlled expiratory and inspiratory holds and record the volume and respective pressure differences for automatic P–V curve construction. We tested the performance of this software after studies using a lung model in four ARDS patients on three different PEEP levels (0, 5, 10 cm H<sub>2</sub>O). Data obtained automatically from the ventilator were compared with independent calibrated pressure and volume measuring system consisting of proximal airway and oesophageal pressure transducers, and heated pneumotachograph connected to differential pressure transducer. Data were processed and collected via sensor interface card into the same computer operating the ventilator and analysed using customized laboratory software. There was a good correlation between the two independent measurement systems thus suggesting that ARM software driven ventilator is sufficient to automatically perform static P–V curve measurement without the need of disconnecting the patient from the ventilator, and without the need for additional equipment other than mechanical ventilator and external ARM software controlled end expiratory valve.

Such tools might help us, once validated in a prospective manner, to better ventilate our patients in the future.

51

## OPEN LUNG MANEUVERS – HOW TO PERFORM, HOW TO MONITOR, POSSIBLE SIDE EFFECTS

Pavlík M.

*Clinic of Anaesthesiology and Intensive Care, St. Anne's University Hospital Brno, Czech Republic*

No abstract available.

52

## NON-INVASIVE VENTILATION IN ACUTE RESPIRATORY FAILURE

Šrámek V.

*St. Ann's University Hospital, Brno, Czech Republic*

### History

By definition, non-invasive ventilation (NIV) means a ventilatory support avoiding endotracheal intubation (ET). Though historically attempted first and the concept not forgotten completely negative pressure ventilation (e. g. Emerson iron lung) is currently not used in the ICU environment and **Positive Pressure Ventilation** is applied noninvasively in acute respiratory failure (ARF).

### Technical aspects

Modern ICU ventilators can be safely and conveniently used for NIV though usage of special devices – high-flow bilevel positive airway pressure generators and CPAP systems – developed exclusively for NIV is also possible (e. g. Respiroics<sup>®</sup>).

Pressure support ventilation (5–15 cm H<sub>2</sub>O) with PEEP (4–10 cm H<sub>2</sub>O) is the most frequently ventilatory mode used though PEEP alone was proved to be also efficient (and sometimes even superior) in several studies (cardiac patients) and pressure controlled ventilation is sometimes used when mask leaks cannot be avoided. Other ventilatory modes are used less frequently.

Probably the most important for NIV to be successful is a soft and gently fitting face mask. (nasal masks are less convenient in critically ill patients).

### Indications

Two criteria may be used for NIV list of indications:

- I. timing during ARF (ET prevention, ET alternative, Weaning and ET reintubation prevention)

NIV is frequently applied to facilitate weaning. It is the most frequent indication in our institution and seems to work. Nevertheless the possibility to shorten ET time to minimum as advocated by some authors (Torres – COPD patients) was not confirmed by others (Kaczmarek – lecture on WORC Congress 2002).

- II. primary diagnosis leading to ARF

#### A. basic:

- Hypercapnic ARF – COPD
- Hypoxemic ARF – ALI/ARDS
- Cardiogenic Pulmonary Oedema (CPE)

#### B. specific:

- Pneumonia
- Thorax trauma
- Immunocompromised patients
- Obesity hypoventilation syndrome (OHS)

1. Hypercapnic ARF – COPD:

This was the original patients' population in whom NIV was applied (Wysocki) and still remains the one with best results achieved. NIV is considered a new standard of care in COPD patients (Brochard).

2. Hypoxemic ARF – ALI/ARDS:

The profit is not so clear. Probably NIV should be attempted when no contraindication is present but if treatment goals are not reached within 60–120 minutes, ET should not be delayed (Antonelli).

3. Cardiogenic Pulmonary Oedema (CPE):

NIV is a good option with high success rate but should not be attempted in unstable patients due to increased risk of acute myocardial infarction.

Success rate (i. e. avoiding ET) in pneumonia remains to be limited (50 %) in contrast to thorax trauma where NIV is a very good option (20 % failure). Immunocompromised patients seem to profit from NIV substantially. This profit is maximal when NIV is applied soon in the course of ARF ("preventively").

### Contraindications of NIV

- Cardiac or respiratory arrest
- Hemodynamic instability (AIM, unstable cardiac arrhythmia)
- Significantly impaired consciousness
- Upper airway obstruction
- Facial problems (surgery, trauma, deformity...)
- Severe upper GI bleeding
- Mental problems (claustrophobia...)

### Specific problems

#### Sedation:

- best sedation is personnel at the bedside
- drugs not contraindicated – often necessary
- drugs used depend on ICU experience

#### Feeding:

- intermittent per os (monitor gastric distension)
- fine bore tube to avoid air leak of face mask
- special face masks with opening for gastric tube
- nasal masks – no major problem with feeding

#### Bronchial secretions:

- pulmonary rehabilitation
- cough when NIV disconnected
- minitracheostomy?

#### Face bruise and other local problems:

- change different face masks
- face mask applied firmly but not tightly
- avoid position of face mask over eyes
- cushioning materials (over nasal bridge)
- eye irritation

## Conclusion

Current practice in the European ICU with regards to the use of NIV differs vastly. NIV is still used seldom mainly in hypoxemic ARF (attempted in 16 % patients before ET in a study covering France, Switzerland and Spain). About 50 % of ICUs in UK do not have equipment. This should be changed right now as profits for especially some groups of ARF patients are well documented and workload for ICU personnel connected with NIV is acceptable.

## Reference

International Consensus Conferences in Intensive Care Medicine: non-invasive positive pressure ventilation in acute Respiratory failure. Organised jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Societe de Reanimation de Langue Francaise, and approved by ATS Board of Directors, December 2000. *Am J Respir Crit Care Med* 2001, 163: 283–91.

53

## MUSCLE FATIGUE AND RESPIRATORY FAILURE

Mutz N.

*Department of Anesthesiology and Critical Care Medicine, Leopold Franzens Universität, Innsbruck, Austria*

No abstract available.

54

## THE INFLUENCE OF CO-MORBIDITY ON THE OUTCOME OF NON-INVASIVE VENTILATORY SUPPORT IN PATIENTS WITH ACUTE RESPIRATORY FAILURE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Matuška P., Pilařová O., Merta Z., Skříčková J.<sup>1</sup>, Dušek L.<sup>2</sup>

<sup>1</sup> *Department of Respiratory Diseases and TB, University Hospital, Brno, Czech Republic*

<sup>2</sup> *Centre of Biostatistic Analysis, Brno, Czech Republic*

## Introduction

Non-invasive positive pressure ventilation (NPPV) has been commonly used for treating acute respiratory failure (ARE), especially in acute exacerbation of chronic obstructive pulmonary disease (COPD) patients<sup>1</sup>. As yet, however, no unequivocal evidence exists on whether the success of NPPV depends on the patients' respiratory parameters or on their co-morbidity.

## Aim

To verify the importance of NPPV and to clarify the influence of co-morbidity on the success of NPPV in COPD patients with ARF.

## Methods

Thirty-six patients with COPD (24 men, 12 women) hospitalized on the ICU because of ARP were evaluated retrospectively. The patients received NPPV (BiPAP ST, Respironics Inc.) via face mask. Their mean age was  $62 \pm 9.1$  years. Their baseline parameters were as follows: pH  $7.28 \pm 0.07$ ;  $PO_2$   $9.7 \pm 2.7$  kPa;  $pCO_2$   $9.2 \pm 2.4$  kPa; breathing frequency (BF)  $27 \pm 7.9$ ; heart rate (HR)  $115.2 \pm 24.8$ ; APACHE III score  $40.8 \pm 11.6$ ; body mass index (BMI)  $27.7 \pm 7.8$ . The initial and final values of pH,  $PO_2$ ,  $pCO_2$ , BF, BIR, and the presence of concomitant diseases were compared. The concomitant diseases were classified as heart disease (H), neuromuscular (NM), vascular (V), metabolic (M), gastrointestinal (GI), cancer (C), psychiatric (P), renal (R), liver (L). Obstructive sleep apnea (OSA), the need for long-term oxygen treatment (LTOT), and the occurrence of other diseases than those mentioned above were also noted. The duration of ventilation, ventilatory parameters, the stay on ICU, the numbers of the intubations and deaths were followed up. The occurrence of adverse effects was evaluated. The reasons for intubation, causes of death, and factors influencing NPPV were also evaluated. Ventilatory parameters, co-morbidity, APACHE III, BMI, and ventilatory parameters following 4-h ventilation were compared in patients treated successfully (5) vs patients in need on intubation, considered as treatment failures (F).

## Results

Significant improvements in pH ( $p = 0.001$ ),  $pCO_2$  ( $p = 0.001$ ), BF ( $p < 0.001$ ), and HR ( $p = 0.04$ ) were recorded. The number of intubated patients was 5 (13.9 %), the number of deaths 4 (8.3 %). Improvements of ventilatory parameters after NPPV were observed in 33 patients (91.7 %). In total, 84 diseases were counted (i. e. 2.33 diseases in one patient). Heart diseases (BI) were present in 40 patients, vascular (V) in 14, neuromuscular (NM) in 2, psychiatric (P) in 6, metabolic (M) in 6, endocrine (E) in 2, gastrointestinal (GI) in 4, cancer (C) in 2, and renal (R) in 1 patient, liver (L) in 5, OSA in 1, TB in 1; 13 patients were using LTOT. The duration of ventilation was  $51.5 \pm 49$  hours, the ICU stay lasted  $7.6 \pm 5.5$  hours. The inspiratory pressure was  $13.3 \pm 3$  mm H<sub>2</sub>O, the expiratory pressure was  $5.3 \pm 1.2$  mm H<sub>2</sub>O. The patients with intubation (ID) had the same ventilatory support, mean age, initial pH,  $PO_2$ ,  $pCO_2$ , BF and the same improvement over 4 hours compared with the success group (5). The F group had a significantly higher APACHE III ( $p = 0.049$ ), more concomitant diseases ( $p = 0.001$ ). There were significant improvements after 4 hours MPPV in BE ( $p = 0.024$ ).

The reasons for intubation were worsening of acidosis, hypercapnia within 4 hours in two patients; heart failure with hypotension in 2 patients; hypercapnia and coma in one. All patients died of heart failure. Among adverse effects, stomach inflation was observed in one case (relieved by introduction of nasogastric probe). Ileus was noted in 1 case, face lesions due to the mask in none.

## Discussion

The results are indicative of a certain trend, but their power is limited by the unbalanced sample and its small size. However, in certain parameters the trends are substantial. Further research, based on a larger group of patients, is needed to confirm our results. Careful observation of patients is necessary to avoid delays of intubation.

## Conclusion

We have observed beneficial effects, including improvements of respiratory parameters, in COPD patients with ARP. If hospitalized on the

ICU. The success of NPPV was less obvious in patients with polymorbidity, APACHE III score, low BMI, and high HR. Adverse events were not of serious nature, only one patient had to be transferred to surgical department because of ileus.

## References

1. Brochard L, Isabey D, Piquet J, et al. Reversal of acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1990; 323: 1523–1530.
2. Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive pressure ventilation in acute respiratory failure. *Am J Respir Crit Care Med* 1995; 151: 1799–1806.
3. Bot J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airway disease. *Lancet* 1993; 341: 1555–57.

55

## POSTINTUBATION TRACHEAL LESIONS WITH ACUTE RESPIRATORY FAILURE – SERIOUS PROBLEM OF THE INTENSIVE CARE TODAY

Rindoš R., Hamžík J., Piovarči D., Havelka V.

*Department of Thoracic Surgery, Institute of Respiratory Diseases and TB Vyšné Hágy, Slovakia*

Tracheal injury (stenosis or tracheo-esophageal fistula) with acute respiratory failure is usually urgent, life-threatening complication of long-term tracheal intubation. Tracheal resection and the reconstruction of airways is the treatment of choice, but it is often risk procedure for patients after polytrauma, sepsis, severe inflammatory diseases, multiple organs failure and other serious cases. The authors presents in three cases reports serious problem of intensive care today and own outcomes of the treatment for last five years.

56

## STENT INSERTION IN BENIGN STENOSES OF CENTRAL AIRWAYS

Kolek V.<sup>1</sup>, Marek O.<sup>2</sup>

<sup>1</sup> *Department of Pneumology*

<sup>2</sup> *Department of Anesthesiology, University Hospital, Olomouc, Czech Republic*

Incidence of tracheal stenoses due to long lasting intubation and/or tracheotomy is increasing probably because of better postoperative intensive care and improved survival of critically ill patients. Value of endotracheal/bronchial stent was evaluated. Series of 53 stent insertions in 38 patients is present. Stents were inserted in 26 males and 12 females, mean age was 52.2 years. Dumon plastic stents and Strecker metallic stents were used. Strategy of indication, application and extraction of stents is discussed in context with other therapeutic methods (tracheal resection or tracheostomy). Stent was inserted definitively in 24 and temporally in 14 pts. Restenosis appeared in 50 % of them. Migration, bacterial colonisation, mucus stagnation,

bleeding and granulation overgrowth were the most frequent complications. There was no life threatening complication. Median time of follow-up after stenting was 42.5 months. Tracheostomy or resection were done in cases of stent dysfunction, on the contrary stent was inserted in 2 cases with restenosis after surgical resection. Present results show that stent is one of potent tools in definitive or temporal treatment of central airway stenoses, but there are many problems in individual decision of therapeutic strategy.

57

## CRITERIA FOR PREDICTION OF HFOV TREATMENT EFFICIENCY IN ADULT PATIENTS WITH ARDS

Pachl J.<sup>1</sup>, Záborský V.<sup>2</sup>, Roubík K.<sup>3</sup>, Waldauf P.<sup>1</sup>, Krejzl J.<sup>1</sup>

<sup>1</sup> *3<sup>rd</sup> School of Medicine, Charles University Prague, Czech Republic*

<sup>2</sup> *University Thomayer Hospital Krc, Prague, Czech Republic*

<sup>3</sup> *Czech Technical University, FEE, Czech Republic*

## Introduction

The study evaluates suitability of criteria describing ARDS severity for prediction of HFOV treatment efficiency.

## Methods

A group of 15 adults with ARDS ventilated on HFO ventilator (Sensor-Medics 3100B) after conventional ventilation (CV) failure.  $\text{PaO}_2$ ,  $\text{PaCO}_2$ ,  $\text{FiO}_2$ , MAP, PIP, PEEP,  $V_T$ ,  $R_{AW}$ ,  $C_L$ ,  $\text{PaO}_2/\text{FiO}_2$  and LIS were determined before conversion to HFOV. HFOV protocol:  $f = 5$  Hz,  $Ti/T = 0.5$ , initial  $\text{CDP} = \text{MAP} + 5$  cm  $\text{H}_2\text{O}$ ,  $\text{FiO}_{2\text{HFOV}} = \text{FiO}_2$ , DP and  $V_T$  according to arterial gases, bias flow = 40–60 l/min.  $\text{PaO}_{2\text{HFOV}}$  and  $\text{PaCO}_{2\text{HFOV}}$  measured continuously. The group was retrospectively split into two subgroups: 1. Increase in  $\text{PaO}_{2\text{HFOV}}/\text{FiO}_{2\text{HFOV}}$  by  $> 10\%$  ( $n = 10$ ). 2. Increase in  $\text{PaO}_{2\text{HFOV}}/\text{FiO}_{2\text{HFOV}}$  by  $< 10\%$  or decrease ( $n = 5$ ). MAP, PEEP,  $\text{PaO}_2/\text{FiO}_2$ ,  $R_{AW}$ ,  $C_L$  and LIS recorded during CV were compared between the created groups.

## Results

The CV parameters evaluated for both groups are displayed in table:

## Conclusion

The most specific parameters for HFOV efficiency prediction are LIS and  $C_L$ .

## Acknowledgement

*Supported by GA CR 305/00/0651.*

58

## ARDS DUE TO FAT EMBOLISM – A CASE WITH A PROLONGED COURSE

Pavlík M., Štětka P., Šrámek V.

*Clinic of Anaesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czech Republic*

### Case report

A 38 year old patient was admitted to surgical department after a car accident. On admission diagnosis of cerebral commotion, contusion of the right shoulder and fracture of the left femur was established. The patient was stable, no fat embolism prevention was given and operation was scheduled for the next morning. On arrival to the OR the patient was in mild respiratory distress ( $SpO_2$  90 while breathing air), chest X ray showed raised diaphragm on both sides. Intramedullary osteosynthesis was done in general anaesthesia. After operation the patient was admitted to the ICU and extubated after several hours. Oxygenation while breathing air remained marginal, the patient was co-operative and was transferred to the high dependency surgical unit (HDU) next morning when chest X ray revealed raised diaphragm and otherwise clear lung parenchyma. In the HDU the patient deteriorated after 48 hours, severe respiratory distress developed and was transferred back to general ICU. Blood gas analysis (BGA) and chest X ray revealed severe form of ARDS (OI 100). Due to the history of femur fracture and mild thrombocytopenia connected with agitation fat embolism was considered to be the most probable cause of ARDS. On the next morning oxygenation remained critical, pulmonary artery catheter was inserted revealing severe pulmonary hypertension (pre-capillary as judged from PAOP tracing). Due to this fact and because prone positioning was considered to be contraindicated due to huge oedema of the left trunk and leg, inhaled NO (10 ppm, synchronised with inspiration) was tested. The effect on oxygenation and pulmonary hypertension was only mild. First open lung manoeuvre (OLA – modified 40/40 manoeuvre described by Marini) was performed at noon with an excellent effect. OLA was needed several times on following days. Patients was extubated on Day 4 but respiratory distress reappeared and chest X-ray showed bilateral opacities again. Non-invasive ventilation with face mask – NIV (PEEP 10, PS 10–12,  $FiO_2$  0.4) was started and respiratory distress has improved with improvement of the X-ray as well. NIV was applied for almost 24 hours/day during the next 2 days. Then NIV was intermittently replaced with nebulisation with supplementary oxygen and incentive spirometry was also used. On Day 10 the patient was transferred to HDU and then home.

### Conclusion

In our case we stress the importance of a complex approach to the ARDS patient. OLA are often successful in non-pulmonary ARDS, might be effective not only during the first days of ARDS and oxygenation response to them might be monitored by pulse oximetry. The oxygenation response to inhaled NO might be tested in severe ARDS cases especially when prone positioning is considered risky but effect is unpredictable even in cases of predominant pre-capillary hypertension. Non-invasive ventilation is an attractive method during weaning and may lead to lung recruitment at lower pressure compared to mechanical ventilation.

59

## DIFFUSE ALVEOLAR HEMORRHAGE – UNUSUAL COMPLICATION OF COMBINED ANTIAGGREGATION THERAPY FOR ACUTE MYOCARDIAL INFARCTION

Škulec R., Bělohávek J., Pšenička M.,  
Holm F., Aschermann M.

*2<sup>nd</sup> Department of Internal Medicine, 1<sup>st</sup> School of Medicine, Charles University, Prague, Czech Republic*

Combined antiaggregation and anticoagulation therapy for acute coronary syndromes including administration of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors has been commonly used. Complications include major bleeding, but diffuse alveolar hemorrhage (DAH) has been reported very rarely. We refer the case of 71 years old man with acute myocardial infarction of the inferior wall. He was treated by direct percutaneous transluminal coronary angioplasty and standard concomitant medication including eptifibatide was administered. In several hours, DAH developed, presenting typical clinical signs (hemoptysis, pulmonary rales as in pulmonary edema, acute respiratory insufficiency and X-ray scan pattern). Antiaggregation and anticoagulant medication has been discontinued and complex therapy was started. In a few days, pulmonary hemorrhage extincted and the patient was dimited. Six month later is doing well.

Diffuse alveolar hemorrhage is an unusual complication of therapy for acute myocardial infarction with GP IIb/IIIa inhibitors. There is a very few reports in the literature and its appearance in association with eptifibatide administration have not been published yet.

60

## THE PRONE POSITION AS A PART OF THE RESPIRATORY MANAGEMENT IN TETRAPLEGIC PATIENTS

Řehořková D., Bosáková H., Horký P.,  
Hude P., Wendsche P.

*Department of Anaesthesiology and Critical Care, Traumatological Hospital Brno, Czech Republic*

In patients with acute high spinal cord injury, the essential ventilation changes occur in dependence on the level of lesion. The patient with complete transverse spinal cord injury above C4 is permanently dependent on the ventilator (eventually the permanent stimulation of phrenic nerv can be performed). In our report we discuss the role of the prone position in patients with transverse spinal cord injury distally to C4. In healthy individual, the ventilation is ensured by normal function of the diaphragm and the respiratory muscles. The ventilation also depends on elastic forces of thorax and lungs. For optimal gas exchange process, the right function of ciliary epithelium and adequate bronchial secretion are necessary. The parameters such static and dynamic lung volumes, ventilation/perfusion relationship, WOB and blood-gas values fluctuate within physiological limits.

In case of the acute high spinal cord injury-under C4-with tetraplegia, following changes occur:

1. the ventilation is ensured mainly by diaphragma and partly by accessory respiratory muscles, reason is the "denervation" of the intercostal and abdominal muscles
2. the distribution of perfusion is changed by adrenergic denervation
3. the mucociliary transport is impaired

It results in:

1. Static lung volumes (VC, TLC, IRV, ERV) are decreased, RV is affected less than the other volumes
2. FEV<sub>1</sub>, FEV<sub>1</sub> % and PEF are decreased
3. compliance is decreased (dynamic compliance more than static) and resistance is increased, so that WOB is increasing and it, finally, results in higher oxygen consumption
4. various degree of hypoxemia – its is caused by V/Q disproportion, partly by hypoventilation – especially in the dependent parts of the lungs, partly by redistribution of perfusion – due to "sympathectomy" within the acute spinal cord injury
5. stagnation of the bronchial fluid – under normal conditions VC at least 15ml/kg b. w. is necessary – otherwise the effective cough is not possible
6. the character of normal bronchial fluid is changed and the function of mucociliary systems is also negatively affected

The respiratory complications, resulting from mechanisms mentioned above, can be potentially fatal for the tetraplegic patients:

1. collapse of alveoli
2. development and progression of atelectasis
3. hypoxia
4. pneumonia

The goals of the prone position are:

1. to improve ventilation in the dependent parts of lungs
2. to improve ventilation/perfusion relationship
3. to ensure the effective drainage of the bronchial fluid
4. to shorten the weaning from ventilator

The prone position can be performed within:

1. artificial ventilation (ASV Galileo)
2. CPAP
3. spontaneous ventilation

For practical performance the special device – Stryker's bed is usually used.

The patient is placed in the prone position and after 60 min the blood gas analysis is checked:

1. if hypoxemia and/or hypercapnia occurs/worsens, then the patient is placed back to the supine position – this patient is not "respondent".

The next attempt with prone position is performed after 2 days – the patient can become "respondent":

2. if the blood gases values are improved (it means the patient is "respondent") then the patient is left in the prone position for 4–6 hours.

Advantages of the prone position:

1. reduces the necessity of the flexible fiberoptic bronchoscopy, risk of infection complications and traumatism of the bronchial tree is reduced
2. it makes the weaning from ventilator easier – longlasting ALV further deteriorates muscular force of the auxiliary muscles, that increase probability of the insufficient spontaneous ventilation

Possible complications of the prone position:

1. worse tolerance by patient if ALV is performed – in 30 % of cases the analgesia and muscle relaxation is necessary
2. excoriations of the skin, swelling of the forehead and face
3. bradycardia – in 15 % of cases

## Conclusion

The prone position is the necessary part of ventilatory strategy and management in tetraplegic patients. This method decreased number of respiratory complications and accelerates the transition to the spontaneous ventilation.

By this way it shortens the stay of the patients in ICU and improves possibilities for further rehabilitation.

## 61

### RESPIRATORY MANAGEMENT OF PATIENTS WITH SPINAL CORD INJURIES (SCI)

Bosáková H., Řehořková D., Hude P., Horký P., Wendsche P.

*Department of Anaesthesiology and Critical Care, Traumatological Hospital, Brno, Czech Republic*

Pulmonary complications are a major cause of morbidity and mortality after acute SCI.

Dysfunction of respiratory muscles and of auxiliary respiratory muscles depends on the level of injury. Damage of the spinal cord above C4 involves the phrenic nerve nuclei, and therefore voluntary diaphragmatic respiration mediated by the phrenic nerve is not possible.

Changes of ventilation in SCI patients

- changes of the resistance of the airway
- reduction of the lung elasticity
- reduction of vital capacity (VC) – C4–7 by 30–40 %
- reduction of functional residual capacity (FRC) – C4–7 by 10–25 %
- increase of breathing effort
- increase of secretory viscosity in airways – lesion of the autonomic nervous system
- reduction of maximal oesophageal pressure during forced expiratory vital capacity and coughing manoeuvres
- reduction of movement of the ciliary epithelium
- predisposition to retention of secretions with associated pneumonia and atelectasis

Therapy

- aggressive physiotherapeutic technique
  - aerosol inhalation therapy with mucolytic agents, vibrational massage, frequent repositioning including prone position on the Stryker bed
- fiberoptic bronchoscopic toilet – by the means of endotracheal intubation or tracheostomy
- in case of long term ventilation early tracheostomy
  - + classical surgical method but only after 14 days following healing wound (complete) – in case of spinal cord operation
  - + puncture tracheostomy technique under bronchoscopic supervision. This can be performed between 7<sup>th</sup> to 10<sup>th</sup> day.
- non invasive artificial lung ventilation

During this ventilation spontaneous breathing activity is maintained. We use support ventilation. We have a very good experience with ASV – Adaptive Support Ventilation, Hamilton Veolar, Galileo. When cardiovascular stability has been achieved we can use PEEP + 5 cm H<sub>2</sub>O.

Weaning Criteria (MacKenzie C. F., Ducker T. B. – 1986)

– maximum inspiratory force	–20 cm H <sub>2</sub> O
– maximum expiratory force	+20 cm H <sub>2</sub> O
– vital capacity	1000 ml
– expiratory flow	10 L/s (level dependent)
– $\text{pa O}_2/\text{FiO}_2$	250
– $V_{\text{DS}}/V_{\text{T}}$	55
– lung thorax compliance	30 ml/cm H <sub>2</sub> O

Extubation Criteria

– frequency of breathing	35/min
– $V_{\text{T}}$	5 ml/kg
– FVC	10 ml/kg
– NIF	15–25 cm H <sub>2</sub> O
– $\text{paO}_2$ ( $\text{FiO}_2$ 0,4)	60 mmHg

When haemodynamically stable, patients can be placed in a vertical position. Concurrently artificial lung ventilation must be closely controlled. After we discontinue ventilatory support, we continue with intensive physiotherapy.

We have a very good experience with non – invasive lung ventilation CPAP in 3–4 h intervals. This treatment lasts 15 to 30 min depending on patients tolerance.

We administer on daily hours only. At night patient is rested for the period of 8 h.

CPAP currently represents prophylaction of alveolar collaps (Harvey, Ellis 1993).

When the above principles are followed, we can reach satisfactory spontaneous breathing in tetraplegic patients with injury below C4 in 14 days.

## 62

### AUTOMATIC CONTROL OF NEUROMUSCULAR BLOCKER DELIVERY DURING GENERAL ANAESTHESIA DATEX-OHMEDA WORKSHOP

Adamus M.<sup>1</sup>, Adamus P.<sup>2</sup>

<sup>1</sup> Department of Anaesthesia and Intensive Care, Palacký University, Faculty of Medicine, Olomouc, Czech Republic

<sup>2</sup> Rapid System, Olomouc, Czech Republic

Modern general anaesthesia (“balanced anaesthesia”) is based on adequate providing of its three fundamental parts (hypnosis, analgesia and muscle relaxation). Older anaesthetic techniques (using single drug only, e. g. ether) covered these components just by increasing the dose of agent, or by concomitant excessive regional anaesthesia. On the contrary, balanced anaesthesia uses several drugs that more or less selectively affect their relevant target areas. The doses can be reduced to influence just the modality, which is insufficient at that moment. This action, though logical and rational, may be potentially risky. It is possible to induce light general anaesthesia without

adequate analgesia, or we can unintentionally have relaxed patient who is conscious. Accurate information on the level of every part of general anaesthesia is very important.

Data from our study (Adamus, 2000) confirm that only minority of Czech anaesthetic departments have equipment for neuromuscular blockade monitoring. No anaesthetic department in our country uses NMT monitoring as a routine in everyday practice and the degree of neuromuscular block is usually estimated just from clinical signs during general anaesthesia.

During neuromuscular blockade monitoring the muscle response to motor nerve stimulation is quantified. Following administration of muscle relaxant, which acts on neuromuscular plate, the transmission through this synapse is impaired. This results in weakening of strength of muscle contraction. There are various stimulation patterns useful for different degrees of neuromuscular block (single twitch [TW], tetanic stimulation [TET], train-of-four stimulation [TOF], double burst stimulation [DBS], post-tetanic count [PTC]). Quantification of relevant muscle response can be based on different principles (mechanomyography [MMG], electromyography [EMG], accelerometry [ACC], phonomyography [PhMG]).

The degree of neuromuscular block can be monitored by observing the muscle response to nerve stimulation, commonly the ulnar nerve. Bolus doses of neuromuscular blocker are usually administered intermittently based on this response. However, this method inevitably leads to fluctuations in the degree of neuromuscular block, particularly with recently introduced short-acting agents. To reduce this effect, continuous infusions of neuromuscular blocker may be used, but differences in pharmacodynamics and pharmacokinetics between patients make it difficult to choose the correct infusion rate to maintain the desired level of neuromuscular block.

Closed-loop control offers the ability to provide a stable level of neuromuscular block allowing for variation in individual's response to the drug. This benefits the patient in that the minimum quantity of drug is administered and the clinical workload is reduced, allowing more time to be spent on other aspects of anaesthesia. The reliability of neuromuscular block monitoring with electromyography permits a precise control strategy to be implemented.

In our department (Dept. of Anaesthesia, University Hospital, Olomouc, Czech Republic) we have developed and introduced into clinical practice a system for automatic delivery of neuromuscular blocker (**RelaxA**) during general anaesthesia. Fundamental part of the system is a computer interfaced with a NMT monitor Datas AS/3™ and an infusion pump. The monitor is used to determine neuromuscular transmission every 20 seconds. Data are collected and sent to the computer that is programmed to instruct the pump to administer muscle relaxant infusion to maintain stable neuromuscular block. The degree of neuromuscular block is compared to the target level (reference set point). The difference between them (error signal) acts as input information for feedback controller. The controller software automatically exerts those arrangements that return the error signal to zero. If the relaxation is more profound than required the system slows down the infusion pump speed and consequently less neuromuscular blocker is administered. If the blockade is insufficient the pump is instructed to infuse the relaxant faster. The neuromuscular blocker infusion is determined by the difference between actual and target levels of neuromuscular blockade. Precision of the regulation is far beyond that which is clinically required.

System **RelaxA** can maintain stable level of neuromuscular block throughout long surgical operations. Although it is able to manage this task without user intervention, its role must be considered complementary. It must not be a substitution for a continuous presence of the anaesthetist in the operation theatre, which remains *conditio sine qua non* of safe general anaesthesia.



63

## ACTIVATED PROTEIN C – A NOVEL AGENT FOR SEVERE SEPSIS

Černý V.

*Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Charles University, Hradec Králové, Czech Republic*

Sepsis remains a major cause of death in hospitalised patients and the leading cause in non-coronary intensive care units. Despite a massive research effort over the past two decades to identify the innovative therapy for sepsis, current treatment consists primarily of organ support techniques and anti-infective therapies. Activated Protein C (APC), an endogenous protein that inhibits thrombosis and inflammation, while promoting fibrinolysis, plays an important role in the pathogenesis of sepsis. Recombinant APC (drotrecogin alpha), when compared to placebo in randomised study, decreased a relative risk of death at 28 days by 19.4 % (Confidence interval 6.6–30.5), although there was a trend for serious bleeding with its use. APC seems to be the first “anti-sepsis” drug, found to have a mortality benefit and was recently approved by the FDA for the reduction of mortality in adult patients with severe sepsis.

A thorough assessment of bleeding risk should be completed for all potential APC candidates. The use of APC is contraindicated in patients with: bleeding, recent hemorrhagic stroke, recent intracranial or intraspinal surgery, severe head trauma, trauma with an increased risk of life threatening bleeding, an epidural catheters, intracranial neoplasm or mass lesion, or evidence of herniation. The presence for other risk factors bleeding (e. g. thrombocytopenia, concurrent therapy with antithrombotic agents) will require clinicians to make a careful risk/benefit decision regarding the initiation of APC therapy.

Although the price of APC is greater than the cost of many innovative therapies, its beneficial effects on patient mortality coupled with the lack of detrimental effects on patient morbidity may in fact make its using as cost effective intervention. A cost-effectiveness analysis was completed and brings encouraging data in this regard. A new trial aiming to prove efficacy of APC in patients with severe sepsis and low risk of death is on the way.

There is a prescribing guideline in Czech Republic developed by Czech Society of Anaesthesiology and Intensive Care to optimise APC therapy.

64

## TRANSFUSION-ALTERNATIVE STRATEGIES Simple – Safe – Effective

This video program is the first to consider transfusion alternatives from a multi-disciplinary perspective. In all, 18 physicians internationally renowned for their progressive work in the field of transfusion alternatives share their observations and experience. *Transfusion-Alternative Strategies* reviews recent scientific evidence pointing to the benefits of avoiding donor blood and outlines three pillars of transfusion alternative strategies: appropriate tolerance of anemia, optimizing red blood cell mass, and minimizing blood loss. Surgical and anesthesiological techniques to limit blood loss and pharmaceutical agents to increase blood production are explored for application in preoperative, intra-operative and postoperative settings, as well as application to trauma management.

The program has been endorsed by a prestigious committee of academicians for its scientific accuracy. Total running time: 28 minutes.

*Producer:*

Watch Tower Bible and Tract Society of Pennsylvania

## PROFESSIONAL HISTORIES OF INVITED SPEAKERS

### *Josef Briegel*

**Born:** 1957, Ottobeuren, Germany

**Education:** Friedrich-Wilhelms Universität, Bonn – 1978; Ruhr-Universität, Bochum – 1980; Ludwig-Maximilians-Universität, Munich – 1984

**Current position:** Associate Professor, Department of Neuroanaesthesia and Neurointensive Care Medicine, Munich, Germany

### *Vladimír Černý*

**Current position:** Associate Professor of Anaesthesiology and Intensive Care, Head of the Department of Anaesthesiology and Intensive Care, University Hospital Hradec Králové, Czech Republic

### *Jarmila Drábková*



**Born:** 1934, Prague, Czechoslovakia

**Education:**

Faculty of Medicine Charles University Prague – 1958; Scientific degree CSc – 1970

**Current position:**

Head of Department of Chronic Intensive Care, University Hospital Motol, Prague, Czech Republic

### *Philippe Eggimann*



**Born:** 1960

**Current position:**

Chief resident at the Medical Clinic II of the University of Geneva Hospitals, Instructor in general internal medicine, and in Intensive care medicine at the Faculty of Medicine, Geneva, Switzerland

### *Vladimir Gašparović*



**Born:** 1948, Bjelovar, Croatia

**Education:**

School of Medicine, University of Zagreb, Croatia – 1971; Postgraduate study of Nephrologie – 1982; PhD School of Medicine, University of Zagreb – 1988

**Current position:**

Associate Professor of Medicine, School of Medicine, Zagreb, Croatia

**Walter Hasibeder**

**Born:** 1958, Innsbruck, Austria

**Education:**

School of Medicine, University of Innsbruck, MD – 1984; Fellowship in Physiology – 1987, Fellowship in Anaesthesiology and Intensive Care Medicine – 1992 University of Innsbruck

**Current position:**

University Professor of Anaesthesiology and Intensive Care Medicine; Clinical Director of the General and Surgical Intensive Care Unit, Innsbruck, Austria

**Xavier Maurice Pierre Leverve**

**Born:** 1950, Grenoble, France

**Education:**

MD – 1980; PhD in Science – Human Biology, Lyon I University – 1988

**Current position:**

University Professor, Hospital Staff Member, Département de Médecine Aiguë Spécialisée, Unité de Réanimation Médicale et de Nutrition Parentérale, Hôpital Michallon and Université Joseph Fourier, Grenoble, France

**Martin Matějovič**

**Born:** 1969

**Education:** Medical Faculty, Charles University Pilsen, MD – 1993

**Current position:** Specialist in Internal Medicine Intensive Care Unit, Charles University Hospital Pilsen, Czech Republic

**Daniel Nalos**

**Born:** 1949

**Education:**

Medical Faculty of Charles University in Pilsen – 1973; First degree in anaesthesiology and critical medicine – 1976; Second degree in anaesthesiology and critical care – 1979

**Current position:**

Head of Anaesthesiology Department and Intensive Care Unit, Masaryk Hospital, Ústí nad Labem, Czech Republic

**Dermot Phelan**

**Education:** National University of Ireland, Galway – 1974

**Current position:** Consultant in Intensive Care Medicine & Anaesthesia; Honorary Lecturer, Faculty of Medicine, University College Dublin, Dublin, Ireland

### ***Peter Radermacher***

**Born:** 1959, Düsseldorf, Germany

**Education:** University Medical School, Heinrich-Heine University, Düsseldorf – 1984; MD – 1984; PhD – 1992

**Current position:** Professor of Anaesthesiology, Head of Section of Pathophysiology and Process Development, Department of Anaesthesia, University Medical School Ulm, Ulm, Germany

### ***Jacques-André Romand***



**Born:** 1955

**Education:**

Medical School, University of Geneva – 1981; Medical Degree, University of Geneva – 1985

**Current position:**

Fellow of the American College of Critical Care Medicine; Lecturer, Geneva Medical Faculty, Geneva, Switzerland; Adjunct Assistant Professor, Faculty of Medicine, University of Pittsburgh, Pennsylvania, USA

### ***Esko Tapio Ruokonen***



**Born:** 1953, Rovaniemi, Finland

**Education:**

Licentiate of Medicine (MD) – 1978; University of Helsinki; Licensed Physician – 1978; Doctor of Medical Sciences (PhD) University of Kuopio – 1993; Docent of Anesthesiology University of Kuopio – 1997

**Current position:**

Chief, Division of Intensive Care 2000; Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, Kuopio, Finland

### ***Charles L. Sprung***



**Education:**

Yeshiva University – BA – 1971; SUNY Downstate Medical Center Brooklyn, New York – MD – 1974; University of Miami, School of Law Coral Gables, Florida – JD – 1988

**Current position:**

Director of General Intensive Care Unit Hadassah Hebrew University Medical Center; Director of Institute of Medicine, Ethics and Law Hadassah, Hebrew University Medical Center; Professor of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

***Pavel Ševčík*****Education:**

Faculty of Medicine, J. E. Purkyně University Brno – 1978; associate professor – 1997, professor – 2001, Faculty of Medicine, Masaryk University Brno; Candidate of Medical Sciences (CSc.), Faculty of Medicine, J. E. Purkyně University Brno – 1989

**Current position:**

Head of the Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, and the St. Anne's University Hospital Brno, Brno, Czech Republic

***Vladimír Šrámek***

**Born:** 1958

**Education:**

Medical Faculty, Charles University, Pilsen – 1984; First degree in Internal Medicine – 1987, Second degree in Anaesthesiology and Intensive Care – 1992, European Diploma in Intensive Care Medicine – 1999

**Current position:**

Vicehead of the Department of Anaesthesiology and Intensive Care, St. Ann's University Hospital Brno, Brno, Czech Republic

***Karl Träger***

**Born:** 1963

**Education:** Ruhr-Universität Bochum – 1983; Friedrich-Alexander Universität Erlangen-Nürnberg – 1989; Universität Erlangen – Nürnberg, MD – 1992

**Current position:** Staff Anaesthesiologist in der Universitätsklinik für Anästhesiologie der Universität Ulm, Ulm, Germany

***Štefan Trenkler***

**Born:** 1949, Banská Štiavnica, Slovakia

**Education:**

Medical Faculty of Šafarik University in Košice – 1973

**Current position:**

Head of Department of Anaesthesiology and Intensive Medicine, Reimann Hospital, Prešov, Slovakia

***Gorazd Voga***

**Born:** 1953, Celje, Slovenia

**Education:**

Medical Faculty, University in Ljubljana MD – 1976; Medical Faculty, University in Zagreb, Masters degree – 1988; Medical Faculty, University in Ljubljana, PhD – 1998

**Current position:**

Head of Department for Intensive Internal Medicine, Associate Professor of Internal Medicine, Celje, Slovenia

***Dirk F. Zandstra***

**Born:** 1951, Sneek, Netherlands

**Education:**

Medical School, University of Groningen – 1978; PhD – 1989

**Current position:**

Director of Intensive Care Unit, Onze Lieve Vrouwe Gasthuis; Trainer Intensive Care, Amsterdam, Netherlands

# AUTHOR INDEX

## A

Adamus M. 62  
Adamus P. 62  
Adorján K. 28  
Aschermann M. 07, 36, 59  
Avšič-Županc T. 17

## B

Balík M. 16, 24, 29, 35  
Bělohlávek J. 36, 59  
Berta E. 14  
Bílek M. 46  
Blahut L. 14  
Borkowski J. 45  
Bosáková H. 60, 61  
Bračoková I. 27  
Briegel J. 33

## C

Czaban S. L. 45

## Č

Čermák P. 14  
Černý V. 03, 05, 31, 63

## D

Donáth K. 28  
Dostál P. 05  
Drábková J. 02  
Dudek-Dyczkowska D. 47  
Dünser M. 30  
Dušek L. 54  
Dziurdzik P. 47

## E

Eggimann P. 12

## F

Fazakas J. 37, 44  
Firmont J. 27  
Forró M. 08  
Friesenecker B. 30  
Furlan P. 17

## G

Gabršček L. 38, 43  
Gašparović V. 21  
Gondos T. 09, 37, 44

## H

Hamžík J. 55  
Hasibeder W. 30  
Havelka V. 55  
Hendl A. 16, 24  
Hendl J. 35  
Hnátek T. 07  
Holm F. 07, 59  
Horký P. 60, 61  
Horovitz P. 37, 44  
Hruda J. 26, 48  
Hude P. 51, 61

## I

Illias W. 34

## J

Jabor A. 24  
Jałowiecki P. 47  
Jedynak M. 45

## K

Kapš R. 17  
Klásková E. 06  
Kolář M. 14  
Kolář M. (Praha) 16, 24  
Kolek V. 56  
Kondera-Anasz Z. 47  
Král J. 25  
Králova I. 25  
Krawczyk L. 47  
Krejzl J. 57  
Krivec B. 38, 43  
Kroužek A. 20, 23, 40, 46

## L

Látal T. 14  
Leverve X. 19  
Linhart A. 07, 36

## M

Mándli T. 08  
Marek O. 14, 56  
Matějovič M. 20, 23, 40, 46  
Matuška P. 54  
Mayr A. 30  
Mazurek J. 15  
Merta Z. 54  
Mrázek V. 07  
Mutz N. 53

## N

Nalos M. 50  
Nalos D. 03  
Novák I. 03, 18, 20, 23, 40, 46, 50

## O

Ondrovčík P. 18

## P

Pachl J. 35, 57  
Parežnik R. 38, 43  
Pařízková R. 03, 05  
Pavlík M. 51, 58  
Phelan D. 22  
Pilařová O. 54  
Piovarči D. 55  
Plašil P. 29  
Podbregar M. 38, 43  
Pšenička M. 36, 59  
Putensen C. 49

## R

Radermacher P. 39, 41  
Reitinger J. 06  
Rindoš R. 55  
Rokyta R. jr. 20, 23, 40, 46  
Romand J. A. 10  
Roubík K. 57  
Ruokonen E. 04  
Růžicka J. 50

## Ř

Řehořková D. 60, 61

## S

Sárvári E. 44  
Sas I. 18  
Siemiatkowski A. 45  
Skale R. 38, 43  
Skříčková J. 54  
Smolka V. 06  
Sobanska D. 15  
Sprung C. 01  
Starič S. 17  
Stehlíková M. 29  
Stryjska M. 15  
Stryjski A. 15  
Studená A. 27  
Suk P. 26

## Š

Šedivý J. 16  
Šetina M. 25  
Ševčík P. 13  
Škulec R. 07, 36, 59  
Špundová H. 07  
Šrámek V. 18, 26, 48, 50, 52, 58  
Štětka P. 58

## T

Tesařík R. 25  
Träger K. 41  
Trenkler Š. 42

## V

Varga M. 44  
Voga G. 32, 38, 43

## W

Waldauf P. 57  
Wendsche P. 60, 61  
Wiedermann J. 06  
Wolczynski S. 45

## Z

Zábrodský V. 57  
Zandstra D. F. 11  
Zvoniček V. 18, 26

BIOMEDICAL PAPERS

Volume 146, Number 1

Published semiannually  
MK ČR E 12793

Published by Palacký University, Olomouc  
Biskupské nám. 1, 771 11 Olomouc, IČO 61989592  
Olomouc 2002

Printed by Polygrafické středisko UP

**ISSN 1213-8118**